Modified-Release Drug Delivery Technology

References (1,848)

1. GL Amidon, H Lennernas, VP Shah, JR Crison. A theoretical basis for a biopharma- ceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420, 1995.
2. E Lipka, GL Amidon. Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems. J Control Rel 62: 41-49, 1999.
3. D Gardner, R Casper, F Leith, IR Wilding. The InteliSite capsule: a new easy to use approach for assessing regional drug absorption from the gastrointestinal tract. Pharm Technol Eur 9:46-53, 1997.
4. G Fricker, J Drewe, J Huwyler, H Gutmann, C Beglinger. Relevance of p-glycopro- tein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol 118:1841-1846, 1996.
5. MF Paine, M Khalighi, JM Fisher, DD Shen, KL Kunze, CL Marsh, JD Perkins, KE Thummel. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562, 1997.
6. JB Dressman, GL Amidon, C Reppas, VP Shah. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 15:11- 22, 1998.
7. R Lobenberg, GL Amidon. Modern bioavailability, bioequivalence and biopharma- ceutics classification system: new scientific approaches to international regulatory standards. Eur J Pharm Biopharm 50:3-12, 2000.
8. IR Wilding, AJ Coupe, SS Davis. The role of γ-scintigraphy in oral drug delivery. Adv Drug Del Rev 46:103-124, 2001.
9. SS Davis, FN Christensen, JG Hardy. The intestinal transit of pharmaceutical dosage forms. Gut 27:886-892, 1986.
10. CT Rhodes, SC Porter. Coatings for controlled-release drug delivery systems. Drug Dev Ind Pharm 24:1139-1154, 1998.
11. VRS Uppoor. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailabil- ity) correlations. J Control Rel 72:127-132, 2001.
12. V Lenaerts, I Moussa, Y Dumoulin, F Mebsout, F Chouinard, P Szabo, MA Ma- teescu, L Cartilier, R Marchessault. Cross-linked high amylose starch for controlled release of drugs: recent advances, J Control Rel 53:225-234, 1998.
13. U Conte, L Maggi. A flexible technology for the linear, pulsatile and delayed release of drugs, allowing for easy accommodation of difficult in vitro targets. J Control Rel 64:263-268, 2000.
14. HE Hogan, JN Staniforth, L Reeves, T Page. Electrostatic coating. US Patent 6,117,479, 1997.
15. JC Richards, DV Prior, SE Frisbee, J Getz, IR Wilding. Pharmacoscintigraphic eval- uation of novel controlled release microsphere (Ceform) formulations. Proc Int Symp Control Rel Bioact Mater 25:920-921, 1998.
16. C Castan, M Cicquel, R Meyrueix, P Autant, R Jorda, P Vivet, G Soula. Genvir: the first sustained release dosage form of acyclovir. Proc Int Symp Control Rel Bi- oact Mater 27:1198-1199, 2000.
17. WN Charman, CJH Porter, S Mithani, JB Dressman. Physicochemical and physio- logical mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci 86:269-282, 1997.
18. MR Venkatramana, JL Haslam, VJ Stella. Controlled release matrices of poorly water soluble drugs using (SBE) 7M -β-CD as a solubilizing agent. Proc Int Symp Control Rel Bioact Mater 26:929-930, 1999.
19. GG Liversidge, KC Cundy, JF Bishop, DA Czekai. Surface modified drug nanopar- ticles. US Patent 5,145,684, 1992.
20. RA Rajewski, VJ Stella. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci 85:1142-1169, 1996.
21. JN Staniforth, AR Baichwal. Synergistically interacting heterodisperse polysaccha- rides: function in achieving controllable drug delivery. In: MA El-Nokaly, DM Piatt, REFERENCES
22. AM Sakr, HM Elsabbagh. Correlation of water absorption with the disintegration effectiveness of guar gum. Pharm Ind 37:457-459, 1975.
23. EM Rudnic, CR Rhodes, JF Bavitz, JB Schwartz. Some effects of relatively low levels of eight tablet distintegrants on a direct compression system. Drug Dev Ind Pharm 7:347-358, 1981.
24. MZ Iqbal, M Amin, NA Muzaffar. Comparative evaluation of guar gum as disintigrat- ing agent. J Pharm 1:17-34, 1979.
25. SA Altaf, KL Yu, J Parasrampuria, DR Friend. Guar gum-based sustained release diltiazem. Pharm Res 15:1196-1201, 1998.
26. K Yu, M Gebert, SA Altaf, D Wong, DR Fiend. Optimization of sustained-release diltiazem formulations in man by use of an in-vitro/in-vivo correlation. J Pharm Phar- macol 50:845-850, 1998.
27. K Yu, D Wong, J Parasrampuria, DR Friend. In: HG Brittain, ed. Analytical Profiles of Drug Substances and Excipients. Vol. 24. Orlando, FL: Academic Press, 1996, pp. 397-442.
28. AM Goldstein, E Alter, JK Seaman. Guar gum. In: Industrial Gums, Polysaccharides and Their Derivatives. 2nd ed. New York: Academic Press, 1973, pp. 303-321.
29. MS Gebert, DR Friend. Purified guar galactomannan as an improved pharmaceutical excipient. Pharm Dev Technol 3:315-323, 1998.
30. F Langenbucher. Parametric representation of dissolution-rate curves by the RRSBW distribution. Pharm Ind 38:474-477, 1976.
31. H-W Hui, JR Robinson, VHL Lee. Design and fabrication of oral controlled release drug delivery systems. In: Controlled Drug Delivery Fundamentals and Applications. 2nd ed. New York: Marcel Dekker, 1987, Chapter 9.
32. F Theeuwes. Osmotic system for the control and delivery of agent over time. US patent 4,111,202, 1978.
33. F Theeuwes, D Swanson, P Wong, P Bonsen, V Place, K Hiemlich, KC Kwan. Elementary osmotic pump for indomethacin. J Pharm Sci 72:253, 1983.
34. D Stephenson, J Spence. Prolonged release and oral pharmaceutical tablets and their manufacture. UK patent 1,022,171, 1966.
35. A Reid. Shaped tablets. US Patent Number 3,279,995, 1966.
36. RB DePrince. Disc-like sustained release formulations. US patent 4,663,147, 1987.
37. FJ Rippie, JR Johnson. Regulation of dissolution rate by pellet geometry. J Pharm Sci 58:428, 1969.
38. D Brooke, RJ Washkuhn. Zero-order drug delivery systems: theory and preliminary testing. J Pharm Sci 66:159, 1979.
39. SK Chopra, AK Nangia, D Lee, T Molloy. Controlled release device. European patent 0,542,364 A1, 1993.
40. BJ Fahie, A Nangia, SK Chopra, CA Fyfe, H Grondey, A Blazek. Use of NMR imaging in the optimization of a compression-coated regulated release system. J Control Rel 51:179-184, 1998. REFERENCES
41. PS-L Wong, DE Edgren, LC Dong, VJ Ferrari. Active agent dosage form comprising a matrix and at least two insoluble bands. US patent 5,534,263, 1996. REFERENCES
42. E Nelson. Pharmaceuticals for prolonged action. Clin Pharmacol Ther 4:283, 1963.
43. K Mu ¨nzel, Der Einfluss der Formgebung auf die Wirkung eines Arzneimittels (The Effect of the Shape of a Dosage Form on its Efficacy). Basel: Birkha ¨user Verlag, 1966, p. 290.
44. H Bechgaard. Critical factors influencing gastrointestinal absorption-what is the role of pellets? Acta Pharm Technol 28:149, 1982.
45. SS Davis. The design and evaluation of controlled release systems for the gastro- intestinal tract. J Control Rel 12:27, 1985.
46. JN McMullen. Controlled release tablet. US patent 4,816,262, 1989.
47. MA Bayomi. Geometric approach for zero-order release of drugs dispersed in an inert matrix. Pharm Res 11:914-916, 1994.
48. BC Lippold. Slow and extended release products: mechanisms of release and possi- bilities of control. In: Blume, Gundert-Remy, Mo ¨lle, eds. Controlled/Modified Re- lease Products. Stuttgart: Wissensch Verlagsgesellschaft mbH, 1991, pp. 15-34.
49. U Conte, L Maggi. Modulation of the dissolution profiles from Geomatrix multilayer tablets containing drugs of different solubility. Biomaterials 17:889-896, 1996.
50. Y Qiu, N Chidambaram, K Flood. Design and evaluation of layered diffusional ma- trices for zero-order sustained release. J Control Rel 51:123-130, 1998.
51. L Yang, R Fassihi. Examination of drug solubility, polymer types, hydrodynamics and loading dose on drug release behaviour from triple-layer asymmetric configura- tion delivery devices. Int J Pharm 155:219-229, 1997.
52. MA Abraham, A Shirwaikar. Formulation of multilayered sustained release tablets using insoluble matrix system. Indian J Pharm Sci 59:312-315, 1997.
53. A Nangia, T Molloy, BJ Fahie, SK Chopra. Novel regulated release system based on geometric configuration. Proc Int Control Rel Bioact Mater 22:294-295, 1995.
54. N Chidambaram, W Porter, K Flood, Y Qiu. Formulation and characterization of new layered diffusional matrices for zero-order sustained release. J Control Rel 52: 149-158, 1995.
55. K Cremer, B Asmussen. Novel controlled release tablet with erodible layers. Proc Int Symp Control Rel Bioact Mater 22:732-733, 1995.
56. K Cremer. Verfahren zur herstellung von vorrichtungen zur kontrollierten freiset- zung von wirkstoffen. German patent DE 44 16 926, 1995.
57. K Cremer. Vorrichtung zur kontrollierten freisetzung von wirkstoffen sowie ihre verwendung. German patent DE 43 41 442, 1998.
58. W Korsch. Mantelkernpresse. German patent DE 3 819 821, 1990.
59. W Korsch, M Schmett. Presse zur Herstellung ummantelter Tabletten. German pat- ent DE 4 025 484, 1990.
60. T Higuchi. Mechanism of sustained action medication: theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 52:1145-1149, 1963.
61. MS Vora, AJ Zimmer, VP Maney. Sustained release aspririn tablets using an insolu- ble matrix. J Pharm Sci 53:487, 1964.
62. RC Rowe. Sustained release plastic matrix tablets. Manuf Chem Aerosol News 3: 23-56, 1975.
63. P Dietrich. Schichthaftung in Komplex-Mehrschichttabletten. Ph.D. dissertation, Alber-Ludwigs-Universita ¨t, Freiburg I. Breisgau, Germany, 1999. REFERENCES
64. MJ Cima, JS Haggerty, EM Sachs, PA Williams. Three-dimensional printing tech- niques. US patent 5,204,055, 1993.
65. EM Sachs, MJ Cima, P Williams, D Brancazio, J Cornie. Three-dimensional print- ing: Rapid tooling and prototypes directly from a CAD model. J Eng Ind 114:481- 488, 1992.
66. WE Katstra, RD Palazzolo, CW Rowe, B Giritlioglu, P Teung, MJ Cima. Oral dos- age forms fabricated by Three Dimensional Printing. J Control Rel 66:1-9, 2000.
67. CW Rowe, WE Katstra, RD Palazzolo, B Giritlioglu, P Teung, MJ Cima. Multi- mechanism oral dosage forms fabricated by Three Dimensional Printing. J Control Rel 66:11-17, 2000.
68. WE Katstra, CW Rowe, MJ Cima. Controlling drug placement during the fabrication of complex release oral dosage forms by 3DP. Proc Int Symp Control Rel Bioact Mater 27:413-414, 2000.
69. J Yoo, E Bornancini, A Yang, G Shanahan, D Monkhouse. Content uniformity study of microdose tablets fabricated by the TheriForm process. Annual meeting of the American Association of Pharmaceutical Scientists, Boston, Nov 2-6, 1997.
70. LG Cima, JP Vacanti, CA Vacanti, D Ingber, D Mooney, R Langer. Tissue engi- neering by cell transplantation using biodegradable polymer substrates. J Biomech Eng 113:143-151, 1991.
71. BM Wu, SW Borland, RA Giordano, LG Cima, EM Sachs, MJ Cima, Solid free- form fabrication of drug delivery devices. J Control Rel 40:77-87, 1996.
72. Pharma Eugragit Polymers Product Range Information Booklet, Creanova Inc, Som- erset, NJ.
73. S Kumar, AP Sayani, MJ Cima, MM Mason, TG West, AY Yang, DC Monkhouse. In vivo/in vitro correlation of ethinyl estradiol release from biodegradable implants fabricated by the Theriform process. Annual meeting of the American Association of Pharmaceutical Scientists, New Orleans, LA, Nov 14-18, 1999. REFERENCES
74. SS Chrai, B Singh, M Kopcha, R Murari, S Sun, N Kumar, N Desai, A Levine, H Rivenburg, G Kaganowicz. Electrostatic dry deposition technology. Pharm Tech 4:17-20, 1998.
75. G Kupperblatt, A Katdare, G Slack, J-C Chen, M Karetny, S Chrai. Oral delivery using a novel controlled release technology: system design and materials selection. Proc Int Symp Control Rel Bioact Mater 27:1226-1227, 2000.
76. S Rose, JF Nelson. A continuous long-term injector. Aust J Exp Biol 33:415-420, 1955.
77. F Theeuwes. Elementary osmotic pump. J Pharm Sci 64:1987-1991, 1975.
78. P Wong, B Barclay, JC Deter, F Theeuwes. Osmotic device with dual thermody- namic activity. US patent 4,612,008, 1986.
79. G Santus, RW Baker. Osmotic drug delivery: a review of the patent literature. J Control Rel 35:1-21, 1995.
80. P Wong, F Theeuwes, J Eckenhoff, S Larson, H Huynh. Multi-unit delivery system. US patent 5,023,088, 1991.
81. F Theeuwes, P Wong, S Yum. Drug delivery and therapeutic systems. In: J Swar- brick, J Boylan, eds. Encyclopedia of Pharmaceutical Technology. Vol. 4. New York: Marcel Dekker, 1991, pp. 303-348.
82. D Murdoch, RN Brogden. Sustained release nifedipine formulations: an appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders. Drugs 41:737-779, 1991.
83. CH Kleinbloesem, P Van Brummelen, M Danhof, H Faber, J Urquhart, DD Breimer. REFERENCES
84. J Kerc ˇ, LB Rebic ˇ, B Kofler. Three-phase pharmaceutical form with constant and con- trolled release of amorphous active ingredient for single daily application. US patent 6,042,847, 2000.
85. T Eckert, J Mu ¨ller. U ¨ber polymorphe modifikationen des nifedipine aus unterku ¨hlten schmelzen. Arch Pharm (Weinheim) 310:116-118, 1977.
86. J Kerc ˇ, M Mohar, B Kofler. Three-phase pharmaceutical form (Threeform) for nifedi- pine zero order release. Proc Int Symp Control Rel Bioact Mater 25:912-913, 1998.
87. J Kerc ˇ, B Rebic ˇ, B Kofler, M Mohar, J Urbanc ˇic ˇ. Preparation and evaluation of three- phase pharmaceutical form (Threeform) for nifedipine once daily application. Farm Vestn 50:273-274, 1999.
88. J Kerc ˇ, J Urbanc ˇic ˇ. Three-phase pharmaceutical form (Threeform) for nifedipine once daily administration: in vivo studies. Proc Int Symp Control Rel Bioact Mater 26: 879-880, 1999.
89. WL Chiou, S Riegelman. Pharmaceutical application of solid dispersion systems. J Pharm Sci 60:1281-1302, 1971.
90. J Ford. The current status of solid dispersions. Pharm Acta Helv 61:69-88, 1986.
91. H Nogami, T Nagai, A Kondo. Dissolution kinetics of poly vinyl pyrrolidone. Chem Pharm Bull 18:1185-1187, 1970.
92. C Vervaet, L Baert, JP Remon. Extrusion-spheronisation-a literature review. Int J Pharm 116:131-146, 1995.
93. N Follonier, E Doelker, ET Cole. Various ways of modulating the release of diltia- zem hydrochloride from hot-melt extruded sustained release pellets prepared using polymeric materials. J Control Rel 36:243-250, 1995.
94. N Follonier, E Doelker, ET Cole. Evaluation of Hot-Melt-Extrusion as new tech- nique for the production of polymer based pellets for sustained release capsules containing high loadings of freely soluble drugs. Drug Dev Ind Pharm 20:1323- 1339, 1994.
95. M Adel El-Egakey, M Soliva, P Speiser. Hot extruded dosage forms. Pharm Acta Helv 46:31-52, 1971.
96. T Ozeki, H Yuasa, Y Kanaya. Application of the solid dispersion method to the controlled release medicine. IX. Difference in the release of flurbiprofen from solid dispersions with poly(ethylene oxide) and hydroxypropylcellulose and the interac- tion between medicine and polymers. Int J Pharm 155:209-217, 1997.
97. MA Khan, AH Shojaei, AA Karnachi, IK Reddy. Comparative evaluation of con- trolled-release solid oral dosage forms prepared with solid dispersions and coprecipi- tates. Pharm Technol 5:58-72, 1999. REFERENCES
98. KH Bauer, KH Fro ¨mming, C Fu ¨hrer. Lehrbuch der Pharmazeutische Technologie. 6th ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 1999.
99. KH Fro ¨mming. Cyclodextrine-eine vielseitig verwendbare Gruppe neuer Hilfs- stoffe. In: RH Mu ¨ller, GE Hildebrand, eds. Pharmazeutische Technologie: Moderne Arzneiformen. 2nd ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 1998, pp. 13-17.
100. H Sucker. Hydrosole, eine Alternative fu ¨r die parenterale Anwendung von schwer wasserlo ¨slichen Wirkstoffen. In: RH Mu ¨ller, GE Hildebrand, eds. Pharmazeutische Technologie: Moderne Arzneiformen. 2nd ed. Stuttgart: Wissenschaftliche Verlags Gesellschaft, 1998, pp. 383-391.
101. M List, H Sucker. Pharmaceutical colloidal hydrosols for injection. GB patent 2200048, 1992.
102. P Gaßmann, H Sucker. Improvements in pharmaceutical compositions. GB patent 2269536, 1994.
103. P Gaßmann, M List, A Schweitzer, H Sucker. Hydrosols-alternatives for the paren- teral application of poorly water soluble drugs. Eur J Pharm Biopharm 40:64-72, 1994.
104. GG Liversidge, KC Cundy. Particle size reduction for improvement of oral bioavail- ability of hydrophobic drugs. I. Absolute oral bioavailability of nanocrystalline dana- zol in beagle dogs. Int J Pharm 125:91-97, 1995.
105. GG Liversidge, P Conzentino. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm 125:309-313, 1995.
106. GG Liversidge, K Cundy, JF Bishop, DA Czekai. Surface modified drug nanopar- ticles. US patent 5,145,684, 1992.
107. RH Mu ¨ller, R Becker, B Kruss, K Peters. Pharmaceutical nanosuspensions for medi- cament administration as systems with increased saturation solubility and rate of dissolution. US patent 5,858,410, 1999.
108. RH Mu ¨ller. Nanosuspensionen-eine neue Formulierung fu ¨r schwerlo ¨sliche Arz- neistoffe. In: RH Mu ¨ller, GE Hildebrand, eds. Pharmazeutische Technologie: Mod- erne Arzneiformen. 2nd ed. Stuttgart: Wissenschaftliche Verlags Gesellschaft, 1998, pp. 393-399.
109. German Pharmacopoea DAB 6, 1926, p. 347.
110. RH Mu ¨ller, K Peters, R Becker, BN Kruss. Nanosuspensions-a novel formulation for the i.v. administration of poorly soluble drugs. Proceedings of the 1st World Meeting of the Association de Pharmacie Galenique Industriele/International Asso- ciation for Pharmaceutical Technology, Budapest, 1995, pp. 491-492.
111. S Buchmann, W Fischli, FP Thiel, R Alex. Aqueous microsuspension, an alternative intravenous formulation for animal studies. Proceedings of the Annual Congress of the Association de Pharmacie Galenique Industriele/International Association for Pharmaceutical Technology, Mainz, 1994, pp. 124.
112. RH Mu ¨ller, K Peters. Nanosuspensions for the formulation of poorly soluble drugs. I. Preparation by a size-reduction technique. Int J Pharm 160:229-237, 1998.
113. C Schwarz, W Mehnert, RH Mu ¨ller. Influence of production parameters of solid lipid nanoparticles (SLN) on the suitability for intravenous injection. Eur J Pharm Biopharm 40:24, 1994.
114. K Peters. Nanosuspensionen-ein neues Formulierungprinzip fu ¨r schwerlo ¨sliche Arzneistoffe. PhD dissertation, Freie Universita ¨t, Berlin, Germany, 1999.
115. C Nystro ¨m. Dissolution properties of soluble drugs: theoretical background and pos- sibilities to improve the dissolution behavior. In: RH Mu ¨ller, S Benita, B Bo ¨hm, eds. Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs. Stuttgart: Medpharm Scientific Publishers, 1998, pp. 143-147.
116. M Mosharraf, C Nystro ¨m. The effect of particle size and shape on the surface specific Mu ¨ller et al. dissolution rate of micronized practically insoluble drugs. Int J Pharm 122:35-47, 1995.
117. C Jacobs. PhD dissertation, Freie Universita ¨t Berlin, Germany, in preparation.
118. S Jahnke. The theory of high-pressure homogenization. In: RH Mu ¨ller, S Benita, B Bo ¨hm, eds. Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs. Stuttgart: Medpharm Scientific Publishers, 1998, pp. 177-200.
119. GG Liversidge. Presentation at the Workshop of Particulate Drug Delivery Systems. 23rd International. Symposium on Controlled Release of Bioactive Materials, Kyoto, 1996.
120. DJW Grant, HG Brittain. Solubility of pharmaceutical solids. In: HG Brittain, ed. Physical Characterization of Pharmaceutical Solids. New York: Marcel Dekker, 1995, pp. 321-386.
121. RH Mu ¨ller, BHL Bo ¨hm. Nanosuspensions. In: RH Mu ¨ller, S Benita, B Bo ¨hm, eds. Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs. Stutt- gart: Medpharm Scientific Publishers, 1998, pp. 149-174.
122. RH Mu ¨ller, R Becker, B Kruss, K Peters. 1994. Pharmazeutische nanosuspensionen zur arzneistoffapplikation als systeme mit erho ¨hter.
123. PH List. Arzneiformenlehre. 4th ed. Stuttgart: Wissenschaftliche Verlags Gesell- schaft mbH, 1985.
124. H Ahmed, G Buckton, DA Rawlins. Crystallisation of partially amorphous griseoful- vin in water vapour: determination of kinetic parameters using isothermal heat con- duction microcalorimetry. Int J Pharm 167:139-145, 1998.
125. H Kala, U Haak, U Wenzel, G Zessin, P Pollandt. Zum kristallographischen verhal- ten verhalten des carbamazepins unter pressdruck. Pharmazie 42:524-527, 1987.
126. BHL Bo ¨hm, MJ Grau, GE Hildebrand, AF Thu ¨nemann, RH Mu ¨ller. Preparation and physical properties of nanosuspensions (DissoCubes) of poorly soluble drugs. Proc Int Symp Control Rel Bioact Mater 25:956-957, 1998.
127. MJ Grau, RH Mu ¨ller. Increase of dissolution velocity and solubility of poorly soluble drugs by formulation as nanosuspension. Proceedings of the 2nd World Meeting of the Association de Pharmacie Galenique Industriele/International Association for Pharmaceutical Technology, Paris, 1998, pp. 623-624.
128. C Jacobs. Determination of physical stability of bupravaquone nanosuspension for in vivo use. Proceedings of the 3rd World Meeting of the Association de Pharmacie Galenique Industriele/International Association for Pharmaceutical Technology, Berlin, 2000, pp. 415-416.
129. O Kayser. Formulation of the poorly unsoluble antiprotozoal aphidicolin as in- jectable by production as nanosuspension. In: D Burgess, PJ Stout, eds. Injectable Dispersed Systems: Formulation, Processing and Performance. 2000 (in press).
130. S Runge. Feste Lipidnanopartikel (SLN) als kolloidaler Arzneistofftra ¨ger fu ¨r die orale Applikation von Ciclosporin A. PhD dissertation, Freie Universita ¨t, Berlin, Germany, 1998.
131. BHL Bo ¨hm. Herstellung und Charakterisierung von Nanosuspension als neue Arz- neiform fu ¨r Arzneistoff mit geringer Bioverfu ¨gbarkeit. PhD dissertation, Freie Uni- versita ¨t, Berlin, Germany, 1999.
132. M Grau. Untersuchungen zur Lo ¨sungsgeschwindigkeit, Sa ¨ttigungslo ¨slichkeit und Stabilita ¨t von hochdispersen Arzneistoffsuspensionen. PhD dissertation, Freie Uni- versita ¨t, Berlin, Germany, 1999.
133. RH Mu ¨ller, BHL Bo ¨hm, MJ Grau. Nanosuspensions-Formulierungen fu ¨r schwer- lo ¨sliche arzneistoffe mit geringer Bioverfu ¨gbarkeit. II. Stabilita ¨t, biopharmazeu- tische aspekte, mo ¨gliche arzneiformen und zulassungsfragen. Pharm Ind 61:175- 178, 1999.
134. N Scho ¨ler, K Krause, O Kayser, RH Mu ¨ller, H Hahn, O Liesenfeld. In vitro efficacy of atovaquone nanosuspensions against Toxoplasma gondii. Proceedings of the 3rd World Meeting of the Association de Pharmacie Galenique Industriele/International Association for Pharmaceutical Technology, Berlin 2000, pp. 331-332.
135. O Kayser, AF Kiderlen, H Laatsch. Antiparasita ¨re Wirkung von N1-alkyierten 1,4- Naphthinazol-4,9-chinonen. German patent 100 20 812.6, 2000.
136. O Kayser. Nanosuspensions for the formulation of aphidicolin to improve drug tar- geting effects against Leishmania infected macrophages. Int J Pharm 196:253-256, 2000.
137. RH Mu ¨ller, O Kayser, C Jacobs. Nanosuspensions as particular drug formulations in therapy. Adv Drug Del Rev (in press).
138. RH Mu ¨ller, MJ Grau, GE Hildebrand. Increase of solubility of poorly soluble drugs by transfer to DissoCubes using high pressure homogenization. Proc Int Symp Con- trol Rel Bioact Mater 26:112-113, 1999.
139. T Schneppe, RH Mu ¨ller. Qualita ¨tsmanagement und Validierung in der pharmazeu- tischen Praxis. Aulendorf: Editio Cantor Verlag, 1999, pp. 81-163.
140. RH Mu ¨ller, S Gohla, A Dingler, T Schneppe. Large scale production of solid lipid nanoparticles (SLN) and nanosuspensions (DissoCubes). In: D Wise, ed. Handbook of Pharmaceutical Controlled Release Technology (in press).
141. KP Krause, O Kayser, K Ma ¨der, R Gust, RH Mu ¨ller. Heavy metal contamination of nanosuspensions produced by high-pressure homogenisation. Int J Pharm 196: 169-172, 2000.
142. DH Haynes. Phospholipid-coated microcrystals: injectable formulations of water- insoluble drugs. US patent 5,091,187 and 5,091,188, 1992.
143. DH Haynes. Microdroplets of water insoluble drugs and injectable formulations con- taining same. US patent 4,725,442, 1988.
144. A Dearn. Atovaquone pharmaceutical compositions. PCT International Publication WO 94/14426, 1994.
145. D Fleisher, C Li, Y Zhou, LH Pao, A Karim. Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications. Clin Phar- macokinet 36:233-254, 1999.
146. LL Ponto, RD Schoenwald. Furosemide (frusemide): a pharmacokinetic/pharmaco- dynamic review (Part I). Clin Pharmacokinet 18:381-408, 1990.
147. J Posti, K Katila, T Kostiainen. Dissolution rate limited bioavailability of flutamide, and in vitro-in vivo correlation. Eur J Pharm Biopharm 49:35-39, 2000.
148. HM Abdou. Methods for enhancement of drug dissolution characteristics. Dissolu- tion, Bioavailability & Bioequivalence. Easton, PA: Mack Publishing Company, 1989, pp. 265-284.
149. HC Ansel, NG Popovich. Dosage from design. In: HC Ansel, NG Popovich, eds. Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lea & Febiger, 1990, pp. 56-58.
150. DH Haynes. Microdroplets of water insoluble drugs. International patent W085/ 00011, 1985.
151. DH Haynes. Method of inducing local anesthesia using microdroplets of a general anesthetic. US patent 4,622,219, 1986.
152. DH Haynes. Phospholipid-coated microcrystals: injectable formulations of water- insoluble drugs. US patents 5,091,187 and 5,091,188, 1992.
153. DH Haynes. Microdroplets of water-insoluble drugs and injectable formulations con- taining same. US patent 4,725,442, 1988.
154. SN Pace, GW Pace, I Parikh, AK Mishra. Novel injectable formulations of insoluble drugs. Pharm Technol 23:116-134, 1999.
155. A Mishra, G Robinson, G Pace. Novel injectable formulations of water-insoluble drugs. Controlled Release Newslett 17:21-30, 2000.
156. GG Liversidge, KC Cundy, JF Bishop, DA Czekai. Surface modified drug nanopar- ticles. US patent 5,145,684, 1992.
157. KJ Illig, P Sarpotdar. Formulations comprising Olin 10-G to prevent particle aggre- gation and increase stability. US patent 5,340,564, 1994.
158. HW Bosch, DM Marcera, RL Mueller, JR Swanson, DS Mishra. Process for prepar- ing therapeutic compositions containing nanoparticles. US patent 5510118, 1996.
159. RH Muller, R Becker, B Kruss, K Peters. Pharmaceutical nanosuspensions for medi- cament administration as systems with increased saturation solubility and rate of solution. US patent 5,858,410, 1999.
160. PP Speiser. Nanoparticles and liposomes: a state of the art. Methods Find Exp Clin Pharmacol 13:337-342, 1991.
161. J Kreuter. Nanoparticles. In: J Kreuter, ed. Colloidal Drug Delivery Systems. New York: Marcel Dekker, 1994, pp. 219-342.
162. H Okada, H Toguchi. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carr Syst 12:1-99, 1995.
163. JC Wunderlich, U Schick, J Werry, J Freidenreich. Gelatin or collagen hydrolysate containing drug formulation that provides for immediate release of nanoparticle drug compounds. US patent 5,932,245, 1999.
164. D Bar-Shalom, T Kindt-Larsen. Controlled release erodible composition. US patent 5,618,560, 1997. See also http://www.egalet.dk/home.htm.
165. JG Devane, S Mulligan, M Kavanagh, SD Davis, RA Sparrow, IR Wilding. New developments in sustained-release antihypertensive therapy: formulation and phar- macokinetic considerations. Am J Cardiol 69:23E-27E, 1992. See also http:// www.elan.ie/drugdel/technologies/oral/indas.asp.
166. RH Muller, K Mader, S Gohla. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 50:161-177, 2000.
167. MNS Santos, S Benita, M Seiller. Les emulsions orales: obtention et biodisponibilite (Oral emulsions: preparation and bioavailability). J Pharm Belg 48:211-226, 1993.
168. JA Rogers, KE Anderson. The potential of liposomes in oral drug delivery. Crit Rev Ther Drug Carr Syst 15:421-480, 1998.
169. T Gershanik, S Benita. Self-dispersing lipid formulations for improving oral absorp- tion of lipophilic drugs. Eur J Pharm Biopharm 50:179-188, 2000.
170. S Tenjarla. Microemulsions: an overview and pharmaceutical applications. Crit Rev Ther Drug Carr Syst 16:461-521, 1999.
171. AT Serajuddin. Solid Dispersion of poorly water-soluble drugs: Early promises, sub- sequent problems, and recent breakthoughs. J Pharm Sci 88:1058-1066, 1999. Mishra et al.
172. BA Klyashchitsky, AJ Owen. Drug delivery systems for cyclosporine: achievements and complications. J Drug Target 5:443-458, 1998.
173. PP Constantinides. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res 12:1561-1572, 1995.
174. DO Thompson. Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. Crit Rev Ther Drug Carr Syst 14:1-104, 1997.
175. BJ Aungst. Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J Pharm Sci 82:979- 987, 1993.
176. I Genta, P Perugini, F Pavanetto, T Modena, B Conti, RA Muzzarelli. Microparticu- late drug delivery systems. EXS 87:305-313, 1999.
177. J Lansman, DH Haynes. Kinetics of a CA 2ϩ -triggered membrane aggregation reac- tion of phospholipid membranes. Biochim Biophys Acta 394:335-347, 1975; and unpublished data.
178. DH Haynes, AF Kirkpatrick. Ultra-long duration local anesthesia produced by intra- dermal injection of lecithin-coated methoxyflurane microdroplets. Proc Int Symp Control Rel Bioact Mater 14:293-294, 1987.
179. A Vivier, JC Vuillemard, HW Ackermann, D Poncelet. Large-scale blood substitute production using a microfluidizer. Biomater Artif Cells Immobiliz Biotechnol 20: 377-397, 1992.
180. MD White, D Marcus. Disintegration of microorganisms. Adv Biotechnol Processes 8:51-96, 1988.
181. DM Lidgate, T Trattner, RM Shultz, R Maskiewicz. Sterile filtration of a parenteral emulsion. Pharm Res 9:860-863, 1992.
182. R Bodmeier, H Chen, P Tyle, P Jarosz. Spontaneous formation of drug-containing acrylic nanoparticles. J Microencapsul 8:161-170, 1991.
183. DM Lidgate, RC Fu, NE Byars, LC Foster, JS Fleitman. Formulation of vaccine adjuvant muramyldipeptides. 3. Processing optimization, characterization, and bio- activity of an emulsion vehicle. Pharm Res 6:748-752, 1989.
184. KJ Illig, RL Mueller, KD Ostrander, JR Swanson. Use of microfluidizer processing for preparation of pharmaceutical suspensions. Pharm Technol 20:78-88, 1996.
185. IB Henriksen, AK Mishra, GW Pace, KP Johnston, S Mawson. Insoluble drug deliv- ery. WIPO WO9714407A1, 1997.
186. TJ Young, S Mawson, KP Johnstron, IB Henriksen, GW Pace, AK Mishra. Rapid expansion from supercritical to aqueous solution to produce submicron suspension of water-insoluble drugs. Biotechnol Progr 16:402-407, 2000.
187. GW Pace, MG Vachon, AK Mishra, IB Henriksen, V Krukonis, A Godinas. Pro- cesses to generate submicron particles of water-insoluble compounds. WIPO WO9965469A2, 1999.
188. I Parikh, AK Mishra, R Donga. MG Vachon. Dispersible phospholipid stabilized microparticles. WIPO WO030616A1, 2000.
189. W McCulloch, I Parikh, OM Colvin, G Paro ¨. Development of I.V. busulfan (Sparta- ject-Busulfan). Annual Meeting of the European Group for the Bone Marrow Trans- plantation, Harrogate, UK, March 1994. pp. 116.
190. FAO/WHO. Toxicological evaluations of certain food additives with a review of general principles and of specifications. Tech Rep Ser WHO 1974, No. 539.
191. FAO/WHO. Evaluations of certain food additives and contaminants. Tech Rep Ser WHO 1982, No. 683.
192. FAO/WHO. Evaluations of certain food additives and contaminants. Tech Rep Ser WHO 1983, No. 696.
193. FAO/WHO. Evaluations of certain food additives. Tech Rep Ser WHO, 1980, No. 648.
194. JH Growdon et al. Lecithin can suppress tardive dyskinesia. N Engl J Med 298: 1029-1030, 1978.
195. I Ghebre-Sellassie. Multiparticulate Oral Drug Delivery. New York: Marcel Dekker, 1994.
196. SE Walker, K Bedford, T Eaves. Pharmaceutical preparations in solid unit dosage form. British patent 1,572,266, 1980.
197. C McTaggart, R Wood, K Bedford, SE Walker. The evaluation of an automatic system for filling liquids into hard gelatin capsules. J Pharm Pharmacol 36:119- 121, 1984.
198. A Cuine ´, C Mathis, A Stamm, D. Franc ¸ois. Das einbringen viskoser lo ¨sungen von aktivstoffen in hartgelatinekapseln. Pharm Ind 40:654-657, 1987.
199. P Ghirardi, G Catenazzo, O Mantero, GC Merotti, A Marzo. Bioavailability of di- goxin in a new soluble pharmaceutical formulation in capsules. J Pharm Sci 66: 267-269, 1977.
200. W Lahr. Flu ¨ssig befu ¨llte hartgelatinekapseln. Pharm Ztg 131:871-874, 1986.
201. R Herrmann. Bioverfu ¨gbarkeit zweier neuer nifedipin-formulierungen. Pharm Ztg 131:869-870, 1986.
202. CA Lipinski. Strategies for optimizing oral drug delivery: Consideration of drug solu- bility in high throughput screening of oral drug candidates. Kobe, April 19-21, 1999.
203. JR Robinson. Introduction: Semi-solid formulations for oral drug delivery. Bull Tech Gattefosse ´No. 89:11, 1996.
204. JM Kovarik, EA Mueller, J-B Van-Bree, W Tetzloff, K Kutz. Reduced inter-and intraindividual variability in cyclosporin pharmacokinetics from a microemulsion formulation. J Pharm Sci 83:444-446, 1994.
205. A Meinzer, F Richter, JF Vonderscher. Oil-free pharmaceutical compositions con- taining cyclosporin A. WO 93/20833, 1988.
206. SE Walker, JA Ganley, K Bedford, T Eaves. The filling of molten and thixotropic formulations into hard gelatin capsules. J Pharm Pharmacol 32:389-393, 1980.
207. JR Howard, PL Gould. Drug release from thermosetting fatty vehicles filled into hard gelatin capsules. Drug Dev Ind Pharm 13:1031-1045, 1987.
208. A-C Bernasconi, E Doelker, P Buri. Diffusion and erosion controlled drug release from lipid matrix formulations incorporated into hard gelatin capsules. Proc Int Symp Control Rel Bioact Mater 12:272-273, 1985.
209. AB Dennis, IW Kellaway, R Davidson. Investigation of in vitro aging on in vivo release from a prolonged release liquid filled hard gelatin capsule formulation. Proc Int Symp Control Rel Bioact Mater 15:390-391, 1988.
210. Y Seta, F Higuchi, Y Kawahara, K Nishimura, R Okada. Design and preparation of captopril sustained-release dosage forms and their biopharmaceutical properties. Int J Pharm 41:245-254, 1988.
211. Y Seta, F Higushi, T Otsuka, Y Kawahara, K Nishimura, R Okada and H Koyke. Preparation and pharmacological evaluation of captopril sustained-release dosage forms using oily semisolid matrix. Int J Pharm 41:255-262, 1988.
212. Y Seta, T Otsuka, H Tokiwa, H Naganuma, Y Kawahara, K Nishimura, R Okada. Design of captopril sustained-release preparation with oily semisolid matrix intended for use in human subjects. Int J Pharm 41:263-269, 1988.
213. ET Cole. Liquid filled and sealed hard gelatin capsules. Bull Tech Gattefosse ´No. 92:67-77, 1999.
214. M Duerr, HU Fridolin, KD Gneuss. Entwicklung von rezepturen und verfahren zur abfu ¨llung von flu ¨ssigen massen in hartgelatinekapseln unter produktionsbedin- gungen. Acta Pharm Technol 29:245-251, 1983.
215. D Cade ´, ET Cole, J-Ph Mayer, F Wittwer. Liquid filled and sealed hard gelatin capsules. Acta Pharm Technol 33:97-100, 1987.
216. RA Lucas, WJ Bowtle, R Ryden. Disposition of vancomycin in healthy volunteers from oral solution and semi-solid matrix capsules. J Clin Pharm Ther 12:27-31, 1987.
217. WJ Bowtle, NJ Barker, J Wodhams. A new approach to vancomycin formulation using filling technology for semisolid matrix capsules. Pharm Technol 12:86-97, 1988.
218. C Doelker, E Doelker, P Buri, L Waginaire. The incorporation and in vitro release profile of liquid, deliquescent or unstable drugs with fusible excipients in hard gelatin capsules. Drug Dev Ind Pharm 12:1553-1565, 1986.
219. RF Jimerson. Soft gelatin capsule update. Drug Dev Ind Pharm 12:1133-1144, 1986.
220. KH Bauer. Die herstellung von hart-und weichgelatinekapseln. In: W Fahrig. UH Hofer, eds. Die Kapsel. Stuttgart: Wissenschaftliche Verlags GmbH, 1983, pp. 58- 82.
221. NA Armstrong, KC James, WKL Pugh. Drug migration into soft gelatin capsule shells and its effect on in-vitro availability. J Pharm Pharmacol 36:361-365, 1984.
222. FS Hom, SA Veresh, WR Ebert. Soft gelatin capsules. II. Oxygen permeability study of capsule shells. J Pharm Sci 64 (5):851-857, 1975.
223. WJ Bowtle. Liquid filling of hard gelatin capsules: a new technology for alternative formulations. Pharm Tech Eur 10:84-90, 1998.
224. D Cade ´, N Madit. Liquid filling in hard gelatin capsules-preliminary steps. Bull Tech Gattefosse ´No. 89:15-19, 1996.
225. CM Bond, KA Lees, JL Packington. Cephalexin: a new oral broad-spectrum antibi- otic. Pharm J 205:210-214, 1970.
226. MJ Kontny, CA Mulski. Gelatin capsule brittleness as a function of relative humidity at room temperature. Int J Pharm 54:79-85, 1989.
227. M Dey, R Enever, M Kraml, DG Prue, D Smith, R Weierstall. The dissolution and bioavailability of etodolac from capsules exposed to conditions of high relative hu- midity and temperatures. Pharm Res 10:1295-1300, 1993.
228. Anonymous. Collaborative development of two-tier dissolution testing for gelatin capsules and gelatin-coated tablets using enzyme-containing media. Pharmacopeial Forum 24:7045-7050, 1998. Cole
229. RM Mhatre, H Malinowski, H Nguyen, MC Meyer, AB Straughn, L Lesko, RL Williams. The effects of cross-linking in gelatin capsules on the bioequivalence of acetaminophen. Pharm Res 14:3251, 1997.
230. J Brown, N Madit. ET Cole, IR Wilding, D Cade ´. The effect of cross-linking on the in vivo disintegration of hard gelatin capsules. Pharm Res 15:1026-1030, 1998.
231. SM Chatham. The use of bases in semi-solid matrix formulations. STP Pharma 3: 575-582, 1987.
232. ET Cole. Liquid filled hard gelatin capsules. Pharm Technol Int Sept/Oct 1989, pp. 29-33.
233. F Wittwer. New developments in hermetic sealing of hard gelatin capsules. Pharm Manufac 2:24-27, 1985.
234. USP 23, General Information. Pharmaceutical Dosage Forms 1151, 1995, pp. 1942- 1943. REFERENCES
235. TA Jennings. Lyophilisation-Introduction and Basic Principles. Interpharm Press, 1999, pp. 1-13.
236. Copyright © 2003 Marcel Dekker, Inc. Zydis Oral Fast-Dissolving Dosage Form 201
237. GKE Gregory, DSS Ho. Pharmaceutical dosage form packages. US patent 4,305,502, 1981.
238. GKE Gregory, JM Peach, JD Du Mayne. Articles for carrying chemicals. US patent 4,371,516, 1983.
239. R Green, P Kearney. Process for preparing fast dispersing solid oral dosage form. US patent 5,976,577, 1999.
240. MC Iles, AD Atherton, NM Copping. Freeze-dried dosage forms and methods for preparing the same. US patent 5,188,825, 1993.
241. P Kearney, AR Thompson, RJ Yarwood. Method for manufacturing freeze dried dosages in a multilaminate blister pack. US patent 5,729,958, 1994.
242. N Washington, CG Wilson, JL Greaves, S Norman, JM Peach, KA Pugh. A gamma scintigraphic study of gastric coating by Expidet, tablet and liquid formulations. Int J Pharm 57:17-22, 1989.
243. RJ Yarwood, P Kearney, AR Thompson. Process for preparing solid pharmaceutical dosage forms. US patent 5,837,287, 1998.
244. L Grother, R Green, M Hall, P Kearney. Taste masking in the Zydis freeze dried dosage form. Proceedings of the 17th Pharmaceutical Technology Conference, Dub- lin, 1998, pp. 239-250.
245. AR Thompson, RJ Yarwood, P Kearney. Method of identifying freeze-dried dosage forms. US patent 5,457,895, 1995.
246. A Clarke, F Brewer, ES Johnson, EA Kelly. Proceedings of the 122nd Annual Meet- ing of the American Neurological Association, 1997, M69.
247. R Green, M Hall, F Brewer, J Lacy, N Mallard, S Rowkins, S Taylor, A Clarke, P Kearney. Pharmaceutical aspects relating to pre-gastric absorption from the Zydis dosage form. Proceedings of the 17th Pharmaceutical Technology Conference, Dub- lin, 1998, pp. 10-21.
248. CG Wilson, N Washington, JL Peach, GR Murray, J Kennerley. The behaviour of a fast-dissolving dosage form (Expidet) followed by gamma-scintigraphy. Int J Pharm 40:119-123, 1987.
249. W Habib, R Khankari, J Hontz. Fast-dissolve drug delivery systems. Crit Rev Ther Drug Carr Syst 17:61-72, 2000. Pather et al.
250. F Wehling, S Schuele, N Madamala. Effervescent dosage form with microparticles. US patent 5,178,878, 1993.
251. J Amborn, V Tiger. Apparatus for handling and packaging friable tablets. US patent 6,269,615, 2001.
252. J Amborn, V Tiger. Apparatus for handling and packaging friable tablets. US patent 6,311,462, 2001.
253. LD Katzner, B Jones, J Khattar, J Kosewick. Blister package and packaged tablet. US patent 6,155,423, 2000.
254. RK Khankari, J Hontz, SJ Chastain, L Katzner. Rapidly dissolving robust dosage form. US patent 6,024,981, 2000.
255. RK Khankari, J Hontz, SJ Chastain, L Katzner. Rapidly dissolving robust dosage form. US patent 6,221,392, 2001.
256. H Seager. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 50:375-382, 1998.
257. GKE Gregory, JM Peach, JD Du-Mayne. Articles for carrying chemicals. US patent 4,371,1516, 1983.
258. RJ Yarwood, P Kearney, AR Thompson. Process for preparing solid pharmaceutical dosage forms. US patent 5,738,875, 1998.
259. RC Fuisz, SR Cherukuri. Process and apparatus for making tablets and tablets made therefrom. US patent 5,654,003, 1997.
260. GL Myers, GE Battist, RC Fuisz. Process and apparatus for making rapidly dissolv- ing dosage units and product therefrom. US patent 5,866,163, 1999.
261. RC Fuisz, GE Battist, GL Myers. Method of making crystalline sugar and products resulting therefrom. US patent 5,597,416, 1997.
262. TK Misra, JW Currington, SP Kamath, PP Sanghvi, JR Sisak, MG Raiden. Fast- dissolving comestible units formed under high-speed/light-pressure conditions. US patent 5,869,098, 1999.
263. SR Cherukuri, GL Myers, GE Battist, RC Fuisz. Process for forming quickly dispers- ing comestible unit and product therefrom. US patent 5,587,172, 1996.
264. T Mizumoto, Y Masuda, M Fukui. Intrabuccally dissolving compressed moldings and production process thereof. US patent 5,576,014, 1996.
265. G Cousin, E Bruna, E Gendrot. Rapidly disintegratable multiparticular tablet. US patent 5,464,632, 1995.
266. JM Hebden, PJ Gilchrist, RC Spiller, P Boulby, P Gowland, AC Perkins, CG Wilson. Dispersion, transit, water content and ascending colon volumes in subjects treated with lactulose and codeine: scintigraphic and M.R.I assessment. Neurogastroenterol Motil 175:8, 1996.
267. JM Hebden, E Blackshaw, AC Perkins, CG Wilson, RC Spiller. Limited exposure of the healthy distal colon to orally dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther 14:155-161, 2000.
268. CG Wilson, M Bakhshaee, HE Stevens, AC Perkins, M Frier, PE Blackshaw, JS Binns. Evaluation of a gastro-resistant pulsed release delivery system (Pulsincap) in humans. J Drug Del 4:201-206, 1997.
269. L Barrow, RC Spiller, CG Wilson. Pathological influences on colonic motility: impli- cations for drug delivery. Adv Drug Del Rev 7:201-218, 1991.
270. O Carrette, C Favier, C Mizon, C Neut, A Cortot, JF Colombel, J Mizon. Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease. Dig Dis Sci 40:2641-2646, 1995.
271. N Washington, C Washington, CG Wilson. Colon and rectal delivery. In: N Washing- ton, C Washington, CG Wilson, eds. Physiological Pharmaceutics: Barriers to Drug Absorption. London: Taylor & Francis: 2001, pp. 143-180.
272. JG Hardy, DF Evans, I Zaki, AG Clark, HH Tonnenson, ON Gamst. Evaluation of an enteric-coated tablet using gamma scintigraphy and pH monitoring. Int J Pharm 37:245-250, 1987.
273. A Tomlin, NW Read, CA Edwards, BI Duerden. The degradation of guar gum by a fecal incubation system. Br J Nutr 55:481-486, 1986.
274. D Wong, S Larrabee, K Clifford, J Tremblay, DR Friend. USP dissolution apparatus III (reciprocating cylinder) for screening of guar-based colonic delivery formula- tions. J Control Rel 47:173-179, 1997.
275. YSR Krishnaiah, S Satyanarayana, YVR Prasad, SN Rao. Gamma scintigraphic studies on guar gum matrix tablets for colonic drug delivery in healthy human volun- teers. J Control Rel 55:245-252, 1998.
276. A Rubinstein, I Gliko-Kabir. Synthesis and swelling dependent enzymatic degrada- tion of borax modified guar gum for colonic delivery purposes. STP Pharma Sci 5: 41-46, 1995.
277. A Rubinstein, D Nakar, A Sintov. Colonic drug delivery: enhanced release of indo- methacin from cross-linked chondroitin matrix in rat cecal content. Pharm Res 9: 276-278, 1992.
278. M Ashford, J Fell, D Attwood, H Sharma, P Woodhead. Studies on pectin formula- tions for colonic drug delivery. J Control Rel 30:225-232, 1994. Mukherji and Wilson
279. P Sriamornsak, S Prakongpan, S Puttipipatkhachorn, RA Kennedy. Development of sustained release theophylline pellets coated with calcium pectinate. J Control Rel 47:221-232, 1997.
280. Z Wakerly, JT Fell, D Attwood, D Parkins. Pectin/ethylcellulose film coating formu- lations for colonic drug delivery. Pharm Res 13:1210-1212, 1996.
281. O Munjeri, JH Collett, JT Fell. Hydrogel beads based on amidated pectins for colon- specific drug delivery: the role of chitosan in modifying drug release. J Control Rel 46:273-278, 1997.
282. DA Adkin, CJ Kenyon, EI Lerner, I Landau, E Strauss, D Caron, A Penhasi, A Rubinstein, IR Wilding. The use of scintigraphy to provide "proof of concept" for novel polysaccharide preparations designed for colonic drug delivery. Pharm Res 14:103-107, 1997.
283. S Milojevic, JM Newton, JH Cummings, GR Gibson, RL Botham, SG Ring, M Stockham, MC Allwood, Amylose as a coating for drug delivery to the colon: prepa- ration and in vitro evaluation using 5-aminosalicylic acid pellets. J Control Rel 38: 75-84, 1996.
284. SG Ring, DB Archer, MC Allwood, JM Newton. Delayed release formulations. US patent 5,294,448, 1994.
285. L Cartilier, I Moussa, C Chebli, S Buczkowski. Substituted amylose as a matrix for sustained drug release. US patent 5,879,707, 1999.
286. L Simonsen, L Hovgaard, PB Mortensen, H Brondsted. Dextran hydrogels for colon- specific drug delivery. 5. Degradation in human intestinal incubation models. Eur J Pharm Sci 3:329-337, 1995.
287. L Hovgaard, H Brondsted. Dextran hydrogels for colon-specific drug delivery. J Control Rel 36:159-166, 1995.
288. P Watts. Colonic drug delivery composition. US patent 6,228,396, 2001.
289. S Tominaga, T Takizawa, M Yamada. Large intestinal delivery composite. US patent 6,248,362, 2001.
290. WE Wood, NJ Beaverson. Barrier material comprising a thermoplastic and a com- patible cyclodextrin derivative. US patent 6,218,013, 2001.
291. K Uekama, K Minami, F Hirayama. 6(A)-O-[(4-biphenylyl)acetyl]-alpha-, beta-and gamma-cyclodextrins and 6(A)-deoxy-6(A)-[[(4-biphenylyl)acetyl]-amino]-alpha-, beta-and gamma-cyclodextrins: potential prodrugs for colon-specific delivery. Med Chem 40:2755-2761, 1997.
292. V Siefke, HP Weckenmann, KH Bauer. β-Cyclodextrin matrix films for colon- specific drug delivery. Proc Int Symp Control Rel Bioact Mater 20:182-183, 1993.
293. L Vervoort, R Kinget. In vitro degradation by colonic bacteria of inulin HP incorpo- rated in Eudragit RS films. Int J Pharm 129:185-190, 1996.
294. L Vervoort, G Vanden Mooter, P Augustins, R Bousson, S Toppet, R Kinget. Inulin hydrogels as carriers for colonic drug targeting. I. Synthesis and characterization of methacrylated inulin and hydrogen formation. Pharm Res 14:1730-1737, 1997.
295. L Vervoort, P Rombaut, G Vanden Mooter, P Augustins, R Kinget. Inulin hydrogels. II. In vitro degradation study. Int J Pharm 172:137-145, 1998.
296. EP Kakoulides, JD Smart, J. Tsibouklis. Azocrosslinked poly(acrylic acid) for co- lonic delivery and adhesion specificity: in vitro degradation and preliminary ex vivo bioadhesion studies. J Control Rel 54:95-109, 1998.
297. GL Amidon, GD Leesman. Pulsatile drug delivery system. US patent 5,229,131, 1993.
298. GL Amidon, GD Leesman, LB Sherman. Multi-stage drug delivery system. US patent 5,387,421, 1995.
299. GL Amidon, JR Crison. Method for making multi-stage drug delivery system. US patent 5,674,530, 1997.
300. JR Crison, GL Amidon. Method for making multi-stage drug delivery system. US patent 5,976,571, 1999.
301. JR Crison, GL Amidon. Multi-stage drug delivery system. US patent 6,207,191, 1999. REFERENCES
302. HNE Stevens. Chronopharmaceutical drug delivery. J Pharm Pharmacol 50:S5, 1998.
303. A Rashid. Dispensing device. EP 0,384,642, 1990.
304. IR Wilding, SS Davis, M Bakhshaee, HNE Stevens, RA Sparrow, J Brennan. Gastro- intestinal transit and systemic absorption of captopril from a pulsed-release formula- tion. Pharm Res 9:654-657, 1992.
305. ME McNeill, A Rashid, HNE Stevens. Drug dispensing device. GB patent, 2,230,442, 1993.
306. JS Binns, M Bakhshaee, CJ Miller, HNE Stevens. Application of a pH independent PEG based hydrogel to afford pulsatile delivery. Proc Int Symp Control Rel Bioact Mater 20:226-227, 1993.
307. M Bakhshaee, JS Binns, HNE Stevens, CJ Miller. Pulsatile drug delivery to the colon monitored by gamma scintigraphy. Pharm Res 9(suppl):F230, 1992.
308. JM Hebden, CG Wilson, RC Spiller, PJ Gilchrist, PE Blackshaw, M Frier, AC Per- kins. Regional differences in quinine absorption from the undisturbed human colon assessed using a timed release delivery system. Pharm Res 16:1087-1092, 1999.
309. JS Binns, HNE Stevens, J McEwen, G Pritchard, FM Brewer, A Clarke, ES Johnson, I McMillan. The tolerability of multiple oral doses of Pulsincap capsules in healthy volunteers. J Control Rel 38:151-158, 1996.
310. HNE Stevens, JS Binns, MI Guy. Drug expelled from oral delivery device by gas. International patent application WO 95/17173, 1995.
311. HNE Stevens, A Rashid, M Bakhshaee, JS Binns, CJ Miller. Expulsion of material from a delivery device. US patent 5,897,874, 1999.
312. M Hegarty, G Atkins. Controlled release device. International patent application WO 95/10263A1, 1995.
313. HNE Stevens, A Rashid, M Bakhshaee. Drug dispensing device. US patent 5,474,784, 1995.
314. AC Ross, RJ MacRae, M Walther, HNE Stevens. Chronopharmaceutical drug deliv- ery from a pulsatile capsule device based on programmable erosion. J Pharm Phar- macol 52:903-909, 2000.
315. I Kro ¨gel, R Bodmeier. Pulsatile drug release from an insoluble capsule body con- trolled by an insoluble plug. Pharm Res 15:474-481, 1998.
316. HNE Stevens, AC Ross, JR Johnson. The hydrophilic sandwich (HS) capsule: a convenient time-delayed oral probe device. J Pharm Pharmacol 52:S41, 2000.
317. S Soutar, B O'Mahony, M Bakhshaee, AC Perkins, T Grattan, CG Wilson, HNE Stevens. Pulsed release of paracetamol from the hydrophilic sandwich (HS) capsule. Proc Int Symp Control Rel Bioact Mater 28:790-791, 2001.
318. P Buri. Formes Pharmaceutiques Nouvelles. Paris: Lavosier Technique et Documenta- tion, 1985.
319. SL Krill. The Drug Delivery Companies Report. Pharma Ventures. Oxford, England, 2000, pp. 43-45.
320. ES Prosser. The road to drug delivery. Chem Ind 19:632-634, 2000.
321. N Rouge, P Buri, E Doelker. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int J Pharm 136:117-139, 1996. Prior et al.
322. IR Wilding. Site-specific delivery in the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst 17:557-622, 2000.
323. IR Wilding. In search of a simple solution for complex molecules. Scrip Magazine May:9-11, 2001.
324. G Gwinup, AN Elias, ES Domurat. Insulin and C-peptide levels following oral ad- ministration of insulin in intestinal-enzyme protected capsules. Gen Pharmac 22: 243-246, 1990.
325. IR Wilding. Evolution of the Biopharmaceutics Classification System (BCS) to oral modified release (MR) formulations: what do we need to consider? Eur J Pharm Sci 8:157-159, 1999.
326. Ophthalmic Drug Facts. St. Louis, MO: Facts and Comparisons. A Wolters Kluwer Company, 2000.
327. JS Cumming. Relevant anatomy and physiology of the eye. In: JR Robinson. ed. Ophthalmic Drug Delivery Systems. Washington, DC: American Pharmaceutical Association, 1980, pp. 1-27.
328. JL Greaves. Ocular drug delivery. In: CG Wilson, N Washington, eds. Physiologi- cal Pharmaceutics: Biological Barriers to Drug Absorption. Chichester: Ellis Hor- wood Ltd., 1989, pp. 121-138.
329. JC Robinson. Ocular anatomy and physiology relevant to ocular drug delivery. In: AK Mitra, ed. Ophthalmic Drug Delivery Systems. New York: Marcel Dekker, 1993, pp. 29-57.
330. J Stjernschantz, M Astin. Physiological aspects of ocular drug therapy. In: P Edman, ed. Biopharmaceutics of Ocular Drug Delivery. Boca Raton, FL CRC Press, 1993, pp. 1-25.
331. SS Chrai, TF Patton, A Mehta, JR Robinson. Lacrimal and instilled fluid dynamics in rabbit eye. J Pharm Sci 62:1112-1121, 1973.
332. A Ludwig, M Van Ooteghem. The influence of the drop size on the elimination of an ophthalmic solution from the precorneal area of human eyes. Pharm Acta Helv 62:56-60, 1987.
333. MM Van Ooteghem. Factors influencing the retention of ophthalmic solutions on the eye surface. In: MF Saettone, G Bucci, P Speiser, eds. Ophthalmic Drug Deliv- ery: Biopharmaceutical, Technological and Clinical Aspects. Fidia Research Series, Vol. 11, Padova, Italia: Liviana Press, 1987, pp. 7-17.
334. WL White, AT Glover, AB Buckner. Effect of blinking on tear elimination as eval- uated by dacryoscintigraphy. Ophthalmology 98:367-369, 1991.
335. VHL Lee. Precorneal, corneal and postcorneal factors. In: AK Mitra, ed. Ophthal- mic Drug Delivery Systems. New York: Marcel Dekker, 1993, pp. 59-81.
336. NEML Tang, PL Zuure, RD Pardo, RJW de Keizer, JA Van Best. Reflex lacrima- tion in patients with glaucoma and healthy control subjects by fluorophotometry. Invest Ophthalmol Vis Sci 41:709-714, 2000.
337. I Ahmed, TF Patton. Importance of non corneal absorption route in topical ophthal- mic drug delivery. Invest Ophthalmol Vis Sci 26:584-587, 1985.
338. RD Schoenwald, GS Deshpande, DG Rethwisch, CF Barfknecht. Penetration into the anterior chamber via the conjunctival/scleral pathway. J Ocul Pharmacol Ther 13:41-59, 1997.
339. Pilocarpine (monograph Nr 7578). In: SB Budavari, ed. The Merck Index. 12th ed. Whitehouse Station, NJ: Merck & Co, 1996, pp. 1277.
340. JR Robinson. Ocular drug delivery mechanism(s) of corneal drug transport and mucoadhesive delivery systems. STP Pharma Sci 5:839-846, 1989.
341. D Maurice. The effect of the low blink rate in rabbits on topical drug penetration. J Ocul Pharmacol Ther 11:297-303, 1995.
342. MF Sugrue. The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J Ocul Pharmacol Ther 12:363-376, 1996.
343. K Schmitz, P Banditt, M Motschmann, FP Meyer, W Bebrens-Baumann. Popula- tion pharmacokinetics of 2% topical dorzolamide in the aqueous humor of humans. Invest Ophthalmol Vis Sci 40:1621-1624, 1999.
344. A Ludwig, M Van Ooteghem. The study of the precorneal dynamics of ophthalmic solutions by fluorophotometry. Pharm Acta Helv 61:236-240, 1986.
345. CG Wilson. Scintigraphic evaluation of polymeric formulations for ophthalmic use. In: MF Saettone, G Bucci, P Speiser, eds. Ophthalmic Drug Delivery: Biopharma- ceutical, Technological and Clinical Aspects. Fidia Research Series, Vol. 11. Pa- dova, Italia: Liviana Press, 1987, pp. 141-150.
346. JL Greaves, CG Wilson, A Rozier, J Grove, B Plazonnet. Scintigraphic assessment of an ophthalmic gelling vehicle in man and rabbit. Curr Eye Res 9:415-420, 1990.
347. G Meseguer, R Gurny, P Buri, A Rozier, B Plazonnet. Gamma scintigraphic study of precorneal drainage and assessment of miotic response in rabbits of various oph- thalmic formulations containing pilocarpine. Int J Pharm 95:229-234, 1993. Plazonnet
348. G Meseguer, P Buri, B Plazonnet, A Rozier, R Gurny. Gamma scintigraphic com- parison of eyedrops containing pilocarpine in healthy volunteers. J Ocul Pharmacol Ther 12:481-488, 1996.
349. G Vaidyanathan, M Jay, RK Bera, PR Mayer, RK Brazzell. Scintigraphic evalua- tion of the ocular disposition of 18 F-imirestat in rabbits. Pharm Res 7:1198-1200, 1990.
350. NJC Bauer, M Motamedi, JP Wicksted, WF March, CAB Webers, F Hendrikse. Non-invasive assessment of ocular pharmacokinetics using confocal Raman spec- troscopy. J Ocul Pharmacol Ther 15:123-134, 1999.
351. DDS Tang-Liu, A Acheampong, DS Chien, JI Usansky. Pharmacokinetics and pharmacodynamic correlations of ophthalmic drugs. In: J Reddy, ed. Ocular Thera- peutics and Drug Delivery: A Multiplisciplinary Approach. Lancaster, PA: I-Tech- nomic Publishing Co., 1996, pp. 133-147.
352. B Plazonnet. Ophthalmics. In: Bioequivalence of special dosage forms. Kurz nr 442 APV symposium. Berlin, April 3, 2000. Arbeitsgemeinschaft fu ¨r Pharmaceutische Verfahrenstechnik e.v., Kurfurstenstrasse 59-D55118, Mainz.
353. JH Draize, G Woodard, HO Calvery. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther 82:377-390, 1944.
354. FDA Illustrated Guide for Grading Eye Irritation by Hazardous Substances. Wash- ington, DC: Government Printing Office, 1965.
355. IPEC Europe Safety Committee. The proposed guidelines for the safety evaluation of new excipients. Eur Pharm Rev 2:13-20, 1997.
356. JR Robinson, ed. Ophthalmic Drug Delivery Systems. Washington, DC: American Pharmaceutical Association, 1980.
357. VHL Lee, JR Robinson. Review: Topical drug delivery: recent developments and future challenges. J Ocul Pharmacol 2:67-108, 1986.
358. MF Saettone, G Bucci, P Speiser, eds. Ophthalmic Drugs Delivery: Biopharmaceu- tical, Technological, Clinical Aspects. Fidia Research Series, Vol. 11. Padova, Italia: Liviana Press, 1987.
359. VHL Lee. Review: New directions in the optimization of ocular drug delivery. J Ocul Pharmacol 6:157-164, 1990.
360. P Edman. Biopharmaceutics of Ocular Drug Delivery. Boca Raton, FL: CRC Press, 1993.
361. AK Mithra, ed. Ophthalmic Drug Delivery Systems. New York: Marcel Dekker, 1993.
362. M Van Ooteghem, ed. Pre ´parations Ophtalmiques, Paris: Technique & Documenta- tion, 1995.
363. JP Frangie. Clinical pharmacokinetics of various topical ophthalmic delivery sys- tems. Clin Pharmacokin 29:130-138, 1995.
364. C Le Bourlais, L Acar, H Zia, PA Sado, T Needham, R Leverge. Ophthalmic drug delivery systems-recent advances. Prog Ret Eye Res 17:33-58, 1998.
365. S Ding. Recent developments in ophthalmic drug delivery. Pharm Sci Technol To- day 8:328-335, 1998.
366. WC Stewart. Timolol hemihydrate: a new formulation of timolol for the treatment of glaucoma. J Ocul Pharmacol Ther 12:225-236, 1996.
367. O Felt, P Buri, R Gurny. Chitosan: a unique polysaccharide for drug delivery. Drug Dev Ind Pharm 24:979-993, 1998.
368. O Felt, P Furrer, JM Mayer, B Plazonnet, P Buri, R Gurny. Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention. Int J Pharm 180:185-193, 1999.
369. O Felt, A Carrel, P Baehni, P Buri, R Gurny. Chitosan as tear substitute: a wetting agent endowed with antimicrobial efficacy. J Ocul Pharmacol Ther 16:261-270, 2000.
370. HE Schaeffer, DL Krohn. Liposomes in topical drug delivery. Invest Ophthal Vis Sci 22:220-227, 1982.
371. JM Gu, JR Robinson, SHS Leung. Binding of acrylic polymers to mucin/epithelial surfaces: structures-property relationships. Crit Rev Ther Drug Carr Syst 5:21-67, 1988.
372. NM Davies, SJ Farr, J Hadgraft, IW Kellaway. Evaluation of mucoadhesive poly- mers in ocular drug delivery. I. Viscous solutions. Pharm Res 8:1039-1043, 1991.
373. EM Slovin, JR Robinson. Bioadhesives in ocular drug delivery. In: P Edman, ed. Biopharmaceutics of Ocular Drug Delivery. Boca Raton, FL: CRC Press, 1993, pp. 145-157.
374. R Krishmamoorthy, AK Mitra. Mucoadhesive polymers in ocular drug delivery. In: AK Mitra, ed. Ophthamic Drug Delivery Systems. New York: Marcel Dekker, 1993, pp. 199-221.
375. MF Saettone, D Monti, MT Torracca, P Chetoni. Mucoadhesive ophthalmic vehi- cles: evaluation of polymeric low-viscosity formulations. J Ocul Pharmacol 10:83- 92, 1994.
376. F Thermes, J Grove, G Chastaing, A Rozier, K Soper, B Plazonnet. Effects of a mucolytic agent, acetylcysteine, on bioadhesion and ocular penetration. STP Pharma Sci 2:88-92, 1992.
377. R Patel. US patent 5,340,572, 1994.
378. JA Schulman, GA Peyman. Intracameral, intravitreal and retinal drug delivery. In: AK Mitra, ed. Ophthalmic Drug Delivery Systems. New York: Marcel Dekker, 1993, pp. 383-425.
379. DC Metrikin, R Anand. Intravitreal drug administration with depot devices. Curr Opin Ophthalmol 5:21-29, 1994.
380. P Ashton, DL Blandford, PA Pearson, GJ Jaffe, DF Martin, RB Nussenblatt. Re- view: Implants. J Ocul Pharmacol 10:691-701, 1994.
381. Ganciclovir intravitreal implant (Vitrasert). In: Ophthalmic Drug Facts. St. Louis, MO: Facts and Comparisons. A Wolters Kluwer Co., 2000, pp. 150-153.
382. P Ashton, JD Brown, PA Pearson, DL Blandfor, TJ Smith, R Anand, SD Nightin- gale, GE Sanborn. Intravitreal ganciclovir pharmacokinetics in rabbits and man. J Ocul Pharmacol 8:343-347, 1992.
383. T Yasukawa, H Kimura, N Kunou, H Miyamoto, Y Honda, Y Ogura, Y Ikada. Biodegradable scleral implant for intravitreal controlled release of ganciclovir. Graefes Arch Clin Exp Ophthalmol 238:186-190, 2000.
384. DT Tan, SP Chee, L Lim, AS Lim. Randomized clinical trial of a new dexametha- sone delivery system (Surodex) for treatment of post-cataract surgery inflammation. Ophthalmology 106:223-231, 1999.
385. A Acheampong, M Shackleton, S Lam, P Rudewiez, D Tang-Liu. Cyclosporine distribution into the conjuctiva, cornea, lacrimal gland, and systemic blood follow- ing topical dosing of cyclosporine to rabbit, dog, and human eyes. Adv Exp Med Biol 438:1001-1004, 1998.
386. A Acheampong, M Shackleton, D Tang-Liu, S Ding, M Stern, R Decker. Distribu- tion of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs. Curr Eye Res 18:91-203, 1999.
387. D Stevenson, J Tauber, BL Reis. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose ranging, randomized trial: the cyclosporin A phase 2 study group. Ophthalmology 107:967- 974, 2000.
388. BA Klyashchitzky, AJ Owen. Drug delivery systems for cyclosporine: achieve- ments and complications. J Drug Target 5:443-458, 1998.
389. O Angelov, A Wiese, Y Yuan, J Anderson, A Acheampong, B Brar. Preclinical safety studies of cyclosporine ophthalmic emulsion. Adv Exp Med Biol 438:991- 995, 1998.
390. T Loftssona, T Jarvinen. Cyclodextrins in ophthalmic drug delivery. Adv Drug Del Rev 1:59-79, 1999.
391. DC Bibby, NM Davies, IG Tucker. Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. Int J Pharm 197:1-11, 2000.
392. E Guomundstottir, E Stefansson, G Bjarnadottir, JF Sigurjonsdottir, G Guomuns- dottir, M Masson, T Loftsson. Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension. Invest Ophthalmol Vis Sci 41:3552-3554, 2000.
393. JK Kristinsson, H Fridriksdottir, S Thorisdottir, AM Sigurdardottier, E Stefansson, T Loftsson. Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans. Invest Ophthalmol Vis Sci 37:1199-1203, 1996.
394. NM Davies, G Wang, IG Tucker. Evaluation of a hydrocortisone/hydroxypropyl- β-cyclextrin solution for ocular drug delivery. Int J Pharm 156:201-209, 1997.
395. J Grove, MP Quint, B Plazonnet. Influence of β-cyclodextrin on intraocular penetra- tion of the topical carbonic anhydrase inhibitor, L-671-152 in rabbits. Poster pre- sented at 5th International Symposium on Cyclodextrins, Paris, March 28-30, 1990.
396. M Diestelhorst, S Grunthal, R Suverkrup. Dry drops: a new preservative-free drug delivery system. Graefes Arch Clin Exp Ophthalmol 237:394-398, 1999.
397. SD Alain. The ophthalmic rod: description of a disposable ophthalmic drug delivery device. Acta Pharm. Suec 15:237-240, 1978.
398. DL Meadows. US patent 5,173,298, 1992.
399. DL Meadows. US patent 5,518,731, 1996.
400. Y Zhu, CG Wilson, D Meadows, O Olejnik, M Frier, N Washington, R Musson. Dry powder dosing in liquid vehicles: ocular tolerance and scintigraphic evaluation of a perfluorocarbon suspension. Int J Pharm 191:79-85, 1999.
401. EA Doe, JA Campagna. Pilocarpine spray: an alternative delivery method. J Ocul Pharmacol Ther 14:1-4, 1998.
402. HE Kaufman, AR Gasset. Therapeutic soft bandage lenses. Int Ophthalmol Clin 10: 379-385, 1970.
403. SR Waltman, HE Kaufman. Use of hydrophilic contact lenses to increase ocular penetration of topical drugs. Invest Ophthalmol 9:250-255, 1970.
404. HE Kaufman, MH Uotila, AR Gasset. The medical uses of soft contact lenses. Trans Am Acad Ophthalmol Otolaryngol 75:361-373, 1971.
405. JW Aquavella, GK Jackson, LF Guy. Therapeutic effects of bionite lenses: mecha- nisms of action. Ann Ophthalmol 3:1341-1345, 1971.
406. YT Maddox, HN Bernstein. An evaluation of bionite hydrophilic contact lens for use in a drug delivery system. Ann Ophthalmol 4:789-790, 1972.
407. SM Podos, B Becker, CF Asseff, J Harlstein. Pilocarpine therapy with soft contact lenses. Am J Ophthalmol 73:336-341, 1972.
408. CF Assef, RL Weisman, SM Podos. Ocular penetration of pilocarpine in primates. Am J Ophthalmol 75:212-215, 1973.
409. FE Leaders, G Hecht, M VanHoose, M Kellog. New polymers in drug delivery. Ann Ophthalmol 5:513-516, 1973.
410. AI Mandell, RM Stewart, MA Kass. Multiclinic evaluation of a pilocarpine gel. Invest Ophthalmol Vis Sci April (Suppl): 1979 (abstract).
411. U Ticho, M Blumenthal, S Zonis, A Gal, I Blank, ZW Mazor. A clinical trial with piloplex; a new long-acting pilocarpine compound: preliminary report. Ann Ophthal- mol 11:555-561, 1979.
412. A Mazor, U Ticho, U Rehany, L Rose. Piloplex, a new long acting pilocarpine polymer salt. B. Comparative study of the visual effects of pilocarpine and piloplex eye drops. Br J Ophthalmol 63:48-51, 1979.
413. U Ticho, M Blumenthal, S Zonis, A Gal, I Blank, ZW Mazor. Piloplex, a new long acting pilocarpine polymer salt: a long term study. Br J Ophthalmol 63:45-47, 1979.
414. JW Shell, RW Baker. Diffusional systems for controlled release of drugs to the eye. Ann Ophthalmol 6:1037-1043, 1974.
415. S Lerman, P Davis, WB Jackson. Prolonged release hydrocortisone therapy. Can J Ophthalmol 8:114-118, 1973.
416. CH Dohlman, D Pavan-Langston, J Rose. A new ocular insert device for continuous constant-rate delivery of medication to the eye. Ann Ophthalmol 4:823-832, 1972. REFERENCES
417. R Lloyd. Applicators for pharmacologically active agents, their preparation and use. UK patent 2,097,680, 1985.
418. P Fitzgerald, CG Wilson, JL Greaves, M Frier, D Hollingsbee, D Gilbert, M Richard- son. Scintigraphic assessment of the precorneal residence of new ophthalmic delivery system (NODS) in man. Int J Pharm 83:177-185, 1992.
419. JL Greaves, CG Wilson, AT Birmingham, PH Bentley, M Richardson. Scintigraphic studies on the corneal residence of a new ophthalmic delivery system (NODS): rate of clearance of a soluble marker in relation to duration of pharmacological action of pilocarpine. Br J Clin Pharmacol 33:603-609, 1992.
420. MC Richardson. An investigation of tropicamide NODS compared with tropicamide solution in human volunteers. Poster at the 9th Pharmaceutical Technology Confer- ence, Veldhoven, The Netherlands, 1990.
421. DA Hollingsbee, K Hughes, D Gilbert. A comparison of the human ocular bioavail- ability of chloramphenicol administered as a solution, an ointment and a water soluble polymeric film insert. Poster at the International Symposium on Ophthalmic Drug Delivery, Pisa, Italy, 1986.
422. JA Kelly, PD Molyneux, SA Smith, SE Smith. Relative bioavailability of pilocarpine from a novel ophthalmic delivery system and conventional eye drop formulations. Br J Ophthalmol 73:360-362, 1989.
423. MC Richardson, PH Bentley. A new ophthalmic delivery system. In: AK Mitra, ed. Ophthalmic Drug Delivery Systems. New York: Marcel Dekker, 1993, pp. 355-367.
424. F Gurtler, R Gurny. Insert ophtalmique bioadhe ´sif. European patent 934 00677-61, 1993.
425. F Gurtler, V Kaltsatos, B Boisrame ´, R Gurny. Development of a novel soluble oph- thalmic insert: evaluation of ocular tolerance in rabbits. Eur J Pharm Biopharm 42: 393-398, 1996.
426. F Gurtler, V Kaltsatos, B Boisrame ´, R Gurny. Long-acting soluble bioadhesive oph- thalmic drug insert (BODI) containing gentamicin for veterinary use: optimization and clinical investigation. J Control Rel 33:231-236, 1995.
427. F Gurtler, V Kaltsatos, B Boisrame ´, J Deleforge, M Gex-Fabry, LP Balant, R Gurny. Ocular availability of gentamicin in small animals after topical administration of a conventional eye drop solution and a novel long acting bioadhesive ophthalmic drug insert. Pharm Res 12:1791-1795, 1995.
428. V Baeyens, V Kaltsatos, B Boisrame ´, M Fathi, R Gurny. Evaluation of soluble bio- adhesive ophthalmic drug inserts (BODI) for prolonged release of gentamicin: lacry- mal pharmacokinetics and ocular tolerance. J Ocul Pharmacol Ther 14:263-272, 1998.
429. PI Punch, DH Slatter, ND Costa, ME Edwards. Investigation of gelatin as a possible biodegradable matrix for sustained delivery of gentamicin to the bovine eye. J Vet Pharmacol Ther 8:335-338, 1985.
430. FQ Liang, RS Viola, M DelCerro, JV Aquavella. Non cross-linked collagen discs and cross-linked collagen shields in the delivery of gentamicin to rabbit eyes. Invest Ophthalmol Vis Sci 33:2194-2198, 1992.
431. RB Phinney, D Schwartz, DA Lee, BJ Mondino. Collagen-shield delivery of genta- micin and vancomycin. Arch Ophthalmol 106:1599-1604, 1988.
432. SE Bloomfield, T Miyata, MW Dunn, N Bueser, KH Stenzel, AL Rubin. Soluble gentamycin ophthalmic inserts as a drug delivery system. Arch Ophthalmol 96:885- 887, 1978.
433. V Baeyens, V Kaltsatos, B Boisrame ´, E Varesio, J-L Veuthey, M Fathi, LP Balant, M Gex-Fabry, R Gurny. Optimized release of dexamethasone and gentamicin from a soluble ocular insert for the treatment of external ophthalmic infections. J Control Rel 52:215-220, 1998.
434. R Gurny, V Kaltsatos, V Baeyens, B Boisrame ´. Therapeutic or hygienic composi- tions with controlled and prolonged release of the active principles, in particular for ophthalmic use. WO 98/56346, 1998.
435. GA Stern, M Buttross. Use of corticosteroids in combination with antimicrobial drugs in the treatment of infectious corneal disease. Ophthalmology 98:847-853, 1991.
436. F Gurtler, R Gurny. Patent literature review of ophthalmic inserts. Drug Dev Ind Pharm 21:1-18, 1995.
437. CA Lesch, CA Squier, AH Cruchley, DM Williams, PM Speight. The permeability of human oral mucosa and skin to water. J Dent Res 68:1345-1349, 1989.
438. HE Schroeder. Differentiation of Human Oral Stratified Epithelium. Basel: S Karger, 1981, p. 33.
439. CA Squier, NW Johnson, RM Hopps. Human Oral Mucosa: Development, Structure and Function. Oxford: Blackwell Scientific, 1976.
440. LMC Collins, C Dawes. The surface area of the adult human mouth and the thickness of the salivary film covering the teeth and oral mucosa. J Dent Res 66:1300-1302, 1987.
441. CA Squier. Membrane coating granules in nonkeratinized oral epithelium. J Ultra- struct Res 60:212-220, 1977.
442. AF Hayward. Membrane coating granules. Int Rev Cytol 59:97-127, 1979.
443. PW Wertz, DC Swartzendruber, CA Squier. Regional variation in the structure and permeability of oral mucosa and skin. Adv Drug Del Rev 12:1-12, 1993.
444. PB Innes. The nature of granules within sulcular epithelial cells. J Periodont Res 8: 252-262, 1973.
445. S Silverman Jr. Nonkeratinization and keratinization: the extremes of the human range. In: CA Squier, J Meyer, eds. Current Concepts of the Histology of Oral Mu- cosa. Springfield, IL: Charles C Thomas, 1971.
446. AF Hayward. Electron microscopic observations on cell coat and membrane-coating granules of the epithelium of the hard and soft palate in the rat. Arch Oral Biol 18: 67-75, 1973.
447. CA Squier, PW Wertz, P Cox. Thin-layer chromatographic analysis of lipids in dif- ferent layers of porcine epidermis and oral epithelium. Arch Oral Biol 36:647-653, 1991.
448. WM Edgar. Saliva: its secretion, composition and functions. Br Dent J 172:305- 312, 1992.
449. ID Mandel, S Wotman. The salivary secretions in health and disease. Oral Sci Rev 8:25-47, 1976.
450. LA Tabak, MJ Levine, ID Mandel, SA Ellison. Role of salivary mucins in the protec- tion of the oral cavity. J Oral Pathol 11:1-17, 1982.
451. I Lindqvist, KB Augustinsson. Esterases in human saliva. Enzyme 20:277-291, 1975.
452. LB Hansen, LL Christup, H Bundgaard. Saliva-catalysed hydrolysis of a ketobemi- done ester: factors influencing human salivary esterase activity. Int J Pharm 88:221- 227, 1991.
453. LB Hansen, LL Christup, H Bundgaard. Ketobemidone prodrugs for buccal delivery: prediction of the extent of saliva-catalysed hydrolysis of various ester prodrugs under simulated in vivo conditions. Int J Pharm 88:229-235, 1992.
454. CA Squier. The permeability of keratinized and non-keratinized oral epithelium to horseradish peroxidase. J Ultrastruct Res 43:160-177, 1973.
455. CA Squier, L Rooney. The permeability of keratinized and non-keratinized oral epi- thelium to lanthanum in vivo. J Ultrastruct Res 54:286-295, 1976.
456. G Ponchel. Formulation of oral mucosal drug delivery systems for the systemic delivery of bioactive materials. Adv Drug Del Rev 13:75-87, 1994.
457. A Sobrero. Sur plusieurs compose ´s de ´tonnants produits avec l'acide nitrique et le sucre, la dextrine, la lactine, la mannite et la glyce ´rine. Compt Rend Hebdomad Se ´ances Acad Sci 24:247-248, 1847.
458. TH Stanley, MA Ashburn. Novel delivery systems: oral transmucosal and intranasal transmucosal. J Pain Sympt Manage 7:163-171, 1992.
459. M Lagas, AMJA Duchateau. Sublingual nitroglycerin. I. Comparative evaluation of the physical stability of commercially available tablets. Pharmaceutisch Weekblad Sci Ed 10:246-253, 1988.
460. M Lagas, AMJA Duchateau. Sublingual nitroglycerin. II. In vitro and in vivo avail- ability of Nitrostat and Nitrobaat tablets. Pharmaceutisch Weekblad Sci Ed 10:254- 258, 1988.
461. DH Maddox, BA Burnside, AD Keith. Buccal delivery of progesterone. Proc Int Symp Control Rel Bioact Mater 17:291-292, 1990.
462. CG Wilson, N Washington, J Peach, GR Murray. J Kennerley. The behaviour of a fast-dissolving dosage form (Expidet) followed by γ-scintigraphy. Int J Pharm 40: 119-123, 1987.
463. BA Burnside, AD Keith, W Snipes. Microporous hollow fibers as a peptide delivery system via the buccal cavity. Proc Int Symp Control Rel Bioact Mater 16:93-94, 1989.
464. G Ponchel, D Duche ˆne. Development of a bioadhesive tablet. In M Szycher, ed. High Performance Biomaterials: A Comprehensive Guide to Medical and Pharmaceutical Applications. Lancaster: Technomic, 1992, pp. 231-242.
465. MJ Rathbone, G Ponchel, F Ghazali. Systemic oral mucosal drug delivery and deliv- ery systems. In: MJ Rathbone, ed. Oral Mucosal Drug Delivery. New York: Marcel Dekker, 1996, pp. 241-284.
466. KV Ranga Rao, A Ben-Amor, P Buri. Studies on buccoadhesive tablet formulation of codeine phosphate. STP Pharma 5:899-903, 1989.
467. Y Jacques, D Chulia, A Verain, P Ozil. A propos d'un comprime ´mucoadhe ´sif des- tine ´a `la cavite ´buccale. Pharm Acta Helv 64:163-167, 1989.
468. G Ponchel, F Touchard, D Duche ˆne, NA Peppas. Bioadhesive analysis of controlled- release systems. I. Fracture and interpenetration analysis in poly(acrylic acid)-con- taining systems. J Control Rel 5:129-141, 1987.
469. NA Peppas, G Ponchel, D Duche ˆne. Bioadhesive analysis of controlled-release sys- tems. II. Time-dependent bioadhesive stress in poly(acrylic acid)-containing sys- tems. J Control Rel 5:143-149, 1987.
470. G Ponchel, F Touchard, D Wouessidjewe, D Duche ˆne, NA Peppas. Bioadhesive analysis of controlled-release systems. III. Bioadhesive and release behavior of met- ronidazole-containing poly(acrylic acid)-hydroxypropyl methylcellulose systems. Int J Pharm 38:65-70, 1987.
471. F Lejoyeux, G Ponchel, D Duche ˆne. Influence of some technological parameters on the bioadhesive characteristics of poly(acrylic acid) matrices. STP Pharma 5:893- 898, 1989.
472. JD Smart. An evaluation of some mucosa-adhesive dosage forms for drug delivery to the oral cavity. J Pharm Pharmacol 42:141P. 1990.
473. P Forget, P Gazzeri, F Moreau, M Sabatier, C Durandeau, JP Merlet, P Aumonier. Comprime ´s mucoadhe ´sifs: mesure de l'adhe ´sivite ´in vitro. STP Pharma 4:176-181, 1988.
474. WG Chen, GC-C Hwang. Adhesive and in vitro characteristics of propranolol bioad- hesive disc system. Int J Pharm 82:61-66, 1992.
475. O Kislal, N Celebi. Studies on bioadhesive tablet formulation of propranolol HCl. Proc Int Symp Control Rel Bioact Mater 19:397-398, 1992.
476. PB Deasy, CT O'Neill. Bioadhesive dosage form for peroral administration of timo- lol base. Pharm Acta Helv 64:231-235, 1989.
477. N Garcia-Gonzalez, H Blanco-Fuente, S Anguiano-Igea, B Delgado-Charro, FJ Otero-Espinar, J Blanco-Me ´ndez. In vitro characterization of bioadhesive metoclo- pramide tablets for buccal application prepared with polyacrylic acid and hydroxy- propyl methylcellulose. STP Pharma Sci 2:494-499, 1992.
478. T Nagai, R Konishi. Buccal/gingival drug delivery systems. J Control Rel 6:353- 360, 1987.
479. JM Schor, SS Davis, A Nigalaye, S Bolton. Susadrin transmucosal tablets. Drug Dev Ind Pharm 9:1359-1377, 1983.
480. S Anlar, Y Capan, AA Hincal. Studies on buccoadhesive tablet formulation of mor- phine sulfate. 6th Int Conf Technol Pharm, Paris, 2-4 June. 1992, pp. 30-39. REFERENCES
481. K Iga, Y Ogawa. Buccal absorption of oxendolone in dogs after gingival administra- tion of a slow-disintegrating tablet. J Takeda Res Lab 53:57-71, 1994.
482. K Iga, Y Ogawa. Buccal absorption of presystemically eliminated drugs in dogs after gingival administration: avoidance of first-pass elimination and increased bioavail- ability. J Takeda Res Lab 54:108-124, 1995.
483. K Iga, Y Ogawa. Japanese patent 61,093,113, 1986.
484. K Iga, Y Ogawa. Sustained-release buccal dosage forms for nitroglycerin and isosor- bide dinitrate: increased bioavailability and extended time of absorption when admin- istered to dogs. J Control Rel 49:105-113, 1997.
485. YV Kapila, WJ Dodds, JF Helm, WJ Hogan. Relationship between swallow rate and salivary flow. Dig Dis Sci 29:528-533, 1984.
486. W Schurmann, P Turner. A membrane model of the human oral mucosa as derived from buccal absorption performance of the β-blocking drugs atenolol and propranolol. J Pharmacol Exp Ther 30:137-147, 1978.
487. M Dellborg, G Gustafsson, K Swedberg. Buccal versus intravenous nitroglycerin in unstable angina pectoris. Eur J Clin Pharmacol 41:5-9, 1991.
488. DE Hilleman, UV Banakar. Issues in contemporary drug delivery. Part VI. Advanced cardiac drug formulations. J Pharm Tech 8:203, 1992. REFERENCES
489. GM Duckworth, HR Millward, CDO Potter, G Hewson, TL Burkoth, BJ Bellhouse. Oral PowderJect: a novel system for administering local anaesthetic to the oral mu- cosa. Br Dent J 185:536-539, 1998.
490. II Glass, GN Patterson. A theoretical and experimental study of shock-tube flows. J Aeronaut Sci 22:73-100, 1955.
491. JD Anderson Jr. Modern Compressible Flow. New York: McGraw-Hill, 1990.
492. SM Nabulsi, HR Millward, BJ Bellhouse. The use of a shock tube for the delivery of powdered drugs into the oral mucosa. 22nd Int. Symp. on Shock Waves, Imperial College, London, 1999, Paper #170.
493. GM Duckworth. Trial reports PJP-OPJ-BUCCAL-001 to 004, 2000. REFERENCES
494. L Flotra. Different modes of chlorhexidine application and related local side effects. J Periodont Res 8:41-44, 1973.
495. GR Pitcher, HN Newman, JD Strahan. Access to subgingival plaque by disclosing agents using mouthrinsing and direct irrigation. J Clin Perio 7:300-308, 1980.
496. G Greenstein. Effects of subgingival irrigation on periodontal status. J Periodont 58: 827-836, 1987.
497. G Greenstein. The role of supra-and subgingival irrigation in the treatment of peri- odontal diseases. Position paper published by the American Academy of Periodon- tology. J Periodont 66: 1995.
498. JM Goodson, A Haffajee, SS Socransky. Periodontal therapy by local delivery of tetracycline. J Clin Perio 6:83-92, 1979.
499. RL Dunn, BH Perkins, JM Goodson. Controlled release of tetracycline from bio- degradable fibres. J Dent Res 62:289, 1983.
500. JM Goodson, D Holborow, RL Dunn, P Hogan, S Dunham. Monolithic tetracycline- containing fibres for controlled delivery to periodontal pockets. J Periodont 54:575- 579, 1983.
501. M Addy, L Rawle, R Handley, HN Newman, JF Coventry. The development and in vitro evaluation of acrylic resin strips and dialysis tubing for local drug delivery. J Periodont 53:693-699, 1982.
502. M Friedman, G Golomb. New sustained release dosage form of chlorhexidine for dental use. J Periodont Res 17:323-328, 1982.
503. A Soskolne, G Golomb, M Friedman, MN Sela. New sustained release dosage form of chlorhexidine for dental use. II. Use in periodontal therapy. J Periodont Res 18: 330-336, 1983.
504. M Donbrow, M Friedman. Timed release from polymeric films containing drugs and kinetics of drug release. J Pharm Sci 64:76-80, 1975.
505. A Stabholz, MN Sela, M Friedman, G Golomb, A Soskolne. Clinical and microbio- logical effects of sustained release chlorhexidine in periodontal pockets. J Clin Perio 13:783-788, 1986.
506. R Elkayam, M Friedman, A Stabholz, AW Soskolne, MN Sela, L Golub. Sustained release device containing minocycline for local treatment of periodontal disease. J Control Rel 7:231-236, 1988.
507. R Elkayam, M Friedman, A Stabholz, AW Soskolne, R Azoury. Sustained release device of tetracycline for dental use, structure and kinetics of drug release in vitro and in vivo. Proc Int Conf Pharm Tech 2:346-354, 1989.
508. A Stabholz, R Elkayam, M Friedman, MN Sela, R Azoury, AW Soskolne. Clinical and microbiological evaluation of sustained release device of tetracycline in peri- odontal pockets. Proc Int Conf Pharm Tech 2:336-345, 1989.
509. A Stabholz, WA Soskolne, M Friedman, MN Sela. The use of sustained release delivery of chlorhexidine for the maintenance of periodontal pockets: 2-year clinical trial. J Periodont 62:429-433, 1991.
510. D Steinberg, M Friedman, A Soskolne, MN Sela. A new degradable controlled re- lease device for treatment of periodontal disease: In vitro release study. J Periodont 61:393-398, 1990.
511. WA Soskolne, T Chajek, M Flashner, et al. An in vivo study of the chlorhexidine release profile of the PerioChip in the gingival crevicular fluid, plasma and urine. J Clin Perio 25:1017-1021, 1998.
512. WA Soskolne, PA Heasman, A Stabholz, et al. Sustained local delivery of chlorhexi- dine in the treatment of periodontitis: a multi-center study. J Periodont 68:32-38, 1997.
513. MK Jeffcoat, KS Bray, SG Ciancio, et al. Adjunctive use of a subgingival controlled- release chlorhexidine chip reduces probing depth and improves attachment level compared with scaling and root planing alone. J Periodont 69:989-997, 1998.
514. MK Jeffcoat, KG Placanis, TW Weatherford, M Reese, NC Geurs, M Flashner. Use of a boidegradable chlorhexidine chip in the treatment of adult periodontitis: clinical and radiological findings. J Periodont 71:256-262, 2000.
515. A Stabholz, L Shapira, D Mahler, et al. Using the PerioChip in treating adult pe- riodontitis: an iterim report. Compend Contin Edu Dent 21:325-338, 2000.
516. PA Heasman, L Heasman, F Stacey, GI McCraken. Local delivery of chlorhexidine gluconate (PerioChip) in periodontal maintenance patients. J Clin Perio. 28:90-95, 2001. REFERENCES
517. CA Lesch, CA Squier, A Crutchley, DM Williams, P Speight. The permeability of human oral mucosa and skin to water. J Dent Res 68:1345-1349, 1989.
518. MJ Rathbone, BK Drummond, IG Tucker. The oral cavity as site for systemic drug delivery. Adv Drug Del Rev 13:1-22, 1994.
519. Z Marom, J Shelhamer, M Kaliner. Nasal mucus secretion. Ear Nose Throat J 63: 36, 1984.
520. HJM van de Donk, AGM Van der Heuvel, J Zuidema, FWHM Merkus. The effects of nasal drops and their additives on human nasal mucociliary clearance. Rhinology 20:127, 1982.
521. AG de Boer, DD Breimer, H Mattie, J Pronk, JM Gubbens-Stibbe. Rectal bioavail- ability of lidocaine in man: partial avoidance of "first-pass" metabolism. Clin Phar- macol Ther 26:701-709, 1979.
522. IA Siegel, SH Hall, R Stambaugh. Permeability of the oral mucosa. In: CA Squier, Alur et al.
523. J Meyer, eds. Current Concepts of the Histology of Oral Mucosa. Springfield, IL: Charles C Thomas, 1971, p. 274.
524. AS Manning, DF Evered. The absorption of sugars from the human buccal cavity. Clin Sci Mol Med 51:127-132, 1976.
525. DF Evered, JV Vadgama. Absorption of amino acids from the human buccal cavity. Biochem Soc Trans 9:132-133, 1981.
526. RB Gandhi. Some permselectivity and permeability characteristics of rabbit buccal mucosa. Ph.D. thesis, University of Wisconsin, Madison, 1990.
527. MK Hunjen, DF Evered. Absorption of glutathione from the gastro-intestinal tract. Biochem Biophys Acta 815:184-188, 1985.
528. DF Evered, C Mallet. Thiamine absorption across human buccal mucosa in vivo. Life Sci 32:1355-1358, 1983.
529. DF Evered, F Sadoogh-Abasian, PD Patel. Absorption of nicotinic acid and nicotin- amide across human buccal mucosa in vivo. Life Sci 27:1649-1661, 1980.
530. N Utoguchi, Y Watanabe, T Suzuki, J Maehara, Y Matsumoto, M Matsumoto. Car- rier-mediated transport of monocarboxylic acids in primary cultured epithelial cells from rabbit oral mucosa. Pharm Res 14:320-324, 1997.
531. N Utoguchi, Y Watanabe, Y Takase, T Suzuki, M Matsumoto. Carrier-mediated absorption of salicylic acid from hamster cheek pouch mucosa. J Pharm Sci 88:142- 146, 1999.
532. Y Kurosaki, H Nishimura, K Terao, T Nakayama, T Kimura. Existence of special- ized absorption mechanism for cefadroxil, an aminocephalosporin antibiotic, in hu- man oral cavity. Int J Pharm 82:165-169, 1992.
533. RB Gandhi, JR Robinson. Oral cavity as a site for bioadhesive drug delivery. Adv Drug Del Rev 13:43-74, 1994.
534. HE Junginger, JA Hoogstraate, JC Verhoef. Recent advances in buccal drug delivery and absorption-in vitro and in vivo studies. J Control Rel 62:149-159, 1999.
535. HH Alur, TP Johnston, AK Mitra. Peptides and proteins: buccal absorption. In: J Swarbrick, JC Boylan, eds. Encyclopedia of Pharmaceutical Technology. Vol. 20. New York: Marcel Dekker, 2001, pp. 193-218.
536. HL Luessen, JC Verhoef, G de Boer, HE Junginger, BJ de Leeuw, G Borchard, CM Lehr. Multifunctional polymers for the peroral delivery of peptide drugs. In: E Mathiowitz, DE Chickering III, CM Lehr, eds. Bioadhesive Drug Delivery Systems. New York: Marcel Dekker, 1999, p. 299.
537. PFK Eagles. Structures of complex plant polysaccharides, exudates from Hakea seri- cea and Hakea gibbosa. Ph.D. thesis, Department of Chemistry, University of Cape- town, South Africa, 1992.
538. HH Alur, SI Pather, TP Johnston, AK Mitra. Evaluation of the gum from Hakea gibbosa as a mucoadhesive and sustained-release component of buccal tablets. Pharm Dev Tech 4:347-358, 1999.
539. NA Peppas, JJ Sahlin. A simple equation for the description of solute release. III. Coupling of diffusion and relaxation. Int J Pharm 57:169-172, 1989.
540. TF Dillon, RG Douglas, V du Vigneaud, ML Barber. Transbuccal administration of pitocin for induction of labor. Obstet Gynecol 15:587-592, 1960.
541. GW Miller. Induction of labor by buccal administration of oxytocin: review of 50 cases. J Am Osteopath Assoc 72:1110-1113, 1973.
542. MY Dawood, O Ylikorkala, F Fuchs. Plasma oxytocin levels and disappearance rate after buccal pitocin. Am J Obstet Gynecol 138:20-24, 1980.
543. M Ishida, Y Machida, N Nambu, T Nagai. New mucosal dosage form of insulin. Chem Pharm Bull 29:810-816, 1981.
544. R Anders, HP Merkle, W Schurr, R Ziegler. Buccal absorption of protirelin: an effective way to stimulate thyrotropin and prolactin. J Pharm Sci 72:1481-1483, 1983.
545. W Schurr, B Knoll, R Ziegler, R Anders, HP Merkle. Comparative study of intrave- nous, nasal, oral, and buccal TRH administration among healthy subjects. J Endocri- nol Invest 8:41-44, 1985.
546. BJ Aungst, NJ Rogers. Site dependence of absorption-promoting actions of laureth- 9, Na salicylate, Na 2 EDTA, and aprotinin on rectal, nasal, and buccal insulin deliv- ery. Pharm Res 5:305-308, 1988.
547. BJ Aungst, NJ Rogers, E Shefter. Comparison of nasal, rectal, buccal, sublingual and intramuscular insulin efficacy and the effects of a bile salt absorption promoter. J Pharmacol Exp Ther 244:23-27, 1988.
548. Y Nakada, N Awata, C Nakamichi, I Sugimoto. The effect of additives on the oral mucosal absorption of human calcitonin. J Pharmacobio Dyn 11:395-401, 1988.
549. WA Ritschel, GB Ritschel, H Forusz, M Kraeling. Buccal absorption of insulin in the dog. Res Commun Chem Pathol Pharmacol 63:53-67, 1989.
550. NFH Ho, CL Barsuhn. Buccal delivery of drugs. Proc Int Symp Control Rel Bioact Mater 16:24, 1989.
551. CK Oh, WA Ritschel. Biopharmaceutic aspects of buccal absorption of insulin. Methods Find Exp Clin Pharmacol 12:205-212, 1990.
552. GJM Wolany, J Munzer, A Rummelt, HP Merkle. Buccal absorption of sandostatin (octreotide) in conscious beagle dogs. Proc Int Symp Control Rel Bioact Mater 17: 1990 (abstract D341).
553. A al-Achi, R Greenwood. Buccal administration of human insulin in streptozocin- diabetic rats. Res Commun Chem Pathol Pharmacol 82:297-306, 1993.
554. SJ Heiber, CD Ebert, SC Dave, K Smith, SW Kim, D Mix. In vivo buccal delivery of calcitonin. J Control Rel 28:269-270, 1994.
555. D Bayley, C Temple, V Clay, A Steward, N Lowther. The transmucosal absorption of recombinant human interferon-alpha B/D hybrid in the rat and rabbit. J Pharm Pharmacol 47:721-724, 1995.
556. MK Gutniak, H Larsson, SJ Heiber, OT Juneskans, JJ Holst, B Ahren. Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Diabetes Care 19:843-848, 1996.
557. S Nakane, M Kakumoto, K Yukimatsu, YW Chien. Oral mucosal delivery of LHRH: pharmacokinetic studies of controlled and enhanced transmucosal permeation. Pharm Dev Technol 1:251-259, 1996.
558. AJ Hoogstraate, J Coos Verhoef, A Pijpers, LA van Leengoed, JH Verheijden, HE Junginger, HE Bodde. In vivo buccal delivery of the peptide drug buserelin with glycodeoxycholate as an absorption enhancer in pigs. Pharm Res 13:1233-1237, 1996.
559. C Li, RL Koch, VA Raul, PP Bhatt, TP Johnston. Absorption of thyrotropin releasing Alur et al. hormone in rats using a mucoadhesive buccal patch. Drug Dev Ind Pharm 23:239- 246, 1997.
560. C Li, PP Bhatt, TP Johnston. Transmucosal delivery of oxytocin to rabbits using a mucoadhesive buccal patch. Pharm Dev Technol 2:265-274, 1997.
561. HH Alur, JD Beal, SI Pather, AK Mitra, TP Johnston. Evaluation of a novel, natural oligosaccharide gum as a sustained-release and mucoadhesive component of calcito- nin buccal tablets. J Pharm Sci 88:1313-1319, 1999. REFERENCES
562. R Hendrickson. The Great American Chewing Gum Book. 1st ed. Radnor, PA: Clin- ton Book Company, 1976.
563. LA Cloys, AG Christensen, JA Christensen. The development and history of chew- ing gum. Bull Hist Dent 40:57-65, 1992.
564. Anonymous. A concise history of chewing gum. Dent Stud Mag 47:626-644, 1969.
565. Council of Europe. European Pharmacopoeia. 4th ed. Strasbourg: European Direc- torate for the Quality of Medicines, 2001, pp. 537-538.
566. H Stone, J Sidel, S Oliver, A Woolsey, RC Singleton. Sensory evaluation by quanti- tative descriptive analysis. Food Technol 28:24-32, 1974.
567. M Meilgaard, GV Civille, BT Carr. Sensory Evaluation Techniques. 2nd ed. Boca Raton, FL: CRC Press. 1991, pp. 162-169.
568. KB Broderick, DJ Townsend, DW Record, JH Song, PG Schnell, CE Sundstrom. Continuous chewing gum manufacturing process yielding gum with improved flavor perception. EP 0763330, 1995.
569. G Gergely, T Gergely, I Gergely. Chewing gum and production method thereof. US patent 4,737,366, 1986.
570. US Angel. Chewing gum and process for manufacture thereof. EP 2078186, 1994.
571. MR Rassing. Specialized oral mucosal drug delivery systems: chewing gum. In: MJ Rathbone, ed. Oral Mucosal Drug Delivery. New York: Marcel Dekker, 1996, pp. 319-357.
572. S Lichtneckert, C Lundgren, O Ferno. Chewable smoking substitute composition. US patent 3,901,248, 1974.
573. J Jacobsen, S Bjerregaard, M Pedersen. Cyclodextrin inclusion complexes of antimy- cotics intended to act in the oral cavity: drug supersaturation, toxicity on TR146 cells and release from a delivery system. Eur J Pharm Biopharm 48:217-224, 1999.
574. J Szejtli, S Pu ¨tter. Chewing gum compositions. EP 0575 977, 1993.
575. GN McGrew, DG Barkalow, SS Johnson, DW Record, MM Patel, JD Nimz, SE Zibell, RJ Yatka, MJ Greenberg, RA Aumann, DJ Zyck, DJ Sitler, JS Hook, JR Maxwell, MA Reed, VV Gudas, PG Schnell, HT Tyrpin, MP Russell, DL Witkewitz, JH Song, DJ Townsend, DA Seielstad. Chewing gum containing medicament active agents. WO 00/35298A1, 1999.
576. AM Morella, S Lukas. Microcapsule composition and process. CA 2068366, 1992.
577. RK Yang. Encapsulation composition for use with chewing gum and edible products. US patent 4,740,376, 1987.
578. RP D'Amelia, TR Cea, JE Beam, RA, White, SC Agro. Chewing gum containing flavorant adsorbed in cross-linked elastomeric polymer. US patent 5,458,891, 1994.
579. JH Song, SB Courtright. Flavor releasing structures for chewing gum. US patent 5,128,155, 1990.
580. W Bell, TJ Carroll. Chewing gum or confection containing flavorant adsorbed on silica. US patent 5,338,809, 1993.
581. C Andersen, M Pedersen. Chewing gum composition with accelerated, controlled release of active agents. EP 486563, 1990.
582. MR Rassing. Chewing gum as a drug delivery system. Adv Drug Del Rev 13:89- 121, 1994.
583. C Kvist, SB Andersson, S Fors, B Wennergren, J Berglund. Apparatus for studying in vitro drug release from medicated chewing gums. Int J Pharm 189:57-65, 1999.
584. P Martinsen. Ureas enhancereffekt pa ˚permeation over cellekulturen TR146 og re- lease fra V6  tyggegummi samt β-lupeols permeation over cellekulturen. Master's thesis, The Royal Danish School of Pharmacy, Copenhagen, 1998.
585. LL Christrup, N Møller. Chewing gum as a drug delivery system. Arch Pharm Chem Sci Ed 14:30-36, 1986.
586. M Pedersen, MR Rassing. Miconazole chewing gum as a drug delivery system: application of solid dispersion technique and lecithin. Drug Dev Ind Pharm 16:2015- 2030, 1990.
587. G Sallstan, J Thoren, L Barrefard, A Schutz, G Skarping. Long-term use of nicotine chewing gum and mercury exposure from dental amalgam fillings. J Dent Res 75: 594-598, 1996.
588. JR Mackert, A Berglund. Mercury exposure from dental amalgam fillings: absorbed dose and the potential for adverse health effects. Crit Rev Oral Biol Med 8:410- 436, 1997.
589. MJ Rathbone. Oral Mucosal Drug Delivery. New York: Marcel Dekker, 1996.
590. AH Shojaei. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Sci 1:15-30, 1998.
591. EL Cavalieri. Molecular origin of cancer: catechol estrogem-3,4-quinones as endog- enous tumor initiators. Proc Natl Acad Sci USA 94:10937-10942, 1997.
592. G Egis. Nitroglycerinhaltige treibgasfreie Aerosolpra ¨parate und Verfahren zu deren Herstellung. DE patent 3922 650 A1, 1990. Dugger et al.
593. W Cholcha. Nitroglycerin-pumpspray. DE patent 4007 705 C1, 1991.
594. K Klokkers-Bethke. Nitroglycerinhaltiger, hydrophiler, wa ¨ssriger pumpspray. EU patent 0471 969 A1, 1991.
595. I Bonnacker. Pharmazeutische spray-zubereitungen mit coronaraktiven wirkstoffen. DE patent 4038 203 A1, 1992.
596. E Silson, J Francos. Composition pour a ´erosols utilisable pour soulager la douleur accompagnant l'angine de poitrine. FR patent FR-A-2735, 1964.
597. PM Dewkand, T Tanner, AJ Woodward. Die bioverfu ¨gbarkeit von nitroglycerin- sprays als voraussetzung fu ¨r a ¨quivalente dosierung beim kardialen notfall. Herz Ge- fa ¨sse 536-544, 1987.
598. JA Deihl. Sprayable analgesic composition and method of use. WO patent 94/13280, 1994.
599. JE Spector. Method for oral spray administration of caffeine. US patent 5,456,677, 1995.
600. J von Wielligh. Product for assisting a smoker in giving-up the habit. EU patent 0 557 129 A1, 1993.
601. R Baker, G Santus, S Vintilla-Friedman. Method and therapeutic system for smoking cessation. US patent 5.593,684, 1997.
602. A Hegasy, K Ra ¨msch. Dihydropyridinspray, verfahren su seiner herstellung and seine pharmazeutische verwendung. DE patent 3544 692 A1, 1987.
603. K Fo ¨mming, G Neugebauer, N Rietbrock, B Woodcock. Verapamil and gallopamil und ihre physiologisch vertra ¨glichen salze zur resorptiven anwendung auf schleim- ha ¨uten des mundes, des nasen-rachen-ra ¨ums und des rektums. DE patent 3338 978 A1, 1984.
604. J Fassberg, J Sequeira, M Kopcha. Non-chlorofluorocarbon aerosol formulations. US patent 5,474,759, 1995.
605. H Dugger. Buccal polar spray or capsule. US patent 6,110,486, 2000.
606. H Dugger. Buccal non polar spray or capsule. US patent 5,955,098, 1999. REFERENCES
607. A Ganem-Quintanar, D Quintanar-Guerrero, P Buri. Monoolein: a review of the pharmaceutical applications. Drug Dev Ind Pharm 26:809-820, 2000.
608. ST Hyde, B Ericsson, S Anderson, K Larsson. A cubic structure consisting of a lipid bilayer forming an infinite periodic minimum surface of the gyriod type in the glycerylmonooleate-water system. Z Kristallogr 168:213-219, 1984.
609. S Engstro ¨m, H Ljusberg-Wahren, A Gustafsson. Bioadhesive properties of the monoolein-water system. Pharm Tech Eur 7:14-17, 1995.
610. B Ericsson, PO Eriksson, JE Lofroth, S Engstro ¨m. Cubic phases as drug delivery systems for peptide drugs. ACS Symp Ser 469:251-265, 1991.
611. Y Sadhale, JC Shah. Glyceryl monooleate cubic phase gel as chemical stability en- hancer of cefazolin and cefuroxime. Pharm Dev Technol 3:549-556, 1998.
612. E Esposito, V Carotta, A Scabbia, L Trombelli, P D'Antona, E Menegatti, C Nas- truzzi. Comparative analysis of tetracycline-containing dental gels: poloxamer-and monoglyceride-based formulations. Int J Pharm 142:9-23, 1996.
613. S Engstro ¨m, L Lindahl, R Wallin, J Engblom. A study of polar lipid drug carrier systems undergoing a thermoreversible lamellar-to-cubic phase transition. Int J Pharm 86:137-145, 1992.
614. J Lee, SA Young, IW Kellaway. Water quantitatively induces the mucoadhesion of liquid crystalline phases of glyceryl monooleate. J Pharm Pharmacol 53:629-636, 2001.
615. T Norling, P Lading, S Engstrom, K Larsson, N Krog, SS Nissen. Formulation of a drug delivery system based on a mixture of monoglycerides for use in the treatment of periodontal disease. J Clin Periodontal 19:687-692, 1992.
616. MJ Rathbone, BK Drummond, IG Tucker. The oral cavity as a site for systemic drug delivery. Adv Drug Del Rev 13:1-22, 1994.
617. J Lee, IW Kellaway. In vitro peptide release from liquid crystalline buccal delivery systems. Int J Pharm 195:29-33, 2000.
618. J Lee, IW Kellaway. Buccal permeation of [d-Ala 2 , d-Leu 5 ]enkephalin from liquid crystalline phases of glyceryl monooleate. Int J Pharm 195:35-38, 2000.
619. J Lee, IW Kellaway. Combined effect of oleic acid and polyethylene glycol 200 on buccal permeation of [d-Ala 2 , d-Leu 5 ]enkephalin from a cubic phase of glyceryl monooleate. Int J Pharm 204:137-144, 2000.
620. C-M Chang, R Bodmeier. Swelling of and drug release from monoglyceride-based drug delivery systems. J Pharm Sci 86:747-752, 1997. REFERENCES
621. AEM Collins, PB Deasy, DJ MacCarthy, DB Shanley. Evaluation of a controlled release compact containing tetracycline hydrochloride bonded to tooth for the treat- ment of periodontal disease. Int J Pharm 51:103-114, 1989.
622. L Samaranayake, M Ferguson. Delivery of antifungal agents to the oral cavity. Adv Drug Del Rev 13:161-179, 1999.
623. T Nagai. Adhesive topical drug delivery system. J Control Rel 2:121-134, 1985.
624. M Ishida, N Nambu, T Nagai. Mucosal dosage form of lidocaine for toothache using hydroxypropyl cellulose and carbopol. Chem Pharm Bull 30:980-984, 1982.
625. KK Peh, CF Wong. Polymeric films as vehicle for buccal delivery: swelling, me- chanical, and bioadhesive properties. J Pharm Pharmaceut Sci 2:53-61, 1999.
626. JH Guo. Bioadhesive polymer buccal patches for buprenorphine controlled delivery: formulation, in vitro adhesion and release properties. Drug Dev Ind Pharm 20:2809- 2821, 1994.
627. Y Kohda, H Kobayashi, Y Baba, H Yuasa, T Ozeki, Y Kanaya, E Sagara. Controlled release of lidocaine from buccal mucosa-adhesive films with solid dispersion. Int J Pharm 158:147-155, 1997.
628. JM Schor, SS Davis, A Nigalaye, S Bolton. Sudarin transmucosal tablets. Drug Dev Ind Pharm 9:1359-1377, 1983.
629. H Chen, R Langer. Oral particulate delivery: status and future trends. Adv Drug Del Rev 34:339-350, 1998.
630. E Esposito, R Cortesi, F Cervellati, E Menegatti, C Nastruzzi. Biodegradable micro- particles for sustained delivery of tetracycline to the periodontal pocket: formulatory and drug release studies. J Microencap 14:175-187, 1997.
631. JP Benoit, H Marchais, H Rolland, VV Velde. Biodegradable microspheres: ad- vances in production technology. In: S Benita, ed. Microencapsulation: Methods and Industrial Applications. New York: Marcel Dekker, 1996, pp. 35-72.
632. DT O'Hagan. Microparticles and polymers for the mucosal delivery of vaccines. Adv Drug Del Rev 34:305-320, 1998.
633. AM Hillery. Microparticulate delivery systems: potential drug/vaccine carriers via mucosal routes. Pharmaceutical Science and Technology Today 1:69-75, 1998.
634. R Arshady. Microspheres, Microcapsules and Liposomes. London: Citus Book, 1999.
635. NJ Medlicott, MJ Rathbone, IG Tucker, DX Holborow. Delivery systems for the administration of drugs to the periodontal pocket. Adv Drug Del Rev 13:181-203, 1994.
636. R Wada, SH Hyon, Y Ikada. Lactic acid oligomer microspheres containing hydro- philic drugs. J Pharm Sci 79:919-924, 1990.
637. V Joly, GG Encina, MS Cohen, C Thies. Effect of salts on formation of lactide- glycolide microparticles in aqueous media. Proc Int Symp Control Rel Bioact Mater 21:282-283, 1994.
638. TJ Sigurdsson, L Nygaard, DN Tatakis, E Fu, TJ Turek, L Jin, JM Wozney, UM Wikesjo. Periodontal repair in dogs: evaluation of rhBMP-2 carriers. Int J Periodont Restor Dent 16:524-537, 1996.
639. R Bodmeier, H Chen. Preparation of biodegradable poly(Ϯ)lactide microparticles using a spray-drying technique. J Pharm Pharmacol 40:754-757, 1988.
640. PC Montgomery, DE Rafferty. Induction of secretory and serum antibody responses following oral administration of antigen with bioadhesive degradable starch micro- particles. Oral Microbiol Immunol 13:139-149, 1998.
641. WT Cooper. Improvements in preparing or making up medicated and other effervesc- ing mixtures. British patent 3160, 1872.
642. JD Eichman, JR Robinson. Mechanistic studies on effervescent-induced permeability enhancement. Pharm Res 15:925-930, 1998.
643. A Martin. Physical Pharmacy. 4th ed. Philadelphia: Lea & Febiger, 1993.
644. D Kietzmann, D Hahne, TA Crozier, W Weyland, P Groger, H Sonntag. Comparison of sufentanil-propofol-anesthesia with fentanyl-propofol in major abdominal surgery. Anaesthesist 45:1151-1157, 1996.
645. LY Yee, JR Lopez. Transdermal fentanyl. Ann Pharmacother 26:1393-1399, 1992.
646. MA Southam. Transdermal fentanyl therapy: system design, pharmacokinetics and efficacy. Anticancer Drugs 6:29-34, 1995.
647. JE Shaw. Controlled topical delivery of drugs for systemic action. Drug Metab Rev 8:223-233, 1978.
648. J Hadgraft. Advances in transdermal drug delivery. Practitioner 240:656-658, 1996.
649. RH Guy. Iontophoresis-recent developments. J Pharm Pharmacol 50:371-374, 1998.
650. JM Gries, N Benowitz, D Verotta. Importance of chronopharmacokinetics in design and evaluation of transdermal drug delivery systems. J Pharmacol Exp Ther 285: 457-463, 1998.
651. I Steinstrasser, HP Merkle. Dermal metabolism of topically applied drugs: pathways and models reconsidered. Pharm Acta Helv 70:3-24, 1995.
652. M Brattsand, T Egelrud. Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. J Biol Chem 274:30033-30040, 1999.
653. B Sondell, LE Thornell, T Egelrud. Evidence that stratum-corneum chymotryptic enzyme is transported to the stratum-corneum extracellular-space via lamellar bod- ies. J Invest Dermatol 104:819-823, 1995.
654. RK Simpson, EA Edmondson, CF Constant, C Collier. Transdermal fentanyl as treatment for chronic low back pain. J Pain Symp Manage 14:218-224, 1997.
655. RJ Feldmann, HI Maibach. Regional variation in percutaneous penetration of 14 C cortisol in man. J Invest Dermatol 48:181-183, 1967.
656. DM Neighbors, TJ Bell, J Wilson, SL Dodd. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J Pain Symptom Manage 21:129-143, 2001.
657. RO Potts, ML Francoeur. The influence of stratum corneum morphology on water permeability. J Invest Dermatol 96:495-499, 1991.
658. PA Cornwell, BW Barry, CP Stoddart, JA Bouwstra. Wide-angle X-ray diffraction of human stratum corneum: effects of hydration and terpene enhancer treatment. J Pharm Pharmacol 46:938-950, 1994.
659. G Flynn. Physicochemical determinants of skin absorption. In: TR Gerrity, CJ Henry, eds. Principles of Route-to-Route Extrapolation for Risk Assessment. New York: Elsevier, 1990, pp. 93-127.
660. J Hadgraft. Pharmaceutical aspects of transdermal nitroglycerin. Int J Pharm 135: 1-11, 1996.
661. MB Delgado-Charro, AM Rodriguez-Bayon, RH Guy. Iontophoresis of nafarelin: effects of current density and concentration on electrotransport in vitro. J Control Rel 35:35-40, 1995.
662. MA Pellett, MS Roberts, J Hadgraft. Supersaturated solutions evaluated with an in vitro stratum corneum tape stripping technique. Int J Pharm 151:91-98, 1997.
663. KR Brain, J Hadgraft, VJ James, VP Shah. In vitro assessment of skin permeation from a transdermal system for the delivery of oestradiol. Int J Pharm 89:R13-R16, 1993.
664. J Hadgraft. Passive enhancement strategies in topical and transdermal drug delivery. Int J Pharm 184:1-6, 1999.
665. D Bommannan, RO Potts, RH Guy. Examination of the effect of ethanol on human stratum corneum in vivo using infrared spectroscopy. J Control Rel 16:299-304, 1991.
666. J Hirvonen, YN Kalia, RH Guy. Transdermal delivery of peptides by iontophoresis. Nature Biotechnol 14:1710-1713, 1996.
667. RH Guy, YN Kalia, MB Delgado-Charro, V Merino, A Lopez, D Marro. Ionto- phoresis: electrorepulsion and electroosmosis. J Control Rel 64:129-132, 2000.
668. V Merino, A Lopez, D Hochstrasser, RH Guy, Noninvasive sampling of phenylala- nine by reverse iontophoresis. J Control Rel 61:65-69, 1999.
669. SK Garg, RO Potts, NR Ackerman, SJ Fermi, JA Tamada, HP Chase. Correlation at fingerstick blood glucose measurements with GlucoWatch biographer glucose re- sults in young subjects with type 1 diabetes. Diabetes Care 22:1708-1714, 1999.
670. VM Knepp, J Hadgraft, RH Guy. Transdermal drug delivery: problems and possibili- ties. Crit Rev Ther Drug Carr Syst 4:13-37, 1987.
671. JP Skelly, VP Shah, HI Maibach, RH Guy, RC Wester, GA Flynn, A Yacobi. FDA and AAPS report of the workshop on principles and practices of in vitro percutane- ous penetration studies: relevance to bioavailability and bioequivalence. Pharm Res 4:265-267, 1987.
672. JE Shaw, SK Chandrasekaran. Controlled topical delivery of drugs for systemic ac- tion. Drug Metab Rev 8:223-233, 1978.
673. AF Kydonieus. Fundamentals of transdermal drug delivery. In: AF Kydonieus, B Berner, eds. Transdermal Delivery of Drugs. Vol. 1. Boca Raton, FL: CRC Press, 1987, pp. 3-16.
674. SK Chandrasekaran, JE Shaw. Factors influencing the percutaneous absorption of drugs. Curr Probl Dermatol 7:142-155, 1978.
675. H Schaefer, TE Redelmeier. Skin Barrier: Principles of Percutaneous Permeations. Basel: Karger, 1996, pp. 1-85.
676. BW Barry. The LPP theory of skin penetration enhancement. In: RL Bronaugh, HI Maibach, eds. In Vitro Percutaneous Absorption: Principles, Fundamentals, and Applications. Boca Raton, FL: CRC Press, 1991, pp. 165-185.
677. A Rolland, N Wagner, A Chatelus, B Shroot, H Schaefer. Site-specific drug delivery to pilosebaceous structures using polymeric microspheres. Pharm Res 10:1738- 1744, 1993.
678. PM Elias. Epidermal lipids, barrier function, and desquamation. J Invest Dermatol 80(suppl):44s-49s, 1983.
679. RO Potts, ML Francoeur. The influence of stratum corneum morphology on water permeability. J Invest Dermatol 96:495-499, 1991.
680. GL Flynn. Physicochemical determinants of skin absorption. In: TR Garrity, CL Henry, eds. Principles of Route-to-Route Extrapolations for Risk Assessment. New York: Elsevier, 1990, pp. 93-127.
681. RO Potts, ML Francoeur. Lipid biophysics of water loss through the skin. Proc Natl Acad Sci USA 87:3871-3873, 1990.
682. N Kitson, J Thewalt, M Lafleur, M Bloom. A model membrane approach to the epidermal permeability barrier. Biochemistry 33:6707-6715, 1994.
683. RJ Scheuplein, IH Blank. Permeability of the skin. Physiol Rev 51:702-747, 1971.
684. S Mitragotri. In situ determination of partition and diffusion coefficients in the lipid bilayers of stratum corneum. Pharm Res 17:1026-1029, 2000.
685. S Venkatraman, R Gale. Skin adhesives and skin adhesion. 1. Transdermal drug delivery systems. Biomaterials 19:1119-1136, 1998.
686. RW Baker, J Heller. Materials selection for transdermal delivery systems. In: J Had- graft, RH Guy, eds. Transdermal Drug Delivery. New York: Marcel Dekker, 1989, pp. 293-311.
687. RH Guy, J Hadgraft. Selection of drug candidates for transdermal drug delivery. In: J Hadgraft, RH Guy, eds. Transdermal Drug Delivery. New York: Marcel Dekker, 1989, pp. 59-81.
688. GA Patani, YW Chien. Transdermal drug delivery devices: system design and com- position. In: J Swarbrick, JC Boylan, eds. Encyclopedia of Pharmaceutical Technol- ogy. New York: Marcel Dekker, 1999, pp. 309-337.
689. AS Michaels, PSL Wong, R Prather, RM Gale. A thermodynamic method of pre- dicting the transport of steroids in polymer matrices. Am Inst Chem Eng J 21:1073- 1080, 1975. Padmanabhan et al.
690. KA Walters. Penetration enhancers and their use in transdermal therapeutic systems. In: J Hadgraft, RH Guy, eds. Transdermal Drug Delivery. New York: Marcel Dek- ker, 1989, pp. 197-246.
691. G Cleary. Transdermal delivery systems: a medical rationale. In: V Shah, H Mai- bach, eds. Topical Drug Bioavailability, Bioequivalence and Penetration. New York: Plenum Press, 1993, pp. 17-68.
692. HY Ando, TW Schultz, RL Schnaare, ET Sugita. Percutaneous absorption: a new physicochemical predictive model for maximum human in vivo penetration rates. J Pharm Sci 73:461-467, 1984.
693. EJ Lien, H Gao. QSAR analysis of skin permeability of various drugs in man as compared to in vivo and in vitro studies in rodents. Pharm Res 12:583-587, 1995.
694. R Gale, J Hunt, ME Prevo. Transdermal drug delivery, passive. In: E Mathiowitz, ed. Encyclopedia of Controlled Drug Delivery. New York: J Wiley & Sons, 1999, pp. 975-991.
695. CL Gummer, HI Maibach. Diffusion cell design. In: RL Bronaugh, HI Maibach, eds. In Vitro Percutaneous Absorption: Principles, Fundamentals and Applications. Boca Raton, FL: CRC Press, 1991, pp. 8-16.
696. JP Skelly, VP Shah, HI Maibach, RH Guy, RH Wester, GL Flynn, A Yacobi. FDA and AAPS report of workshop on principles and practices of in vitro percutaneous penetration studies: relevance to bioavailability and bioequivalence. Pharm Res 4: 265-267, 1987.
697. SW Collier, RL Bronaugh. Receptor fluids. In: RL Bronaugh, HI Maibach, eds. In Vitro Percutaneous Absorption: Principles, Fundamentals and Applications. Boca Raton, FL: CRC Press, 1991, pp. 31-49.
698. VP Shah, JP Skelly. Practical considerations in developing a quality control (in vitro release) procedure for topical drug products. In: VP Shah, HI Maibach, eds. Topical Drug Availability, Bioequivalence, and Penetration. New York: Plenum Press, 1993, pp. 107-116.
699. USP 24. Transdermal delivery systems, general drug release standards. In: US Phar- macopeia and National Formulary. Rockwell, MD: United States Pharmacopeial Convention, 1999, pp. 1947-1951.
700. S Gupta, M Southam, R Gale, SS Hwang. System functionality and physiochemcial model of fentanyl transdermal system. J Pain Symptom Manage 7:S17-S26, 1992.
701. A Rougier, D Dupuis, C Lotte, R Roguet, H Schaefer. In vivo correlation between stratum corneum reservoir function and percutaneous absorption. J Invest Dermatol 81:275-278, 1983.
702. A Rougier, D Dupuis, C Lotte, R Roguet, RC Wester, HI Maibach. Regional varia- tion in percutaneous absorption in man: measurement by the stripping method. Arch Dermatol Res 278:465-469, 1986.
703. VH Mak, RO Potts, RH Guy. Percutaneous penetration enhancement in vivo mea- sured by attenuated total reflectance infrared spectroscopy. Pharm Res 7:835-841, 1990.
704. B Sennhenn, K Giese, K Plamann, N Harendt, K Kolmel. In vivo evaluation of the penetration of topically applied drugs into human skin by spectroscopic methods. Skin Pharmacol 6:152-160, 1993.
705. N Higo, A Naik, DB Bommannan, RO Potts, RH Guy. Validation of reflectance infrared spectroscopy as a quantitative method to measure percutaneous absorption in vivo. Pharm Res 10:1500-1506, 1993.
706. C Anderson, T Andersson, M Molander. Ethanol absorption across human skin measured by in vivo microdialysis technique. Acta Derm Venereol 71:389-393, 1991.
707. R Takamoto, R Namba, M Matsuoka, T Sawada. Human in vivo percutaneous ab- sorptiometry using the laser-photoacoustic method. Anal Chem 64:2661-2663, 1992.
708. PM Elias, ER Cooper, A Korc, BE Brown. Percutaneous transport in relation to stratum corneum structure and lipid composition. J Invest Dermatol 76:297-301, 1981.
709. MJ Bartek, JA LaBudde, HI Maibach. Skin permeability in vivo: comparison in rat, rabbit, pig and man. J Invest Dermatol 58:114-123, 1972.
710. M Prevo, M Cormier, K Nichols. Predictive toxicology methods for transdermal delivery systems. Toxicol Meth 6:83-98, 1996.
711. T Maurer, EG Weirich, R Hess. Predictive animal testing for photocontact allergen- icity. Br J Dermatol 103:593-605, 1980.
712. JH Draize, G Woodard, HO Calvery. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther 82:377-390, 1944.
713. A Bulychev, A Trouet, P Tulkens. Uptake and intracellular distribution of neutral red in cultured fibroblasts. Exp Cell Res 115:343-355, 1978.
714. T Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63, 1983.
715. EV Buehler. Occlusive patch method for skin sensitization in guinea pigs: the Buehler method. Food Chem Toxicol 32:97-101, 1994.
716. AM Kligman. The identification of contact allergens by human assay. 3. The maxim- ization test: a procedure for screening and rating contact sensitizers. J Invest Derma- tol 47:393-409, 1966.
717. G Klecak. Test methods for allergic contact dermatitis in animals. In: FN Marzulli, HI Maibach, eds. Dermatotoxicology. 5th ed. Washington, DC: Taylor & Francis, 1996, pp. 437-459.
718. DF Woodward, AL Nieves, LA Williams, CA Spada, SB Hawley, JL Duenes. A new hairless strain of guinea pig: characterization of the cutaneous morphology and pharmacology. In: HI Maibach, NJ Lowe, eds. Models in Dermatology. Basel: Karger, 1989, pp. 71-78.
719. AE Chester, TG Terrell, E Nave, AE Dorr, LR Depass. Dermal sensitization study in hairless guinea pigs with dinitrochlorobenzene and ethyl aminobenzoate. J Tox- icol Cut Ocul Toxicol 7:273-281, 1988.
720. WE Parish. Evaluation of in vitro predictive tests for irritation and allergic sensitiza- tion. Food Chem Toxicol 24:481-494, 1986.
721. I Kimber, RJ Dearman, EW Scholes, DA Basketter. The local lymph node assay: developments and applications. Toxicology 93:13-31, 1994.
722. S Ahmedzai, D Brooks. Transdermal fentanyl versus sustained-release oral mor- phine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manag 13:254-261, 1997.
723. R Payne, SD Mathias, DJ Pasta, LA Wanke, R Williams, R Mahmoud. Quality of REFERENCES
724. AK Banga. Electrically Assisted Transdermal and Topical Drug Delivery. Bristol, PA: Taylor & Fransis, 1998.
725. S Leduc. Electric Ions and Their Use in Medicine. Liverpool, UK: Rebman Ltd., 1908.
726. RR Burnette. Iontophoresis. In: J Hadgraft, RH Guy, eds. Transdermal Drug Deliv- ery: Development Issues and Research Initiatives. New York: Marcel Dekker, 1989, pp. 247-291.
727. E Scott, JB Phipps, JR Gyory, RV Padmanabhan. Electrotransport systems for trans- dermal delivery: a practical implementation of iontophoresis. In: Handbook of Phar- maceutical Controlled Release Technology. D. Wise, ed. New York: Marcel Dekker, 2000, pp. 617-659.
728. JB Phipps, RV Padmanabhan, GA Lattin. Ionotophoretic delivery of model inorganic and organic drugs. J Pharm Sci 78:365-369, 1989.
729. P Tyle. Ionotophoretic devices for drug delivery. Pharm Res 3:318-326, 1986.
730. LE Lindblan, L Ekenvall. Electrode material in ionotophoresis. Pharm Res 4:438, 1987.
731. JB Phipps, DF Untereker. Iontophoresis apparatus and methods of producing the same. US patent 4,744,787, 1988.
732. DF Untereker, JB Phipps, GA Lattin. Iontophoretic drug delivery. US patent 5,573,503, 1998.
733. JB Phipps, JR Gyory. Transdermal ion migration. Adv Drug Del Rev 9:137-176, 1992.
734. J Cornish, OI Corrigan, D Foley. The iontophoretic transdermal delivery of morphine hydrochloride and other salts across excised human stratum corneum. In: RC Scott, RH Guy, J Hadgraft, eds. Proceedings of the Conference on Prediction of Percutane- ous Penetration: Methods, Measurements, Modeling. International Conference. Lon- don: IBC Technical Services, 1990, pp. 302-307.
735. A Jadoul, V Regnier, V Preat. Influence of ethanol and propylene glycol addition on the transdermal delivery by iontophoresis and electroportation. Pharm Res 14: S308-S309, 1997.
736. JE Sanderson, SD Reil, R Dixon. Iontophoretic delivery of non peptide drugs: formu- lation optimization for maximum skin permeability. J Pharm Sci 78:361-364, 1989.
737. HL Webster. Iontophoresis electrode device with gel insert-has electrode plate in cup-like receptacle so that agar gel disc can protrude for pressing against patient's skin. US patent 4,383,529, 1983.
738. JE Beck, LB Lloyd, TJ Petelenz. Iontophoretic delivery device with integral hydrat- ing means. US patent 5,730,716, 1998.
739. T Rosendahl. Studies on the conducting properties of the human skin to direct cur- rent. Acta Physiol Scand 5:130-151, 1942-1943.
740. MJ Cormier, PW Ledger, J Johnson, JB Phipps, S Chao. Reduction of skin irritation and resistance during electrotransport. US patent 5,624,415, 1997.
741. JB Phipps, M Cormier, RV Padmanabhan. In vivo ion efflux from humans and the relationship to skin irritation. In: P Couvreur, D Duchene, P Green, HE Junginger, eds. Transdermal Administration, a Case Study, Iontophoresis. APGI/CRS European Symposium. Paris: Editions de Sante, 1997, pp. 289-291.
742. A Anigbogu, P Singh, P Liu, S Dinh, H Maibach. Effects of iontophoresis on rabbit skin in vivo. Pharm Res 14:S-308, 1997.
743. M Cormier, B Johnson. Skin reactions associated with electrotransport. In: P Cou- vreur, D Duchene, P Green, HE Junginger, eds. Transdermal Administration, a Case Study, Iontophoresis. APGI/CRS European Symposium. Paris: Editions de Sante, 1997, pp. 50-57.
744. M Cormier, PW Ledger, A Amkraut. Reduction or prevention of skin irritation or sensitization during transdermal administration of an irritating or sensitizing drug. US patent 5,451,407, 1995.
745. M Cormier, PW Ledger, A Amkraut. Reduction or prevention of skin irritation of drugs. US patent 5,130,139, 1992.
746. RV Padmanabhan, JB Phipps, GA Lattin, RJ Sawchuk. In vitro and in vivo evalua- tion of transdermal iontophoretic delivery of hydromorphone. J Control Rel 11:123- 125, 1990.
747. R Gyory, JB Phipps, R Padmanabhan. Comparison of in vitro and in vivo iontopho- retic transport rates of several therapeutic compounds. In: P Couvreur, D Duchene, P Green, HE Junginger, eds. Transdermal Administration, a Case Study, Iontophoresis. APGI/CRS European Symposium. Paris: Editions de Sante, 1997, pp. 351-354.
748. SK Gupta, KJ Bernstein, H Noorduin, A Van Peer, G Sathyan, R Haak. Fentanyl delivery from an electrotransport system: delivery is a function of total current, not duration of current. J Clin Pharmacol 38:951-958, 1998.
749. SK Gupta, MA Southam, G Sathyan, M Klausner. Effect of current density on phar- macokinetics following continuous or intermittent input from a fentanyl electrotrans- port system. J Pharm Sci 87:976-981, 1998.
750. SK Gupta, G Sathyan, B Phipps, M Klausner, M Southam. Reproducible fentanyl doses delivered intermittently at different time intervals from an electrotransport system. J Pharm Sci 88:835-841, 1991.
751. JE Moodie, CR Brown, SF Jones, EI Bisley. Efficacy and safety of Transfenta, a transdermal electrotransport delivery system, for the management of postoperative pain following short-stay surgical procedures. Am Pain Soc, San Diego, CA, 1998 (abstract).
752. MB Delgado-Charro, RH Guy. Iontophoretic delivery of Nafarelin across the skin. Int J Pharm 117:165-172, 1995. REFERENCES
753. R Langer. Drug delivery and targeting. Nature 392:5-10, 1998.
754. K Park. Controlled Drug Delivery: Challenges and Strategies. Washington, DC: American Chemical Society, 1997.
755. MR Prausnitz. Reversible skin permeabilization for transdermal delivery of macro- molecules. Crit Rev Ther Drug Carr Syst 14:455-483, 1997.
756. EW Smith, HI Maibach. Percutaneous Penetration Enhancers. Boca Raton, FL: CRC Press, 1995.
757. DV McAllister, MG Allen, MR Prausnitz. Microfabricated microneedles for gene and drug delivery. Annu Rev Biomed Eng 2:289-313, 2000.
758. MS Gerstel, VA Place. Drug delivery device. US patent 3,964,482, 1976.
759. RH Champion, JL Burton, FJG Ebling. Textbook of Dermatology. London: Black- well Scientific, 1992.
760. WR Runyan, KE Bean. Semiconductor Integrated Circuit Processing Technology. New York: Addison-Wesley, 1990.
761. S Henry, DV McAllister, MG Allen, MR Prausnitz. Microfabricated microneedles: a novel method to increase transdermal drug delivery. J Pharm Sci 87:922-925, 1998.
762. DV McAllister, F Cros, SP Davis, LM Latta, MR Prausnitz, MG Allen. Three-di- mensional hollow microneedle and microtube arrays. Proc Transduc 99:1098-1101, 1999.
763. S Kaushik, AH Hord, DD Denson, DV McAllister, S Smitra, MG Allen, MR Praus- nitz. Lack of pain associated with microfabricated microneedles. Anesth Analg 92: 502-504, 2001.
764. D McAllister, S Kaushik, P Patel, J Mayberry, M Allen, M Prausnitz. Solid and hollow microneedles for transdermal protein delivery. Proc Int Symp Control Rel Bioact Mater 26:192-193, 1999.
765. MF Powell. Drug delivery issues in vaccine development. Pharm Res 13:1777- 1785, 1996.
766. JA Wolff. Gene Therapeutics: Methods and Applications of Direct Gene Transfer. Boston: Birkha ¨user, 1994.
767. J Tamada, S Garg, L Jovanovic, K Pitzer, S Fermi, R Potts. Noninvasive glucose monitoring: comprehensive clinical results. Cygnus Research Team. JAMA 282: 1839-1844, 1999.
768. AS Forman, DS Moskowitz. Rising to Another Level. Speciality Pharmaceuticals. New York: UBS Warburg LLC, 2000.
769. TM Morgan. Transdermal drug delivery with topical aerosols. PhD dissertation. Vic- torian College of Pharmacy (Monash University), Parkville, Victoria, Australia, 1998.
770. TM Morgan, BL Reed, BC Finnin. Enhanced skin permeation of sex hormones with novel topical spray vehicles. J Pharm Sci 87:1213-1218, 1998.
771. TM Morgan, RA Parr, BL Reed, BC Finnin. Enhanced transdermal delivery of sex hormones in swine with a novel topical aerosol. J Pharm Sci 87:1219-1225, 1998.
772. TM Morgan, HMM O'Sullivan, BL Reed, BC Finnin. Transdermal delivery of estra- diol in postmenopausal women with a novel topical aerosol. J Pharm Sci 87:1226- 1228, 1998.
773. BC Finnin, TM Morgan. Transdermal penetration enhancers: applications, limita- tions, and potential. J Pharm Sci 88:955-958, 1999.
774. RB Stoughton. Enhanced percutaneous absorption with 1-dodecylazacycloheptan- 2-one (Azone). Arch Dermatol 118:474-477, 1982.
775. R Vaidyanathan, VJ Rajadhyaksha, BK Kim, JJ Anisko. Azone. In: AF Kyodenius, B Berner, eds. Transdermal Delivery of Drugs. Vol. 2. Boca Raton, FL: CRC Press, 1987, pp. 63-83.
776. H Okamoto, M Hasida, H Sezaki. Structure-activity relationship of 1-alkyl-or 1-alkenylazacycloalkanone derivatives as percutaneous penetration enhancers. J Pharm Sci 77:418-424, 1988.
777. UT Lashmar, J Hadgraft, N Thomas. Topical application of penetration enhancers to the skin of nude mice: a histopathological study. J Pharm Pharmacol 41:118- 122, 1989.
778. O Wong, J Huntington, T Nishihata, JH Rytting. New alkyl N,N-dialkyl-substituted amino acetates as transdermal penetration enhancers. Pharm Res 6:286-295, 1989.
779. H Okabe, Y Obata, K Takayama, T Nagai. Percutaneous absorption enhancing effect and skin irritation of monocyclic monoterpenes. Drug Des Del 6:229-238, 1990.
780. Copyright © 2003 Marcel Dekker, Inc. Metered-Dose Transdermal Spray (MDTS) 531
781. E Manabe, K Sugibayashi, Y Morimoto. Analysis of skin penetration enhancing effect of drugs by ethanol-water mixed systems with hydrodynamic pore theory. Int J Pharm 129:211-221, 1996.
782. B Berner, GC Mazzenga, JH Otte, RJ Steffens, R Juang, CD Ebert. Ethanol:water mutually enhanced transdermal therapeutic system. II. Skin permeation of ethanol and nitroglycerin. J Pharm Sci 78:402-407, 1989.
783. BW Barry. Mode of action of penetration enhancers in human skin. J Control Rel 6:85-97, 1987.
784. EL White, BL Reed, BC Finnin. Effect of padimate O, octyl salicylate and lauroca- pram on the thermal profile of a model stratum corneum lipid mixture. Proceedings of the Australian Pharmaceutical Science Association Conference, Sydney, Austra- lia, 1997, p. 45.
785. A Naik, LARM Pechtold, RO Potts, RH Guy. Mechanism of oleic acid-induced skin penetration enhancement in vivo in humans. J Control Rel 37:299-306, 1995.
786. Z Liron, S Cohen. Percutaneous absorption of alkanoic acids. II. Application of regular solution theory. J Pharm Sci 73:538-542, 1984.
787. BL Reed, TM Morgan, BC Finnin. Dermal penetration enhancers and drug delivery systems involving same. WO 9729735A1, 1997.
788. JO Funk, SH Dromgoole, HI Maibach. Sunscreen intolerance. Dermatol Clin 13: 473-481, 1995.
789. M Hori, S Satoh, HI Maibach. Classification of percutaneous penetration enhancers: a conceptual diagram. J Pharm Pharmacol 42:71-72, 1990.
790. Guidance for Industry (Final). Container Closure Systems for Packaging Human Drugs and Biologics. Rockville, MD: Food and Drug Administration, May 1999.
791. D Delanoe, B Fougeyrollas, L Meyer, P Thonneau. Androgenization of female part- ners of men on medroxyprogesterone acetate/percutaneous testosterone contracep- tion. Lancet 1:276, 1984.
792. JP Skelly, VP Shah, HI Maibach, RH Guy, RC Wester, G Flynn, A Yacobi. FDA and AAPS Report of the Workshop on Principles and Practices of In Vitro Percutaneous Penetration Studies: relevance to bioavailability and bioequivalence. J Pharm Sci 4: 265-267, 1987.
793. 3M Drug Deliv News. Vol. 11, 1998.
794. D Ross, M Rees, V Godfree, A Cooper, D Hart, C Kingsland, M Whitehead. Ran- domised crossover comparison of skin irritation with two transdermal oestradiol patches. Br Med J 315:288, 1997.
795. GA Van Buskirk, MA Gonzalez, VP Shah, S Barnhardt, C Barrett, S Berge, G Cleary, K Chan, G Flynn, T Foster, R Gale, R Garrison, S Gochnour, A Gotto, S Govil, VA Gray, J Hammar, S Harder, C Hoiberg, A Hussain, C Karp, H Llanos, J Mantelle, P Noonan, D Swanson, H Zerbe. Scale-up of adhesive transdermal drug delivery systems. Pharm Res 14:848-852, 1997. REFERENCES
796. G Gregoriadis. Liposome Technology. 2nd ed. Boca Raton, FL: CRC Press, 1992.
797. DA Tomalia, AM Naylor, WA Goddard. Starburst dendrimers: molecular-level con- trol of size, shape, surface chemistry, topology, and flexibility from atoms to macro- scopic matter. Angw Chem Int Ed Eng 29:138-175, 1990.
798. G Cevc. Drug delivery across the skin. Exp Opin Invest Drugs 6:1887-1937, 1997.
799. G Cevc, G Blume. New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes. Bio- chim Biophys Acta 1514:191-205, 2001.
800. G Cevc, A Scha ¨tzlein, G Blume. Transdermal drug carriers: basic properties, optimi- zation and transfer efficiency in the case of epicutaneously applied peptides. J Con- trol Rel 36:3-16, 1995. Cevc
801. G Cevc. Preparation for the application of agents in minidroplets. EU patent 0475160, 1996.
802. G Cevc. Electrically controlled transport of charged penetrants across barriers. PCT/ EP 98/05539, 1998.
803. G Cevc. Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates. PCT/EP 98/06750, 1998.
804. G Cevc. Preparation for the transport of an active substance across barriers. PCT/ EP 96/04526, 1996.
805. G Cevc. Preparation for drug application in minute droplet form. European patent EP 0475160, 1992.
806. M Mezei. Liposomes and the skin. In: G Gregoridadis, AT Florence, H Patel, eds. Liposomes in Drug Delivery. London: Harwood Academic Publishers, 1993, pp. 24-135.
807. ML Mezei. Liposomes as a skin drug delivery system. In: DD Breimer, P Speiser, eds. Topics in Pharmaceutical Sciences. Amsterdam: Elsevier, 1985, pp. 345-358.
808. R Schubert, M Joos, M Deicher, J Lasch. Mode of action of topically applied lipo- somes in dermatology and cosmetics. Proc MoBBEL 6:20-32, 1992.
809. D Raskovic, P Piazza. Liposomes: a promising future for dermato-cosmetology and clinical dermatology. J Liposome Res 3:737-751, 1993.
810. HEJ Hofland, R Vander Geest, JA Bouwstra, HE Bodde, HE Junginger. Estradiol permeation from non-ionic surfactant vesicles through human stratum corneum in vitro. Pharm Res 11:659-664, 1994.
811. G Cevc. Transfersomes, liposomes and other lipid suspensions on the skin: perme- ation enhancement, vesicle penetration and transdermal drug delivery. Crit Rev Ther Drug Carr Syst 13:257-388, 1996.
812. ME Planas, P Gonzales, L Rodriguez, S Sanchez, G Cevc. Noninvasive percutaneous induction of topical analgesia by a new type of drug carrier and prolongation of local pain insensitivity by anesthetic liposomes. Anesth Analg 75:615-621, 1992.
813. SI Simo ˆes. Libertac ¸a ˜o transde ´rmica de fa ´rmacos: vesı ´culas lipı ´dicas ultraflexı ´veis. PhD dissertation, IBQTY-INETI-Instituto Nacional de Engenharia e Technologia Industrial, Lisbon, Portugal, 2002.
814. G Cevc, D Gebauer, J Stieber, A Scha ¨tzlein, G Blume. Ultraflexible vesicles, Trans- fersomes, have an extremely low pore penetration resistance and transport therapeu- tic amounts of insulin across the intact mammalian skin. Biochim Biophys Acta 1368:201-215, 1998.
815. A Scha ¨tzlein, G Cevc. Non-uniform cellular packing of the stratum corneum and permeability barrier function on intact skin: a high-resolution confocal laser micros- copy study using highly deformable vesicles (Transfersomes). Br J Dermatol 138: 583-592, 1998. Reference 1600 b.c. Grease, honey, lint, castor oil-Egyptians-Smith [6] papyrus ϳ a.d. 1-200 Plaster, linen bandages-Celus/Galen-initial concept of [7,8] "laudable pus" 1000-1700 General belief maintained throughout this period: "to cure [2] an ulcer was to prevent the efflux of dangerous hu- mours" 1000-1100 Promotion of per secundum intentionem by promoting the [9] production of pus 1200-1300 Bandages soaked in wine-per priman intentionem, with- [9] out infection 1400-1500 Practice of wound cautery, i.e., burning oil/hot irons- [5] Paracelcus ϳ1500 Ligation introduced by Parc; general use of ointments, [9] bandages, and cotton lints ϳ1600 Blood cupping ϭ release of blood through the skin- [9] Schropfkopf ϩ cutting glass 1676 First description of a laced stocking [10] ϳ1700 Introduction of compression bandages for old sores and [11] edema; bandages were usually made out of linen, wool, silk, or parchment 1870s Development of rubber bandages-Martin [9] 1920s Elastoplast released onto the market 1960s Concept of moist wound healing developed-Winter [12] studies → UK registration of Opsite first occulsive [13] dressing 1980s Development of Hydrocolloids (e.g., Granuflex), Foams (e.g., Alleyn), and Hydrogels (e.g., Intrasite)
816. 1990s Development of Alginates (e.g., Sorbsan, Hydropoly- mers (e.g., Tielle), and Hydrofibres (e.g., Aquacel)
817. 2000ϩ Development of biopolymer materials, e.g., Hyalofil, an esterified hyaluronic, acid biopolymer, and therapeutic agents, e.g., drugs-Regranex Possible development of biomaterials and use of tissue en- gineering? REFERENCES
818. Hippocrates. De ulcerbis, De carnabus. In: F Adams, ed. The Genuine Works of Hippocrates. London: Sydenham Society, 1849.
819. Avicenna. De ulceribus, Liber IV. Quoted by M Underwood. In: A Treatise on Ul- cers of the Legs. London: Matthews, 1783.
820. Manuscript number 564, Western Manuscripts Collection on Medicine and Science, Wellcome Institute Library, London.
821. J Hunter. Observations on the inflammation of the internal coats of veins (1775). In: JI Palmer, ed. The Works of John Hunter. London: Longman, Rees, Orme & Longman, 1837, pp. 581-586.
822. J Gay. On varicose disease of the lower extremities and its allied disorders. Lettsom- ian Lectures of 1867. London: Churchill, 1868.
823. BR Reed, RAF Clark. Cutaneous tissue repair: practical implications of current knowledge. II. J Am Acad Dermatol 13:919-941, 1985.
824. AAC Celsus. Of Medicine, in Eight Books (translated by James Grieve; revised by George Futuoge). London: Renshaw, 1838.
825. C Galen. Ad scripti libri. Venice: Vincentium Valgressium, 1562, pp. 34. Quoted by ST Anning. In: H Dodd, F Cockett, eds. The Pathology and Surgery of the Veins of the Lower Limb. London: Churchill Livingstone, 1976, pp. 4.
826. A Scholz. Historical aspects. In: W Westerhof, ed. Leg Ulcer: Diagnosis and Treat- ment. Amsterdam: Elsevier, 1993, pp. 5-15.
827. R Wiseman. Several Chirurgical Treatises. London: Wilthoe & Knapton, 1676.
828. JCA Theden. Neue Bermerkungen und Erfahrungen zue Beriecherung der Wundar- zenykunst und Arzenygelahrteit, Vol. 2. Berlin: Nicolai, 1782.
829. GD Winter. Formation of the scab and re-epithelialisation of superficial wounds in the skin of the young domestic pig. Nature 193:293-294, 1962.
830. DE Seymour, N Da Costa, M Hodgson, J Dow. Adhesive materials patent specifica- tion. UK patent #12800631, 1972.
831. II Tabata. The importance of drug delivery systems in tissue engineering. Pharm Sci Technol Today 3:80-89, 2000.
832. JA Hubbell. Bioactive biomaterials. Curr Opin Biotechnol 10:123-129, 1999.
833. F Arnold, G Cherry, D Cox, JJ Hutchinson, W Weston-Davies. Wound pharmacol- ogy: a report from the wound pharmacology forum. Wound Rep Reg 4:121-126, 1996.
834. R Grahame. Transdermal non-steroidal anti-inflammatory agents. Br J Clin Pract 49:33-35, 1995.
835. M Walker, TA Hulme, MG Rippon. In vitro model(s) for the percutaneous delivery of active tissue repair agents. J Pharm Sci 86:1379-1384, 1997.
836. SE Cross, MS Roberts. Defining a model to predict the distribution of topically Walker applied growth factors and other solutes in excisional full-thickness wound. J Invest Dermatol 112:36-41, 1999.
837. CL Wilson, J Cameron, SM Powell. High incidence of contact dermatitis in leg ulcer patients-implications for management. Clin Exp Dermatol 16:250-253, 1991.
838. J Cameron. The importance of contact dermatitis in the management of leg ulcers. J Tissue Viab 5:52-55, 1995.
839. SRK Karukonda, TC Flynn, EE Boh. The effects of drugs on wound healing. Part I. Int J Dermatol 39:250-257, 2000.
840. SRK Karukonda, TC Flynn, EE Boh. The effects of drugs on wound healing. Part II. Specific classes of drugs and their effects on healing wounds. Int J Dermatol 39: 321-333, 2000.
841. PA Puolakkainen, DR Twardzik, JE Ranchalis. The enhancement in wound healing by transforming growth factor-β 1 (TGF-β 1 ) depends on the topical delivery system. J Surg Res 58:321-329, 1995.
842. M Walker, LA Chambers, DA Hollingsbee, J Hadgraft. In vitro delivery of halcino- nide: significance of applied vehicle quantity to skin penetration. In: RC Scott, RH Guy, J Hadgraft, HE Bodde ´, eds. Predictions of Percutaneous Penetration: Methods, Measurements, Modelling. Vol. 2. Oxford, UK: IBC Technical Services, 1991, pp. 527-532.
843. DA Hollingsbee, RJ White, PAD Edwardson. Use of occluding hydrocolloid patches, in percutaneous penetration enhancers. In: EW Smith, HI Maibach, eds. Percutaneous Penetration Enhancers. Boca Raton, FL: CRC Press, 1995, pp. 35- 43.
844. K Weiss, JP Segel, TL Gerrard. Regulatory issues in clinical applications of cyto- kines and growth factors. Prog Growth Factors Res 5:213-222, 1994.
845. K Stromberh, MS Chapekar, BA Goldman. Regulatory concerns in the development of topical recombinant ophthalmic and cutaneous wound healing biologics. Wound Rep Reg 2:155-164, 1994.
846. F Gottrop, MS Agren, T Karlsmark. Models for use in wound healing research: a survey focusing on in vitro and in vivo adult soft tissue. Wound Rep Reg 8:83-96, 2000.
847. L Ruiz-Cardona, YD Sanzgiri, LM Benedetti. Application of benzyl hyaluronate membranes as potential wound dressings: evaluation of water vapour and gas perme- abilities. Biomaterials 17:1639-1643, 1996.
848. RS Rees, MC Robson, JM Smiell. Becaplermin gel in the treatment of pressure sores: a phase II randomised, double-blind, placebo controlled study. Wound Rep Reg 7:141-147, 1999.
849. MS Miller. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers. J Foot Ankle Surg 38:227-231, 1999.
850. H Reutter, S Bort, MF Jung. Questionable effectiveness of autologous platelet growth factors (PDWHF) in treatment of venous ulcers of the leg. Hautarzi 50:859- 865, 1999.
851. JL Richard, C Parer-Richard, JP Daures. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, ran- domized, double-blind, placebo-controlled trial. Diabetes Care 18:64-69, 1995.
852. E Jaschke, A Zabernigg, C Gattringer. Recombinant human granulocyte-macrophage colony-stimulating factor applied locally in low doses enhances healing and prevents recurrence of chronic venous ulcers. Int J Dermatol 38:380-386, 1999.
853. V Falanga, P Carson, A Greenberg. Topically applied recombinant tissue plasmino- gen activator for the treatment of venous ulcers: preliminary report. Dermatol Surg 22:643-644, 1996.
854. JP Ortonne. A controlled study of the activity of hyaluronic acid in the treatment of venous leg ulcers. J Dermatol Treat 7:75-81, 1996.
855. T Katsumura. Therapeutic effect of Ticlopidine for ischaemic leg ulcers: agents and actions. Suppl, Ticlopidine: Quo Vadis 15:167-172, 1984.
856. O Gauthier. Efficacy and safety of CY 216 in the treatment of specific leg ulcers. In: K Breddin, J Freed, M Samama, eds. Fraxiparine: Analytical and Structural Data, Pharmacology; Clinical Trials. Stuttgart: Schattaver, 1987, pp. 21.
857. MP Colgan, JA Dormandy, PW Jones. Oxypentifylline treatment of venous ulcers of the leg. Br Med J 300:972-975, 1990.
858. JN Fiessinger, M Scha ¨fer. Trial of Iloprost versus aspirin treatment for critical limb ischaemia of thromoangiitis obliterans. Lancet 335:555-557, 1990.
859. V Declair. The usefulness of topical application of essential fatty acids (EFA) to prevent pressure sores. Ostomy Wound Manage 43:48-52, 54, 1997.
860. MC Heng, J Harker, VB Bardakjian. Enhanced healing and cost effectiveness of low pressure oxygen therapy in healing necrotic wound: a feasibility study of technology transfer. Ostomy Wound Manage 46:52-60, 62, 2000.
861. P Ferretti, J Ge ´raudie. Cellular and Molecular Basis of Regeneration: From Inverte- brates to Humans. Chichester, UK: John Wiley & Sons, 1997.
862. JJ Tomasek, G Gabbiani, B Hinz. Myofibroblasts and mechano-regulation of con- nective tissue remodelling. Nat Rev Mol Cell Biol 349-363, 2002.
863. Ultrasound-Mediated Transdermal Drug Delivery Samir Mitragotri University of California, Santa Barbara, California, U.S.A. Joseph Kost Sontra Medical Inc., Cambridge, Massachusetts, U.S.A. REFERENCES
864. RL Bronaugh, HIE Maibach, eds. Percutaneous Absorption: Mechanisms-Method- ology-Drug Delivery. New York: Marcel Dekker, 1989.
865. M Prausnitz. Reversible skin permeabilization for transdermal delivery of macro- molecules. Crit Rev Ther Drug Carr Syst 14:455-483, 1997.
866. J Kost. Ultrasound for controlled delivery of therapeutics. Clin Mater 13:155-161, 1993.
867. K Tachibana. Transdermal delivery of insulin to alloxan-diabetic rabbits by ultra- sound exposure. Pharm Res 9:952-954, 1992.
868. EJ Novak. Experimental transmission of lidocaine through intact skin by ultrasound. Arch Phys Med Rehab 5(May):231-232, 1964.
869. BM Cameroy. Ultrasound enhanced local anesthesia. Am J Orthoped 8:47, 1966.
870. HAE Benson, JC McElnay, R Harland. Use of ultrasound to enhance percutaneous absorption of benzydamine. Phys Ther 69:113-118, 1989.
871. HAE Benson, JC McElnay, J Hadgraft. Influence of ultrasound on the percutaneous absorption of nicotinate esters. Pharm Res 9:1279-1283, 1991.
872. D Bommannan, GK Menon, H Okuyama, PM Elias, RH Guy. Sonophoresis. II. Examination of the mechanism(s) of ultrasound-enhanced transdermal drug delivery. Pharm Res 9:1043-1047, 1992. Mitragotri and Kost
873. CD Ciccone, BQ Leggin, JJ Callamaro. Effects of ultrasound and trolamine sal- icylate phonophoresis on delayed-onset muscle soreness. Phys Ther 71:666-678, 1991.
874. JE Griffin, JL Echternach, RE Proce, C Touchstone. Patients treated with ultrasonic driven hydrocortisone and with ultrasound alone. Phys Ther 47:600-601, 1967.
875. ME Johnson, S Mitragotri, A Patel, D Blankschtein, R Langer. Synergistic effect of ultrasound and chemical enhancers on transdermal drug delivery. J Pharm Sci 85:670-679, 1996.
876. D Levy, J Kost, Y Meshulam, R Langer. Effect of ultrasound on transdermal drug delivery to rats and guinea pigs. J Clin Invest 83:2074-2078, 1989.
877. JC McElnay, MP Matthews, R Harland, DF McCafferty. The effect of ultrasound on the percutaneous absorption of lignocaine. Br J Clin Pharmacol 20:421-424, 1985.
878. JC McElnay, TA Kennedy, R Harland. The influence of ultrasound on the percutane- ous absorption of fluocinolone acetonide. Int J Pharm 40:105-110, 1987.
879. S Mitragotri, D Blankschtein, R Langer. Ultrasound-mediated transdermal protein delivery. Science 269:850-853, 1995.
880. AJ Mortimer, BJ Trollope, OZ Roy. Ultrasound-enhanced diffusion through isolated frog skin. Ultrasonics 26:348-351, 1988.
881. K Tachibana, S Tachibana. Use of ultrasound to enhance the local anesthetic effect of topically applied aqueous lidocaine. Anesthesiology 78:1091-1096, 1993.
882. J Kost, D Levy, R Langer. Ultrasound as a transdermal enhancer. In R Bronaugh, HI Maibach, eds. Percutaneous Absorption: Mechanisms-Methodology-Drug Delivery. New York: Marcel Dekker, 1989, pp. 595-601.
883. S Mitragotri, M Coleman, J Kost, R Langer. Transdermal analyte extraction using low-frequency ultrasound. Pharm Res 17:466-470, 2000.
884. S Mitragotri, J Farrell, H Tang, T Terahara, J Kost, R Langer. Determination of the threshold energy dose for ultrasound-induced transdermal drug delivery. J Control Rel 63:41-52, 2000.
885. S Mitragotri, D Blankschtein, R Langer. Sonophoresis: Enhanced transdermal drug delivery by application of ultrasound. In: J Swarbrick, J Boylan, eds. Encylopedia of Pharmaceutical Technology. NY: Marcel Dekker, 1996, pp. 103-122.
886. S Mitragotri, R Langer, J Kost. Ultrasound for modulation of skin properties. In: D Wise, ed. Biomaterials Engineering and Devices: Human Applications. Totowa, NJ: Humana Press, 1999, pp. 843-854.
887. L Le, J Kost, S Mitragotri. Synergistic effect of ultrasound and iontophoresis on transdermal drug delivery: applications to heparin delivery. Pharm Res 17:1151- 1154, 2000.
888. S Mitragotri, D Ray, J Farrell, H Tang, B Yu, J Kost, D Blankschtein, R Langer. Enhancement of transdermal transport using ultrasound and surfactants. Proc Int Symp Control Rel Bioact Mater 26:176-177, 1999.
889. K Fellinger, J Schmidt. Klinik Therapies des Chromischen Gelenkreumatismus. Vienna, Austria: Maudrich, 1954, pp. 549-552.
890. S Mitragotri, D Blankschtein, R Langer. An explanation for the variation of the sonophoretic transdermal transport enhancement from drug to drug. J Pharm Sci 86: 1190-1192, 1997.
891. Copyright © 2003 Marcel Dekker, Inc. Ultrasound-Mediated Transdermal Delivery 569
892. S Mitragotri, D Blankschtein, R Langer. Transdermal drug delivery using low- frequency sonophoresis. Pharm Res 13:411-420, 1996.
893. W Gaertner. Frequency dependence of acoustic cavitation. J Acoust Soc Am 26: 977-980, 1954.
894. S Mitragotri, J Kost. Transdermal delivery of heparin and low-molecular weight heparin. Pharm Res. In press.
895. S Mitragotri, J Kost. Low-frequency sonophoresis: a non-invasive method for drug delivery and diagnostics. Biotech Progress 16:488-492, 2000.
896. H Tang, S Mitragotri, D Blankschtein, R Langer. Theoretical description of transder- mal transport of hydrophilic permeants: application to low-frequency sonophoresis. J Pharm Sci 90:543-566, 2001.
897. S Mitragotri, D Ray, J Farrell, H Tang, B Yu, J Kost, D Blankschtein, R Langer. Synergistic effect of ultrasound and sodium lauryl sulfate on transdermal drug deliv- ery. J Pharm Sci 89:892-900, 2000.
898. J Kost, S Mitragotri, R Gabbay, M Pishko, R Langer. Transdermal extraction of glucose and other analytes using ultrasound. Nat Med 6:347-350, 2000.
899. L Piazolo, J Harenberg, R Malsch, FG Huttner, DL Heene. Comparison of the phar- macodynamic and pharmacokinetic profiles of two low molecular-weight-mass hep- arins in rats. Semin Thromb Hemost 23:109-117, 1997.
900. CA Phillips, BB Michniak. Transdermal delivery of drugs with differing lipophilicit- ies using Azone analogs as dermal penetration enhancers. J Pharm Sci 84:1427- 1433, 1995.
901. KA Walters. Penetration enhancers and their use in transdermal therapeutic systems. In: J Hadgraft, RH Guy, eds. Transdermal Drug Delivery: Developmental Issues and Research Initiatives. New York: Marcel Dekker, 1989, pp. 197-233.
902. RH Guy, Y Kalia, M Delgado-Charro, V Merino, A Lopez, D Marro. Iontophoresis: electrorepulsion and electroosmosis. J Control Rel 64:129-132, 2000.
903. MR Prausnitz, V Bose, R Langer, JC Weaver. Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery. Proc Natl Acad Sci USA 90: 10504-10508, 1993.
904. RH Mu ¨ller, JS Lucks. Arzneistofftra ¨ger aus festen Lipidteilchen, Feste Lipidna- nospha ¨ren (SLN). European patent 0605497, 1996.
905. RH Mu ¨ller, W Mehnert, JS Lucks, C Schwarz, A zur Mu ¨hlen, H Weyhers, C Freitas, D Ru ¨hl. Solid lipid nanoparticles (SLN)-an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 41:62-69, 1995.
906. RH Mu ¨ller, K Ma ¨der, S Gohla. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 50:161-179, 2000.
907. MR Gasco. Method for producing solid lipid microspheres having a narrow size distribution. US patent 5,250,236, 1993.
908. RH Mu ¨ller, SA Runge, V Ravelli. Pharmaceutical cyclosporin formulation of im- proved biopharmaceutical performance and improved physical quality and stability and process for producing same. German patent application, 1998.
909. A zur Mu ¨hlen, W Mehnert. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles. Pharmazie 53:552, 1998.
910. W Mehnert, A zur Mu ¨hlen, A Dingler, H Weyhers, RH Mu ¨ller. Solid Lipid Nanopar- ticles (SLN)-ein neuartiger Wirkstoff-Carrier fu ¨r Kosmetika und Pharmazeutika. Mu ¨ller and Wissing II. Wirkstoff-Inkorporation, Freisetzung und Sterilisierbarkeit. Pharm Ind 59(6): 511-514, 1997.
911. V Jenning, A Gysler, M Scha ¨fer-Korting, S Gohla. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug penetration into porcine skin. Eur J Pharm Biopharm 49:211-218, 2000.
912. B Siekmann, K Westesen. Preparation and physicochemical characterization of aqueous dispersions of coenzyme Q10 nanoparticles. Pharm Res 12:201-208, 1995.
913. SA Wissing, RH Mu ¨ller. A novel sunscreen system based on tocopherol acetate incorporated into Solid Lipid Nanoparticles (SLN). Int J Cosm Sci 23:233-243, 2001.
914. SA Wissing, K Ma ¨der, RH Mu ¨ller. Solid lipid nanoparticles (SLN) as a novel carrier system offering prolonged release of the perfume Allure (Chanel). Proc Int Symp Control Rel Bioact Mater 27:311-312, 2000.
915. J Schmitt. Parenterale Fettemulsionen als Arzneistofftra ¨ger. In: RH Mu ¨ller, GE Hil- debrand, eds. Pharmazeutische Technologie: Moderne Arzneiformen, Stuttgart, Ger- many: WVGmbh, 1998, pp. 189-194.
916. T Eldem, P Speiser, A Hincal. Optimization of spray-dried and congealed lipid mi- cropellets and characterisation of their surface morphology by scanning electron microscopy. Pharm Res 8:47-54, 1991.
917. P Speiser. Lipidnanopellets als tra ¨gersystem fu ¨r arzneimittel zur peroralen anwen- dung. European patent EP 0167825, 1990.
918. A Domb. Lipospheres for controlled delivery of substances. US patent 5,188,837, 1993.
919. RH Mu ¨ller A Dingler. The next generation after the liposomes: solid lipid nanopar- ticles (SLN, Lipopearls) as dermal carrier in cosmetics. Eurocosmetics 7/8:19-26, 1998.
920. RH Mu ¨ller, S Gohla, A Dingler, T Schneppe. Large scale production of solid lipid nanoparticles (SLN) and nanosuspensions (DissoCubes). In: D Wise, ed. Handbook of Pharmaceutical Controlled Release Technology. 359-376, 2000.
921. A Dingler. Feste Lipid-Nanopartikel als kolloidale Wirkstoffra ¨gersysteme zur der- malen Applikation. PhD thesis, Free University of Berlin, 1998.
922. H Weyhers. Feste Lipid Nanopartikel (SLN) fu ¨r die gewebsspezifische Arzneistof- fapplikation. PhD thesis, Free University of Berlin, 1995.
923. K Westesen, B Siekmann, MHJ Koch. Investigations on the physical state of lipid nanoparticles by synchroton radiation X-ray diffraction. Int J Pharm 93:189-199, 1993.
924. H Bunjes, K Westesen, MJH Koch. Crystallization tendency and polymorphic transi- tions in triglyceride nanoparticles. Int J Pharm 129:159-173, 1996.
925. V Jenning, AF Thu ¨nemann, SH Gohla. Characterisation of a novel solid lipid nano- particle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 199:167-177, 2000.
926. V Jenning. Feste Lipid-Nanopartikel (SLN) als Tra ¨gersystem fu ¨r die dermale Appli- kation von Retinol: Wirkstoffinkorporation,-freisetzung und Struktur. PhD thesis, Free University of Berlin, 1999.
927. A zur Mu ¨hlen, Feste Lipid Nanopartikel mit prolongierter Wirkstoffliberation-Her- stellung, Langzeitstabilita ¨t, Cherakterisierung, Freisetzungsverhalten und mechanis- men. PhD thesis, Free University of Berlin, 1996.
928. E Zimmermann. Feste Lipid-Nanopartikel-Arzneistoffinkorporation, Charakteri- sierung und physikalische Stabilita ¨t. PhD thesis, Free University of Berlin, 2001.
929. RH Mu ¨ller, A Dingler. Feste Lipid-Nanopartikel (Lipopearls) als neuartiger Carrier fu ¨r kosmetische und dermatologische Wirkstoffe. Pharmazeut Zeit Dermopharm 49: 11-15, 1998.
930. A Dingler, GE Hildebrand, J Kielholz, S Gohla, RH Mu ¨ller. Fluorescence and elec- tron microscopic characterisation of solid lipid nanoparticles in aqueous dispersions and ointments. 2nd World Congress on Emulsion, Bordeaux, 1997, 42:297.
931. A Lippacher, RH Mu ¨ller, K Ma ¨der. Investigation on the viscoelastic properties of lipid based colloidal drug carriers. Int J Pharm 196:227-230, 2000.
932. A Lippacher, RH Mu ¨ller, K Ma ¨der. Investigations on semisolid SLN dispersions made from solid-liquid mixtures by means of ESR and rheometry. Proc Int Symp Control Rel Bioact Mater 27:325-326, 2000.
933. A Lippacher. Entwicklung und Charakterisierung von flu ¨ssigen und halbfesten SLN- Dispersionen zur topischen Applikation. PhD thesis, Free University of Berlin. 2000.
934. T de Vringer, HAG de Ronde. Preparation and structure of a water-in-oil cream containing lipid nanoparticles. J Pharm Sci 84:466-472, 1995.
935. E Mariani, C. Neuhoff, A Bargagna, F Bonina, M Giacchi, G De Guidi, A Velardita. Synthesis, in vitro percutaneous absorption and phototoxicity of new benzylidene derivatives of 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octan-6-one as potential UV sun- screens. Int J Pharm 161:65-73, 1998.
936. L Brinon, S Geiger, V Alard, J Doucet, J-F Tranchant, G Couarraze. Percutaneous absorption of sunscreens from liquid crystalline phases. J Control Rel 6:67-76, 1999.
937. C Bennat, CC Mu ¨ller-Goymann. Characterization of skin penetration of microfine titanium dioxide used in sunscreen formulations. Proc 2nd World Meeting APGI/ APV, Paris, 1998, pp. 859-860.
938. A Dingler, G Hildebrand, H Niehus, RH Mu ¨ller. Cosmetic anti-aging formulation based on vitamin E-loaded solid lipid nanoparticles. Proc Int Symp Control Rel Bioact Mater 25:433-434, 1998.
939. A Dingler, RP Blum, H Niehus, S Gohla, RH Mu ¨ller. Solid lipid nanoparticles (SLN/ Lipiopearls)-a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J Microencap 16:751-767, 1999. REFERENCES
940. AC Williams, BW Barry. Skin absorption enhancers. Crit Rev Ther Drug Carr Syst 9:305-353, 1992.
941. LR Hsu, YH Tsai, YB Huang. The effect of pretreatment by penetration enhancers on the in vivo percutaneous absorption of piroxicam from its gel form in rabbits. Int J Pharm 71:193-200, 1991.
942. P Xu, YW Chien. Enhanced skin permeability for transdermal drug delivery: physio- pathological and physicochemical considerations. Crit Rev Ther Drug Carr Syst 8: 211-236, 1991.
943. FL Tse, R Laplanche. Absorption, metabolism, and disposition of [14C]SDZ ENA 713, and acetylcholinesterase inhibitor, in mini pigs following oral, intravenous, and dermal administration. Pharm Res 15:1614-1620, 1998.
944. F Kompaore, C Dupont, JP Marty. In vivo evaluation in man by two noninvasive methods of stratum corneum barrier function after physical and chemical modifica- tions. Int J Cosm Sci 13:293-302, 1991.
945. JS Nelson, JL McCullough, TC Glenn, WH Wright, LH Liaw, SL Jacques. Mid- infrared laser ablation of stratum corneum enhances in vitro percutaneous transport of drugs. Invest Dermatol 97:874-879, 1991. Cormier and Daddona
946. S Mitragotri, J Farrell, H Tang, T Terahara, J Kost, R Langer. Determination of threshold energy dose or ultrasound-induced transdermal drug transport. J Control Rel 63:41-52, 2000.
947. SK Gupta, G Sathyan, B Phipps, M Klausner, M Southam. Reproducible fentanyl doses delivered intermittently at different time intervals from an electrotransport system. J Pharm Sci 88:835-841, 1999.
948. RH Haak, SK Gupta. Pulsatile drug delivery from electrotransport therapeutic sys- tems. In: R Gurny, HE Junginger, NA Pappas, eds. Pulsatile Drug Delivery: Current Applications and Future Trends. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 1993, pp. 99-112.
949. S Mitragotri, D Blankschtein, R Langer. Ultrasound-mediated transdermal protein delivery. Science 269:850-853, 1995.
950. H Suekt, C Gammal, K Kudoh, AM Kligman. Hairless guinea pig skin: anatomical basis for studies of cutaneous biology. Eur J Dermatol 10:357-364, 2000.
951. S Kumar, H Char, S Patel, D Piemontese, K Iqbal, AW Malick, E Neugroschel, CR Behl. Effect of iontophoresis on in vitro skin permeation of an analogue of growth hormone releasing factor in the hairless guinea pig model. J Pharm Sci 81:635-639, 1992.
952. KC Moon, RC Webster, HI Maibach. Diseased skin models in the hairless guinea pig skin: in vivo percutaneous absorption. Dermatologica 180:8-12, 1990.
953. H Miyauchi, T Horio. A new animal model for contact dermatitis: the hairless guinea pig. J Dermatol 19:140-145, 1992.
954. DF Woodward, AL Nieves, LS Williams, CS Spada, SB Hawley, JL Duenes. A new hairless strain of guinea pig: characterisation of the cutaneous morphology and pharmacology. In: HI Maibach, NJ Lowe, eds. Models in Dermatology. Vol. 4. Ba- sel: Karger, 1989, pp. 71-78.
955. A Fullerton, J Serup. Topical D-vitamins: multiparametric comparison of the irritant potential of calcipotriol, calcitriol in a hairless guinea pig model. Contact Dermat 36:184-190, 1997.
956. PJ Bobrowski, R Capiola, YM Centifanto. Latent herpes simplex virus reactivation in the guinea pig: an animal model for recurrent disease. Int J Dermatol 30:29-35, 1991.
957. H Hanel, B Braun, K Loschkorn. Experimental dermatophytosis in nude guinea pigs compared with infections in pigbright white animals. Mycoses 33:179-189, 1990.
958. SK Brantley, SF Davidson, SK Das. A dose-related curve of wound tensile strength following ultraviolet irradiation in the hairless guinea pig. Am J Med Sci 302:75- 81, 1991.
959. EA Henderson, TJ Louie, K Ramotar, D Ledgerwood, KM Hope, A Kennedy. Com- parison of higher-dose intradermal Hepatitis B vaccination to standard intramuscular vaccination of healthcare workers. Infect Control Hosp Epidemiol 21:264-269, 2000. REFERENCES
960. J Canter, K Mackey, LS Good, RR Roberto, J Chin, WW Bond, MJ Alter, JM Horan. An outbreak of hepatitis B associated with jet injections in a weight reduction clinic. Arch Intern Med 150:1923-1927, 1990.
961. RH Hingson, FHJ Figge. A survey of the development of jet injection in parenteral therapy. Curr Res Anesth Analg 31:361-366, 1952.
962. RA Hingson, JG Hughes. Clinical studies with jet injection: a new method of admin- istration. Curr Res Anesth Analg 26:221-230, 1947.
963. FHJ Figge, DJ Barnett. Anatomic evaluation of a jet injection instrument designed to minimize pain and inconvenience of parenteral therapy. Am Pract 3:197-206, 1948.
964. GS Perkin, GM Todd, TM Brown. Jet injection of insulin in the treatment of diabetes mellitus. Proc Am Diab Assoc 10:184-199, 1950.
965. C Weller, M Linder. Jet injection of insulin versus the syringe-and-needle method. JAMA 195:156-159, 1966.
966. PM Margetis, EP Quarantillo, RB Lindberg. Jet injection local anesthesia in den- tistry. US Armed Forces Med J 9:625-634, 1958.
967. H von Pietschmann. Erfahrungen mit dem "Hypospray Jet Injector" in der lokalen Pass and Hayes prednisolon-therapie rheumatischer erkrankungen. Wien Z Int Med 45:348-352, 1964.
968. GB Pehling, JE Gerich. Comparison of plasma insulin profiles after subcutaneous administration of insulin by jet spray and conventional needle injection in patients with insulin-dependent diabetes mellitus. Mayo Clin Proc 59:751-754, 1984.
969. EI Felner, JL Gonzalez. Comparison of jet stream Medi-Jector and conventional insulin syringe using Humalog insulin. Diab Res 34:113-123, 1999.
970. ECAM Houdijk, E Herdes, HA Delemarre-Van de Waal. Pharmacokinetics and pharmacodynamics of recombinant human growth hormone by subcutaneous jet-or needle-injection in patients with growth hormone deficiency. Acta Paediatr 86: 1301-1307, 1997.
971. GH Verrips, RA Hirasing, M Fekkes, T Vogels, SP Verloove-Vanhorick, HA Delemarre-Van de Waal. Psychological response to the needle-free Medi-Jector or the multidose Disetronic injection pen in human growth hormone therapy. Acta Pae- diatr 87:154-158, 1998.
972. DL Bremseth, F Pass. Delivery of insulin by jet injection; recent observations. Diab Tech Ther 3:225-232, 2001.
973. UKPDS 33. Intensive blood glucose control with sulphonylureas or insulin com- pared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837-853, 1998. REFERENCES
974. JC Sanford, MT Klein. Delivery of substances into cells and tissues using a particle bombardment process. Particulate Sci Tech 5:27-37, 1987.
975. BJ Bellhouse, DF Sarphie, CJ Greenford. Needle-less syringe using gas flow for particle delivery. International patent WO 94 24263, 1994.
976. NJ Quinlan, MAF Kendall, BJ Bellhouse, RW Ainsworth. Investigations of gas and particle dynamics in first generation needle-free drug delivery systems. International Journal on Shock Waves, 10(6):395-404, Jan. 2001.
977. MAF Kendall, NJ Quinlan, SJ Thorpe, RW Ainsworth, BJ Bellhouse. The gas-parti- cle dynamics of a high-speed needle-free drug delivery system. In: GJ Ball, R Hillier, GT Roberts, eds. Shock Waves. Southampton, UK: University of Southampton, 1999, pp. 605-610.
978. TL Burkoth, BJ Bellhouse, G Hewson, DJ Longridge, AG Muddle, DF Sarphie. Transdermal and transmucosal powdered drug delivery. Crit Rev Ther Drug Carr Syst 16:331-384, 1999.
979. MAF Kendall, PJ Wrighton-Smith, BJ Bellhouse. Transdermal ballistic delivery of micro-particles: Investigation into skin penetration. World Congress of Medical Physics and Biomedical Engineering, Chicago, IEEE 0-7803-6568-6/00, 2000.
980. BJ Bellhouse, NJ Quinlan, RW Ainsworth. Needle-less delivery of drugs, in dry powder form, using shock waves and supersonic flow. International Symposium on Shock Waves, Australia, 1997, pp. 51-56.
981. MAF Kendall. The delivery of particulate vaccines and drugs to human skin with a practical, hand-held shock tube-based system. Shock Waves Journal, 12(1), pp. 22-30, July 2002.
982. JF Meyers. Development of Doppler global velocimetry as a flow diagnostics tool. Measurement Sci Tech 6:769-783, 1995.
983. RW Ainsworth, SJ Thorpe, RJ Manners. A new approach to flow field measure- ment-a view of Doppler global velocimetry techniques. J Heat Fluid Flow 18:116- 130, 1997.
984. NJ Quinlan, RW Ainsworth, BJ Bellhouse, RJ Manners, SJ Thorpe. Application of Doppler global velocimetry to supersonic gas-particle flows in drug delivery. In: B Ruck, A Leder, D Dopheide, eds. Laser Aneometry Advances and Applications. Karlsruhe, Germany: GALA, e.V, 1999, pp. 629-636.
985. NJ Quinlan. Gas and particle dynamics in transdermal powdered drug delivery. DPhil thesis, Department of Engineering Science, University of Oxford, UK, 1999. REFERENCES
986. ML Lockhart. Hypodermic injector. US Patent Office serial number 69,199, 1936.
987. RA Hingson, JG Hughes. Clinical studies with jet injection: a new method of drug administration. Anaesth Analg 26:221-230, 1947.
988. RA Hingson, SD Hamilton, M Rosen. The historical development of jet injection and envisioned uses in mass immunization and mass therapy based upon two decades' experience. Milit Med 128:516-524, 1963.
989. S de la Motte, J Klinger, G Kefer, T King, F Harrison. Pharmacokinetics of human growth hormone administered subcutaneously with two different injection systems. Arzneimittelforschung 51:613-617, 2001. REFERENCES
990. J Cleland, A Daugherty, R Mrsny. Emerging protein delivery methods. Curr Opin Biotech 12:212-219, 2001.
991. M Higaki, Y Azechi, T Takase, R Igarashi, S Nagahara, A Sano, K Fujioka, N Nakagawa, C Aizawa, Y Mizushima. Collagen minipellet as a controlled release delivery system for tetanus and diphtheria toxoid. Vaccine 19(23-24):3091-3096, 2001.
992. S Itoh, M Kikuchi, K Takakuda, Y Koyama, HN Matsumoto, S Ichinose, J Tanaka, T Kawauchi, K Shinomiya. The biocompatibility and osteoconductive activity of a novel hydroxyapatite/collagen composite biomaterial, and its function as a carrier of rhBMP-2. J Biomed Mater Res 54:445-453, 2001.
993. WM Saltzman, MW Mak, MJ Hahoney, ET Duenas, JL Cleland. Intracranial deliv- ery of recombinant nerve growth factor: release kinetics and protein distribution for three delivery systems. Pharm Res 16:232-240, 1999.
994. RE Eliaz, D Wallach, J Kost. Delivery of soluble tumor necrosis factor receptor from in-situ forming PLGA implants: in-vivo. Pharm Res 22:563-570, 2000.
995. CH Lee, A Singla, Y. Lee. Biomedical applications of collagen. Int J Pharm 221: 1-22, 2001.
996. P Looss, A-M Le Ray, G Grimandi, G Daculsi, C. Merle. A new injectable bone substitute combining poly(-caprolactone) microparticles with biphasic calcium phos- phate granules. Biomaterials 22:2785-2794, 2001.
997. HB Ravivarapu, KL Moyer, RL Dunn. Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide. Int J Pharm 194:181-191, 2000.
998. JL Cleland, OL Johnson, S Putney, AJS Jones. Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development. Adv Drug Del Rev 28:71-84, 1997.
999. YY Yang, JP Wan, TS Chung, PK Pallathadka, S Ng, J Heller. POE-PEG-POE triblock copolymeric microspheres containing protein-1: preparation and character- ization. J Control Rel 75:115-128, 2001.
1000. JL Cleland, ET Duenas, A Park, A Daugherty, J Kahn, J Kowalski, A Cuthbertson. Development of poly-(d,l-lactide-co-glycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogen- esis. J Control Rel 72:13-24, 2001.
1001. FW Okumu, LN Dao, PJ Fielder, N Dybdal, D Brooks, S Sane, JL Cleland. Sustained delivery of human growth hormone from a novel gel system: SABER. Biomaterials, 2002. In press.
1002. FW Okumu, A Daugherty, LN Dao, PJ Fielder, D Brooks, S Sane, JL Cleland. Sustained delivery of growth hormone from a novel injectable liquid, PLAD. Proc Int Symp Control Rel Bioact Mater 28:abstract #6210, 2001.
1003. KJ Brodbeck, S Pushpala, AJ McHugh. Sustained release of human growth hormone from PLGA solution depots. Pharm Res 16:1825-1829, 1999.
1004. A Gutowska, B Jeong, J Jasionowski. Injectable gels for tissue engineering. Anat Rec 263:342-349, 2001. Okumu and Cleland
1005. B Jeong, YH Bae, DS Lee, SW Kim. Biodegradable block copolymers as injectable drug-delivery systems. Nature 388:860-862, 1997.
1006. RR Kraeling, CR Barb, GB Rampacek, DLJ Thompson, JW Gibson, SA Sullivan, B Simon, PJ Burns. Luteinizing hormone response to controlled-release deslorelin in estradiol benzoate primed ovariectomized gilts. Theriogenology 40:1681-1689, 2000.
1007. GM Zentner, R Ramesh, C Shih, JC McRea, M-H. Seo, H Oh, BG Rhee, J Mestecky, Z Moldoveanu, M Morgan, S Weitman. Biodegradable block copolymers for deliv- ery of proteins and water-insoluble drugs. J Control Rel 72:203-215, 2001.
1008. AA Gabizon, Selective tumor localization and improved theraputic index of anthra- cyclines encapsulated in long-circulating liposomes. Cancer Res 52:891-896, 1992.
1009. M Trif, C Guillen, DM Vaughan, JM Telfer, JM Brewer, A Roseanu, JH Brock. Liposomes as possible carriers for lactoferrin in the local treatment of inflammatory diseases. Exp Biol Med 226:559-564, 2001.
1010. JW Park, DB Kirpotin, K Hong, R Shalaby, Y Shao, UB Nielsen, JD Marks, D Papahadjopoulos, CC Benz. Tumor targeting using anti-her2 immunoliposomes. J Control Rel 74:95-113, 2001.
1011. DH Lewis. Controlled release of bioactive agents from lactide/glycolide polymers. In: M Chasin, R Langer, eds. Biodegradable Polymers as Drug Delivery Systems. New York: Marcel Dekker, 1990, pp. 1-41.
1012. H Okada, H Toguchi. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst 12:1-99, 1995.
1013. JL Cleland. Solvent evaporation processes for the production of controlled release biodegradable microsphere formulations for therapeutics and vaccines. Biotechnol Prog 14:102-107, 1998.
1014. H Toguchi. Pharmaceutical manipulation of leuprorelin acetate to improve clinical performance. J Int Med Res 18(suppl 1):35-41, 1990.
1015. WM Saltzman, MW Mak, MJ Mahoney, ET Duenas, JL Cleland. Intracranial deliv- ery of recombinant nerve growth factor: release kinetics and protein distribution for three delivery systems. Pharm Res 16:232-240, 1999.
1016. YY Hsu, T Hao, ML Hedley. Comparison of process parameters for microencapsula- tion of plasmid DNA in poly(d,l-lactic-co-glycolic) acid microspheres. J Drug Tar- get 7:313-323, 1999.
1017. KJ Lewis, WJ Irwin, S Akhtar. Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotides: characteriza- tion of P(LA-GA) copolymer microspheres in vitro. J Drug Target 5:291-302, 1998.
1018. B Bittner, M Morlock, H Koll, G Winter, T Kissel. Recombinant human erythropoie- tin (rhEPO) loaded poly(lactide-co-glycolide) microspheres: influence of the encap- sulation technique and polymer purity on microsphere characteristics. Eur J Pharm Biopharm 45:295-305, 1998.
1019. A Moore, P McGuirk, S Adams, WC Jones, JP McGee, DT O'Hagan, KH Mills. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8ϩ cytotoxic T lymphocytes and CD4ϩ Th1 cells. Vaccine 13:1741-1749, 1995.
1020. H Okada, Y Doken, Y Ogawa, H Toguchi. Preparation of three-month depot in- jectable microspheres of leuprorelin acetate using biodegradable polymers. Pharm Res 11:1143-1147, 1994.
1021. S Cohen, T Yoshioka, M Lucarelli, LH Hwang, R Langer. Controlled delivery sys- tems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res 8: 713-720, 1991.
1022. L Garcia-Contreras, K Abu-Izza, DR Lu. Biodegradable cisplatin microspheres for direct brain injection: preparation and characterization. Pharm Dev Technol 2:53- 65, 1997.
1023. H Okada. One-and three-month release injectable microspheres of the LH-RH su- peragonist leuprorelin acetate. Adv Drug Del Rev 28:43-70, 1997.
1024. JL Cleland, OL Johnson, S Putney, AJ Jones. Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development. Adv Drug Del Rev 28:71-84, 1997.
1025. GL Yewey, EG Duysen, SM Cox, RL Dunn. Delivery of proteins from a controlled release injectable implant. Pharm Biotechnol 10:93-117, 1997.
1026. HB Ravivarapu, KL Moyer, RL Dunn. Parameters affecting the efficacy of a sus- tained release polymeric implant of leuprolide. Int J Pharm 194: 181-191, 2000.
1027. RA Jain, CT Rhodes, AM Railkar, AW Malick, NH Shah. Comparison of various injectable protein-loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices: in-situ-formed implant versus in-situ-formed microspheres versus isolated micro- spheres. Pharm Dev Technol 5:201-207, 2000.
1028. RE Eliaz, J Kost. Characterization of a polymeric PLGA-injectable implant delivery system for the controlled release of proteins. J Biomed Mater Res 50:388-396, 2000.
1029. PD Graham, KJ Brodbeck, AJ McHugh. Phase inversion dynamics of PLGA solu- tions related to drug delivery. J Control Rel 58:233-245, 1999.
1030. KJ Brodbeck, JR DesNoyer, AJ McHugh. Phase inversion dynamics of PLGA solu- tions related to drug delivery. Part II. The role of solution thermodynamics and bath- side mass transfer. J Control Rel 62:333-344, 1999.
1031. KJ Brodbeck, S Pushpala, AJ McHugh. Sustained release of human growth hormone from PLGA solution depots. Pharm Res 16:1825-1829, 1999.
1032. B Jeong, YH Bae, SW Kim. In situ gelation of PEG-PLGA-PEG triblock copolymer aqueous solutions and degradation thereof. J Biomed Mater Res 50:171-177, 2000.
1033. BF Barton, JL Reeve, AJ McHugh. Observations on the dynamics of nonsolvent- induced phase inversion. J Polym Sci Polym Phys Ed 35:569-585, 1997.
1034. R Bannister, K Baudouin, E Maze, N Modi, K Brodbeck. Biological activity, phar- macokinetics, and safety assessment of human growth hormone (hGH) delivered via a subcutaneous depot. Toxicol Sci 54:407, 2000.
1035. The Merck Index. 12th ed. Whitehouse Station, NJ: Merck & Co., 1996, pp. 1162- 1163.
1036. Physicians' Desk Reference. Oradell, NJ: Medical Economics Company, 2000, pp. 581, 3094. REFERENCES
1037. RL Dunn, JP English, DR Cowsar, DP Vanderbilt. Biodegradable in situ forming implants and methods of producing the same. US patent 4,938,763, 1990.
1038. RL Dunn, AJ Tipton, EM Menardi. A biodegradable in situ forming drug delivery system. Proc Int Symp Control Rel Bioact Mater 22:91-92, 1991.
1039. M Radomsky, L Liu, Z Iwamoto. Synthetic polymers for nanosphere and micro- sphere products. In: J Senior, M Radomsky, eds. Sustained Release Injectable Prod- ucts. Englewood, CO: Interpharm Press, 2000, pp. 181-202.
1040. DH Lewis. Controlled release of bioactive agents from lactide/glycolide polymers. In: M Chasin, R Langer, eds. Biodegradable Polymers as Drug Delivery Systems. New York: Marcel Dekker, 1990, pp. 1-41.
1041. CG Pitt. Poly-ε-caprolactone and its copolymers. In: M Chasin, R Langer, eds. Bio- degradable Polymers as Drug Delivery Systems. New York: Marcel Dekker, 1990, pp. 71-120.
1042. AJ Spiegel, MM Noseworthy. Use of non-aqueous solvents in parenteral products. J Pharm Sci 52:917-927, 1963.
1043. KP Lee, C Chromey, R Culik. Toxicity of N-methyl-2-pyrrolidone (NMP): terato- genic, subchronic and two-year inhalation studies. Fundam Appl Toxicol 9:222- 235, 1987.
1044. B Akesson. Nordic experts group for criteria documentation for health risks to chem- icals: N-methyl-2-pyrrolidone (NMP). Arbete och Halsa 40:1-24, 1994.
1045. SM Fujita, JL Southard, GL Yewey, RL Dunn. Prevention of surgical adhesions using aerosoled biodegradable polymers. Trans Soc Biomater 17:384, 1994.
1046. AJ Tipton, WUV Trumpore, RL Dunn. A biodegradable, injectable delivery system for naltrexone. US-Japan Symposium on Drug Delivery, December 16-20, 1991.
1047. EM Jarr, M Zhou, CM Balliu, JP Mitchell, DM Wilson, RL Dunn. Sustained release of lidocaine from an injectable implant system for treatment of post-operative pain. Proc Int Symp Control Rel Bioact Mater 26:631-632, 1999.
1048. RL Dunn, B Chandrashekar, D Anna, S Garrett, L Southard. An in-situ forming delivery system for peptides and proteins. US-Japan Symposium on Drug Delivery, December 14-19, 1997.
1049. BK Lowe, RL Norton, EL Keeler, KR Frank, AJ Tipton. The effects of gamma irradiation on poly(dl-lactide) as a solid and in N-methyl-2-pyrrolidone solutions. Trans Soc Biomater 16:54, 1993.
1050. AM Polson, RL Dunn, JC Fulfs, KC Godowski, AP Polson, GL Southard, GL Ye- wey. Periodontal pocket treatment with subgingival doxycycline from a biodegrad- able system. J Dent Res 72:360, 1993.
1051. A Polson, S Garrett, N Stoller, C Bandt, P Haner, W Killoy, G Southard, S Duke, G Bogle, C Drisko, L Friesen. Multicenter comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. II. Clinical results. J Periodontol 68:119-126, 1997.
1052. S Garrett. Local delivery of doxycycline for the treatment of periodontitis. Compen- dium 20:437-448, 1999.
1053. AM Polson, G Southard, R Dunn, AP Polson, J Billen, L Laster. Initial study of guided tissue regeneration in class III furcation results after use of a biodegradable barrier. Int J Periodont Rest Dent 15:45-55, 1995.
1054. JS Garrett, KM Holland, BA Coonts, LA Moore, KE Cady, C Yarborough, R Bawa, RL Dunn. An in situ forming guided tissue regeneration barrier with doxycycline. Trans Soc Biomater 22:251, 1999.
1055. HB Ravivarapu, KL Moyer, RL Dunn. Parameters affecting the efficacy of a sus- tained release polymeric implant of leuprolide. Int J Pharm 194:181-191, 2000.
1056. HB Ravivarapu, KL Moyer, RL Dunn. Sustained suppression of pituitary-gonadal axis with an injectable, in-situ forming implant of leuprolide acetate. J Pharm Sci 89:732-741, 2000.
1057. HB Ravivarapu, KL Moyer, RL Dunn. Sustained activity and release of leuprolide acetate from an in-situ forming polymeric implant. Pharm Sci Tech 2000.
1058. M Zhou, C Balliu, K Tow, R Dunn. Preparation and evaluation of an Atrigel con- trolled release formulation for intratumoral delivery of floxuridine. Pharm Sci 1(suppl):S-582, 1998.
1059. CL Stevenson, F Theeuwes, JC Wright. Osmotic implantable delivery systems. In: DL Wise, ed. Handbook of Pharmaceutical Controlled Release Delivery. New York: Marcel Dekker, 2000, pp. 225-254.
1060. JS Patton. Pulmonary delivery of drugs for bone disorders. Adv Drug Del Rev 42: 239-248, 2000.
1061. JS Patton, J Bukar, S Nagarajan. Inhaled insulin. Adv Drug Del Rev 35:235-247, 1999.
1062. A Adjei, J Garren. Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy volunteers. Pharm Res 7:565-569, 1990.
1063. Physician's Desk Reference. Nutropin Depot (somatropin [rDNA origin] for in- jectable suspension). Montvale, NJ: Medical Economics Company, 2000.
1064. JL Cleland, A Mac, B Boyd, J Yang, ET Duenas, D Yeung, D Brooks, C Hsu, H Chu, V Mukku, AJ Jones. The stability of recombinant human growth hormone in poly (lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res 14:420-425, 1997.
1065. Y Ogawa, H Okada, T Heya, T Shimamoto. Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacologi- cal effects in animals. J Pharm Pharmacol 41:439-444, 1989.
1066. JR Peery, KE Dionne, JB Eckenhoff, FA Landrau, SD Lautenbach, JA Magruder, JC Wright. Sustained delivery of leuprolide using an implantable system. US patent 5,728,396, 1998.
1067. L Perkins, C Peer, V Fleming. Pumps/osmotic-ALZET  system. In: E Mathiowitz, ed. Encyclopedia of Controlled Drug Delivery. Vol 2. New York: John Wiley & Sons, 1999, pp. 900-906.
1068. J Magruder. Pumps/osmotic: VITS veterinary implant. In: E Mathiowitz, ed. Ency- clopedia of Controlled Drug Delivery. Vol 2. New York: John Wiley & Sons, 1999, pp. 906-909.
1069. JR Zingerman, JR Cardinal, RT Chern, J Holste, JB Williams, B Eckenhoff, J Wright. The in vitro and in vivo performance of an osmotically controlled delivery system-IVOMEC SR bolus. J Control Rel 47:1-11, 1997.
1070. C Stevenson, P Fereira, M Tan, R Ayer, H Dehnad, S Berry. Glucagon like peptide suspension stability and delivery from a DUROS  implant. Proc Int Symp Control Rel Bioact Mater 27:986-987, 2000.
1071. H Dehnad, S Berry, P Fereira, R Ayer, A O'Brien, G Chen, D Priebe, J Matsuura, A Muchnik, LL Kang, A Chester, JC Wright. Functionality of osmotically driven, implantable therapeutic systems (DUROS  implants): effect of osmotic pressure and delivery of suspension formulations of peptides and proteins. Proc Int Symp Control Rel Bioact Mater 27:1016-1017, 2000.
1072. CL Stevenson, SJ Prestrelski. Non-aqueous polar aprotic peptide formulations. US patent 5,932,547, 1999.
1073. J Wright, G Chen, M Cukierski, C Davis, C Falender, D Mabanglo, J Peery, L Ponnekanti, R Skowronski, C Stevenson, S Tao, J Brown. DUROS leuprolide im- plant for continuous one-year treatment of prostate cancer. Proc Int Symp Control Rel Bioact Mater 25:516-517, 1998.
1074. JC Wright, CL Stevenson. Pumps/osmotic-introduction. In: E Mathiowitz, ed. En- cyclopedia of Controlled Drug Delivery. Vol 2. New York: John Wiley & Sons, 1999, pp. 896-900.
1075. United States Pharmacopeia 23. Rockville, MD: The United States Pharmacopeial Convention, 1995, pp. 1699-1703.
1076. United States Pharmacopeia 24. Rockville MD: The United States Pharmacopeial Convention, 2000, pp. 1832-1836.
1077. ED Crawford, EP DeAntonio, F Labrie, FH Schroder, J Geller. Endocrine therapy of prostate cancer: optimal form and appropriate timing. J Clin Endocrinol Metab 80:1062-1078, 1995.
1078. C Huggins, CV Hodges. Studies of prostate cancer. I. Effect of castration, estrogen, and androgen injections on serum phosphatases in metastatic carcinoma of the pros- tate. Cancer Res 1:293-297, 1941.
1079. JE Fowler, JE Gottesman, CF Reid, GL Andriole, MS Soloway. Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate can- cer. J Urol 164:730-734, 2000.
1080. JE Fowler, M Flanagan, DM Gleason, IW Klimberg, JE Gottesman, R Sharifi. Evalu- ation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer. Urology 55:639-642, 2000.
1081. B Eckenhoff, F Theeuwes, F Urquhart. Osmotically actuated dosage forms for rate- controlled drug delivery. Pharm Tech 11:96-105, 1987.
1082. JC Wright, CL Stevenson, GR Stewart. Pumps/osmotic-DUROS  osmotic implant for humans. In: E Mathiowitz, ed. Encyclopedia of Controlled Drug Delivery. Vol.
1083. JC Wright, ST Leonard, CL Stevenson, JC Beck, G Chen, RM Jao, PA Johnson, J Leonard, RJ Skowronski. An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. J Control Rel 75:1-10, 2001.
1084. RJ Solar. Corrosion resistance of titanium surgical implant alloys: a reveiw. In: BC Syrett, A Acharya, eds. Corrosion and Degradation of Implant Materials. ASTM STP 684. Easton, MD: American Society for Testing and Materials, 1979, pp. 259- 273.
1085. JB Eckenhoff, LL Holladay, JJ Leonard, IKM Leung, SA Tao, JA Magruder, J Carr, J Wright. Peptide/protein suspending formulations. US patent 5,904,935, 1999.
1086. CL Stevenson, SA Tao, SJ Prestrelski, JB Eckenhoff, JC Wright, JJ Leonard. Non- aqueous protic peptide formulations. US patent 5,981,489, 1999.
1087. VM Knepp, A Muchnik, S Oldmark, L Kalashnikova. Stability of nonaqueous sus- pension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures. Pharm Res 15:1090-1095, 1998. REFERENCES
1088. H Okada, T Heya, Y Ogawa, T Shimamoto. One-month release injectable microcap- sules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats. J Pharmacol Exp Ther 244:744-750, 1988.
1089. Okada, H. One and three-month release injectable microspheres of the LH-RH su- peragonist leuprorelin acetate. Adv Drug Del Rev 28:43-70, 1997.
1090. WR Gombotz, MS Healy, LR Brown. Very low temperature casting of controlled release microspheres. Enzytech, 1991.
1091. M Tracy. Development and scale-up of a microsphere protein delivery system. Bio- tech Prog 14:108-115, 1998.
1092. MA Tracy, KL Ward, L Firouzabadian, Y Wang, N Dong, R Qian, Y Zhang. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 20:1057-1062, 1999.
1093. OL Johnson. Development of biodegradable microsphere formulations of proteins, peptides and small molecules. AAPS Workshop: Assuring Quality and Performance of Sustained and Controlled Release Parenterals. Washington, DC: AAPS, 2001.
1094. HJ Lee, G Riley, O Johnson, JL Cleland, N Kim, M Charnis, L Bailey, E Duenas, A Shahzamani, M Marion, AJ Jones, SD Putney. In vivo characterization of sus- tained release formulations of human growth hormone. J Pharmacol Exp Ther 281: 1431-1439, 1997.
1095. RC Reynolds, CI Chappel. Sucrose acetate isobutyrate (SAIB): historic aspects of its use in beverages and a review of toxicity studies prior to 1988. Food Chem Tox- icol 36:81-93, 1988.
1096. AJ Tipton, RJ Holl. High-viscosity liquid controlled-delivery system. US patent 5,747,058, 1998.
1097. DA Smith, AJ Tipton. A novel parenteral delivery system. Pharm Res 13:300, 1996.
1098. AJ Tipton. High-viscosity liquid controlled-delivery system as a device. US patent 5,968,542, 1999.
1099. PJ Burns, JW Gibson, AJ Tipton. Compositions suitable for controlled release of the hormone GnRH and its analogs. US patent 6,051,558, 2000.
1100. AJ Tipton, RL Dunn. In situ gelling formulations. In: J Senior, M Radomsky, eds. Sustained Release Injectable Products. Buffalo Grove, IL: Interpharm Press, 2000.
1101. SA Sullivan, JW Gibson, PJ Burns, L Franz, EL Squires, DL Thompson, AJ Tipton. Sustained release of progesterone and estradiol from the Saber delivery system: in vitro and in vivo release rates. Proc Int Symp Control Rel Bioact Mater 25:653- 654, 1998.
1102. CA Johnson, DL Thompson, SA Sullivan, JW Gibson, AJ Tipton, BW Simon, PJ Burns. Biodegradable delivery systems for estradiol: comparison between poly(dl- lactide) microspheres and the Saber delivery system. Proc Int Symp Control Rel Bioact Mater 26:74-75, 1999.
1103. FW Okumu, A Daugherty, L Dao, PJ Fielder, D Brooks, S Sane, S Sullivan, AJ Tipton, JL Cleland. Evaluation of the Saber delivery system for sustained release of growth hormone: formulation design and in vivo assessment. Proc Int Symp Con- trol Rel Bioact Mater 28:2001 (abstract 6211).
1104. SA Sullivan, RM Gilley, JW Gibson, AJ Tipton. Delivery of Taxol and other anti- neoplastic agents from a novel system based on sucrose acetate isobutyrate. Pharm Res 14:291, 1997.
1105. J Nally, S Artiushin, A Sheoran, J Timoney, JW Gibson, SA Sullivan, R Gilley, B Simon, PJ Burns. Induction of mucosal IgA specific for SeMF3 of Streptococcus equi with intranasal vaccination using a sucrose acetate isobutyrate-based delivery system. Proc Int Symp Control Rel Bioact Mater 26:1168-1169, 1999.
1106. SA Sullivan, JW Gibson, AJ Tipton. Sustained release of bupivacaine from the Saber delivery system. Presented at the AAPS Annual Meeting and Exposition, San Fran- cisco, Nov. 15-19, 1998.
1107. J Fleury, EL Squires, R Betschart, JW Gibson, SA Sullivan, AJ Tipton, PJ Burns. REFERENCES
1108. AD Bangham. Surrogate cells or Trojan horses: the discovery of liposomes. Bioes- says 17:1081-1088, 1995.
1109. G Gregoriadis. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol 13:527-537, 1995.
1110. A Gabizon. Liposomal anthracyclines. New Drug Ther 8:431-450, 1994.
1111. A Gabizon, R Chisin, S Amselem, S Druckmann, R Cohen, D Goren, I Fromer, T Peretz, A Sulkes, Y Barenholz. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated Adriamycin. Br J Cancer 64:1125- 1132, 1991.
1112. D Liu, Q Hu, YK Song. Liposome clearance from blood: different animal species have different mechanisms. Biochim Biophys Acta 1240:277-284, 1995.
1113. RT Proffitt, LE Williams, CA Presant, GW Tin, JA Uliana, RC Gamble, JD Bald- eschwieler. Tumor-imaging potential of liposomes loaded with in-111-NTA: biodis- tribution in mice. J Nucl Med 24:45-51, 1983.
1114. PS Gill, J Wernz, DT Scadden, P Cohen, GM Mukwaya, JH von Roenn, M Jacobs, S Kempin, I Silverberg, G Gonzales, MU Rarick, AM Myers, F Shepherd, C Sawka, MC Pike, ME Ross. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 14:2353-2364, 1996.
1115. TM Allen, C Hansen, J Rutledge. Liposomes with prolonged circulation times: fac- tors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta 981:27-35, 1989.
1116. D Papahadjopoulos, A Gabizon. Liposomes designed to avoid the reticuloendothelial system. Prog Clin Biol Res 343:85-93, 1990.
1117. A Gabizon, D Papahadjopoulos. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 85:6949- 6953, 1988.
1118. DD Lasic, FJ Martin, A Gabizon, SK Huang, D Papahadjopoulos. Sterically stabi- lized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1070:187-192, 1991.
1119. D Needham, TJ McIntosh, DD Lasic. Repulsive interactions and mechanical stabil- ity of polymer-grafted lipid membranes. Biochim Biophys Acta 1108:40-48, 1992.
1120. TM Allen, C Hansen, F Martin, C Redemann, A Yau-Young. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half- lives in vivo. Biochim Biophys Acta 1066:29-36, 1991. Martin and Huang
1121. AK Kenworthy, K Hristova, D Needham, TJ McIntosh. Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol). Biophys J 68:1921-1936, 1995.
1122. XP Hou, JM Zhang, XD Lu. [Effect of membrane modification by PEG on prolonga- tion of circulation time of liposomes in blood in vivo]. Yao Hsueh Hsueh Pao 31: 451-454, 1996.
1123. MC Woodle, DD Lasic. Sterically stabilized liposomes. Biochim Biophys Acta 1113:171-199, 1992.
1124. MC Woodle, KK Matthay, MS Newman, JE Hidayat, LR Collins, C Redemann, FJ Martin, D Papahadjopoulos. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim Biophys Acta 1105:193- 200, 1992.
1125. S Zalipsky, CB Hansen, JM Oaks, TM Allen. Evaluation of blood clearance rates and biodistribution of poly(2-oxazoline)-grafted liposomes. J Pharm Sci 85:133- 137, 1996.
1126. VP Torchilin. Polymer-coated long-circulating microparticulate pharmaceuticals. J Microencapsul 15:1-19, 1998.
1127. VP Torchilin, VS Trubetskoy, KR Whiteman, P Caliceti, P Ferruti, FM Veronese. New synthetic amphiphilic polymers for steric protection of liposomes in vivo. J Pharm Sci 84:1049-1053, 1995.
1128. VP Torchilin, MI Shtilman, VS Trubetskoy, K Whiteman, AM Milstein. Amphiphi- lic vinyl polymers effectively prolong liposome circulation time in vivo. Biochim Biophys Acta 1195:181-184, 1994.
1129. MC Blok, EC van der Neut-Kok, LL van Deenen, J de Gier. The effect of chain length and lipid phase transitions on the selective permeability properties of lipo- somes. Biochim Biophys Acta 406:187-196, 1975.
1130. S Clerc, Y Barenholz. Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. Biochim Biophys Acta 1240:257-265, 1995.
1131. AA Gabizon, R Catane, B Uziely, B Kaufman, T Safra, R Cohen, F Martin, A Huang, Y Barenholz. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Can- cer Res 54:987-992, 1994.
1132. AA Gabizon, Y Barenholz, M Bialer. Prolongation of the circulation time of doxoru- bicin encapsulated in liposomes containing a polyethylene glycol-derivatized phos- pholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 10:703-708, 1993.
1133. Y Gazit, JW Baish, N Safabakhsh, M Leunig, LT Baxter, RK Jain. Fractal character- istics of tumor vascular architecture during tumor growth and regression. Microcir- culation 4:395-402, 1997.
1134. F Yuan, M Leunig, S Huang, DA Berk, D Papahadjopoulos, RK Jain. Distinct leaky patterns of Stealth liposomes in tumor versus normal vessels. Proc Am Assoc Cancer Res 1994 (abstract 2487).
1135. F Yuan, M Leunig, S Huang, DA Berk, D Papahadjopoulos, RK Jain. Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumor xenograft. Cancer Res 54:3352-3356, 1994.
1136. SK Hobbs, WL Monsky, F Yuan, WG Roberts, L Griffith, VP Torchilin, RK Jain. Regulation of transport pathways in tumor vessels: role of tumor type and microenvi- ronment. Proc Natl Acad Sci USA 95:4607-4612, 1998.
1137. F Yuan, M Dellian, D Fukumura, M Leunig, DA Berk, VP Torchilin, RK Jain. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55:3752-3756, 1995.
1138. SK Huang, FJ Martin, G Jay, J Vogel, D Papahadjopoulos, DS Friend. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol 143:10-14, 1993.
1139. SK Huang, KD Lee, K Hong, DS Friend, D Papahadjopoulos. Microscopic localiza- tion of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 52:5135-5143, 1992.
1140. SK Huang, E Mayhew, S Gilani, DD Lasic, FJ Martin, D Papahadjopoulos, Pharma- cokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 52:6774-6781, 1992.
1141. FJ Martin. Clinical pharmacology and antitumor efficacy of DOXIL (pegylated lipo- somal doxorubicin). In: DD Lasic, D Papahadjopoulos, eds. Medical Applications of Liposomes. Amsterdam: Elsevier, 1998, pp. 635-688.
1142. RM Schiffelers, IA Bakker-Woudenberg, SV Snijders, G Storm. Localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue: influence of liposome characteristics. Biochim Biophys Acta 1421:329-339, 1999.
1143. IA Bakker-Woudenberg, MT ten Kate, LE Stearne-Cullen, MC Woodle. Efficacy of gentamicin or ceftazidime entrapped in liposomes with prolonged blood circula- tion and enhanced localization in Klebsiella pneumoniae-infected lung tissue. J In- fect Dis 171:938-947, 1995.
1144. AC Leenders, S de Marie, MT ten Kate, IA Bakker-Woudenberg, HA Verbrugh. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as com- pared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis. J Antimicrob Chemother 38:215-225, 1996.
1145. IA Bakker-Woudenberg, AF Lokerse, MT ten Kate, JW Mouton, MC Woodle, G Storm. Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue. J Infect Dis 168:164-171, 1993.
1146. RM Schiffelers, IA Bakker-Woudenberg, G Storm. Localization of sterically stabi- lized liposomes in experimental rat Klebsiella pneumoniae pneumonia: dependence on circulation kinetics and presence of poly(ethylene)glycol coating. Biochim Bio- phys Acta 1468:253-261, 2000.
1147. ET Dams, WJ Oyen, OC Boerman, G Storm, P Laverman, PJ Kok, WC Buijs, H Bakker, JW van der Meer, FH Corstens. 99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation. J Nucl Med 41:622- 630, 2000.
1148. P Laverman, S Zalipsky, WJ Oyen, ET Dams, G Storm, N Mullah, FH Corstens, OC Boerman. Improved imaging of infections by avidin-induced clearance of 99mTc-biotin-PEG liposomes. J Nucl Med 41:912-918, 2000.
1149. P Laverman, OC Boerman, WJ Oyen, ET Dams, G Storm, FH Corstens. Liposomes for scintigraphic detection of infection and inflammation. Adv Drug Del Rev 37: 225-235, 1999.
1150. E Mayhew, R Lazo, WJ Vail, J King, AM Green. Characterization of liposomes prepared using a microemulsifier. Biochim Biophys Acta 775:169-174, 1984.
1151. F Olson, CA Hunt, FC Szoka, WJ Vail, D Papahadjopoulos. Preparation of liposoms of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta 557:9-23, 1979.
1152. D Papahadjopoulos, TM Allen, A Gabizon, E Mayhew, K Matthay, SK Huang, KD Lee, MC Woodle, DD Lasic, C Redemann. Sterically stabilized liposomes: improve- ments in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA. 88:11460-11464, 1991.
1153. SK Huang, E Mayhew, S Gilani, DD Lasic, FJ Martin, D Papahadjopoulos. Pharma- cokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 52:6774-6781, 1992.
1154. J Vaage, E Barbera-Guillem, R Abra, A Huang, P Working. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on hu- man prostate carcinoma xenografts. Cancer 73:1478-1484, 1994.
1155. J Vaage, D Donovan, E Mayhew, R Abra, A Huang. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized lipo- somes. Cancer 72:3671-3675, 1993.
1156. SS Williams, TR Alosco, E Mayhew, DD Lasic, FJ Martin, RB Bankert. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice us- ing doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res 53: 3964-3967, 1993.
1157. A Gabizon, R Catane, B Uziely, B Kaufman, T Safra, R Cohen, F Martin, A Huang, Y Barenholz. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Can- cer Res 54:987-992, 1994.
1158. DW Northfelt, FJ Martin, P Working, PA Volberding, J Russell, M Newman, MA Amantea, LD Kaplan. Doxorubicin encapsulated in liposomes containing surface- bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in pa- tients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 36:55-63, 1996.
1159. KJ Harrington, CS Gooden, S Mohammedtaghi, AA Epenetos, JS Stewart. Biodistri- bution and pharmacokinetics of 111 In labeled Stealth liposomes in patients with solid tumors. Proc Am Soc Clin Oncol, 1996 (abstract 1511).
1160. SS Stewart, KJ Harrington. The biodistribution and pharmacokinetics of Stealth lipo- somes in patients with solid tumors. Oncology 11(suppl 11):33-37, 1997.
1161. DW Northfelt, BJ Dezube, JA Thommes, BJ Miller, MA Fischl, A Friedman-Kien, LD Kaplan, C Du Mond, RD Mamelok, DH Henry. Pegylated-liposomal doxorubi- cin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16: 2445-2451, 1998.
1162. S Stewart, H Jablonowski, FD Goebel, K Arasteh, M Spittle, A Rios, D Aboulafia, J Galleshaw, BJ Dezube. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Ka- posi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 16:683-691, 1998.
1163. DW Northfelt. Liposomal anthracycline chemotherapy in the treatment of AIDS- related Kaposi's sarcoma. Oncology 11(suppl 11):21-32, 1997.
1164. DW Northfelt, BJ Dezube, JA Thommes, R Levine, JH Von Roenn, GM Dosik, A Rios, SE Krown, C DuMond, RD Mamelok. Efficacy of pegylated-liposomal doxo- rubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 15:653-659, 1997.
1165. FD Goebel, D Goldstein, M Goos, H Jablonowski, JS Stewart. Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The Interna- tional SL-DOX Study Group. Br J Cancer 73:989-994, 1996.
1166. FD Goebel, M Gruenaug, JR Bogner. Survival times of patients with AIDS-related Kaposi's sarcoma with pulmonary involvement using liposomal doxorubicin. Proc Am Soc Clin Oncol, 1996 (abstract 860).
1167. M Harrison, D Tomlinson, S Stewart. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 13:914-920, 1995.
1168. F Muggia, J Blessing, J Sorosky, G Reid. Phase II study of pegylated liposomal doxorubicin (DOXIL) in previously treated metastatic endometrial cancer: a Gyne- cologic Oncology Group study (GOG #129-H). Proc Am Soc Clin Oncol, 2000 (ab- stract 151).
1169. FM Muggia, JD Hainsworth, S Jeffers, P Miller, S Groshen, M Tan, L Roman, B Uziely, L Muderspach, A Garcia, A Burnett, FA Greco, CP Morrow, LJ Paradiso, LJ Liang. Phase II study of liposomal doxorubicin in refractory ovarian cancer: anti- tumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993, 1997.
1170. F Muggia, J Hainsworth, S Jeffers, S Groshen, M Tan. Liposomal doxorubicin (DOXIL) is active against refractory ovarian cancer. Proc Am Soc Clin Oncol, 1996 (abstract 781).
1171. AN Gordon, CO Granai, PG Rose, J Hainsworth, A Lopez, C Weissman, R Rosales, T Sharpington. Phase II study of liposomal doxorubicin in platinum-and paclitaxel- refractory epithelial ovarian cancer. J Clin Oncol 18:3093-3100, 2000.
1172. A Gordon, J Fleagl, D Guthrie, DE Parkin, M Gore, AJ Lacave, D Mutch. Interim analysis of a phase III randomized trial of Doxil/Caelyx (D) versus topotecan (T) in the treatment of patients with relapsed ovarian cancer). Proc Am Soc Clin Oncol, 2000 (abstract 1504).
1173. MR Ranson, J Carmichael, K O'Byrne, S Stewart, D Smith, A Howell. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 15:3185-3191, 1997.
1174. JW Park, K Hong, DB Kirpotin, O Meyer, D Papahadjopoulos, CC Benz. Anti- HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett 118: 153-160, 1997.
1175. D Kirpotin, JW Park, K Hong, S Zalipsky, WL Li, P Carter, CC Benz, D Papahadjo- poulos. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36:66-75, 1997.
1176. JW Park, K Hong, DB Kirpotin, D Papahadjopoulos, CC Benz. Immunoliposomes for cancer treatment. Adv Pharmacol 40:399-435, 1997.
1177. D Goren, AT Horowitz, D Tzemach, M Tarshish, S Zalipsky, A Gabizon. Nuclear REFERENCES
1178. S Kim, MS Turker, EY Chi, S Sela, GM Martin. Preparation of multivesicular lipo- somes. Biochim Biophys Acta 728:339-348, 1983.
1179. MS Spector, JA Zasadzinski, MB Sankaram. Topology of multivesicular liposomes, a model biliquid foam. Langmuir 12:4704-4708, 1996.
1180. JF Ellena, M Le, D Cafiso, RM Solis, M Langston, MB Sankaram. Distribution of phospholipids and triglycerides in multivesicular lipid particles. Drug Del 6:97-106, 1999.
1181. C Pepper, M Patel, H Hartounian. cGMP Manufacturing scale-up of multivesicular lipid based drug delivery system. Pharm Eng 19:8-18, 1999.
1182. C Pepper, M Patel, H Hartounian. CGMP pharmaceutical scale-up. Part 1. Design. BioPharm 12:26-34, 1999.
1183. C Pepper, M Patel, H Hartounian. CGMP pharmaceutical scale-up. Part 2. Contrac- tors and request for proposal. BioPharm 12:36-55, 1999.
1184. C Pepper, M Patel, H Hartounian. CGMP pharmaceutical scale-up. Part 3. Automa- tion. BioPharm 12:52-54, 1999.
1185. C Pepper, M Patel, H Hartounian. CGMP pharmaceutical scale-up. Part 4. Installa- tion, commissioning, development. BioPharm 13:28-34, 2000.
1186. RRC New. Influence of liposome characteristics on their properties and fate. In: JR Philippot, F Schuber, eds. Liposomes as Tools in Basic Research and Industry. Boca Raton, FL: CRC Press, 1995, pp. 3-20.
1187. S Kim. Cyclodextrin liposomes encapsulating pharmacologic compounds and meth- ods for their use. US patent 5,759,573, 1998.
1188. MB Sankaram, S Kim. Multivesicular liposomes with controlled release of encapsu- lated biologically active substances. US patent 5,766,627, 1998. Mantripragada
1189. RC Willis. Method for utilizing neutral lipids to modify in vivo release from multive- sicular liposomes. US patent 5,891,467, 1999.
1190. MB Sankaram, S Kim. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances. US patent 5,993,850, 1999.
1191. Q Ye, MB Sankaram. Method for producing liposomes with increased percent of compound encapsulated. US patent 5,997,899, 1999.
1192. Q Ye, N Katre, MB Sankaram. Modulation of drug loading in multivesicular lipo- somes. US patent 6,106,858, 2000.
1193. S Mantripragada. DepoFoam technology for sustained release injectable drug deliv- ery. Drug Del Syst Sci 1:13-16, 2001.
1194. Q Ye, J Asherman, M Stevenson, E Brownson, NV Katre. DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs. J Control Rel 64:155- 166, 2000.
1195. MC Chamberlain, S Khatibi, JC Kim, SB Howell, E Chatelut, S Kim. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101): a phase I study. Arch Neurol 50:261-264, 1993.
1196. SB Howell. Clinical applications of a novel sustained-release injectable drug deliv- ery system: DepoFoam technology. Cancer J 7:219-227, 2001.
1197. T Kim, J Kim, S Kim. Extended-release formulation of morphine for subcutaneous administration. Cancer Chemother Pharmacol 33:187-190, 1993.
1198. T Kim, S Murdande, A Gruber, S Kim. Sustained-release morphine for epidural analgesia in rats. Anesthesiology 85:331-338, 1996.
1199. S Murdande, T Kim, A Gruber, S Kim. DepoBupivacaine for prolonged epidural analgesia. XV Annual ESRA Congress, Nice, France, 1996 (abstract).
1200. J Huh, JC Chen, GM Furman, C Malki, B King, F Kafie, SE Wilson. Local treatment of prosthetic vascular graft infection with multivesicular liposome-encapsulated ami- kacin. J Surg Res 74:54-58, 1998.
1201. AA Roehrborn, JF Hansbrough, B Gualdoni, S Kim. Lipid-based slow-release for- mulation of amikacin sulfate reduces foreign body-associated infections in mice. Antimicrob Agents Chemother 39:1752-1755, 1995.
1202. S Shakiba, KK Assil, AD Listhaus, D Munguia, M Flores-Aguilar, C Vuong, CA Wiley, RL Tolman, JD Karkas, G Bergeron-Lynn. Evaluation of retinal toxicity and liposome encapsulation of the anti-CMV drug 2′-nor-cyclic GMP. Invest Ophthal- mol Vis Sci 34:2903-2910, 1993.
1203. G Besen, M Flores-Aguilar, KK Assil, BD Kupperman, P Gangan, M Pursley, D Munguia, C Vuong, E De Clercq, G Bergeron-Lynn. Long-term therapy for herpes retinitis in an animal model with high-concentrated liposome-encapsulated HPMPC. Arch Ophthalmol 113:661-668, 1995.
1204. BD Kuppermann, KK Assil, C Vuong, G Besen, CA Wiley, E De Clercq, G Bergeron-Lynn, JD Connor, M Pursley, D Munguia, WR Freeman. Liposome- encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for long- acting therapy of viral retinitis. J Infect Dis 173:18-23, 1996.
1205. KK Assil, J Frucht-Perry, E Ziegler, DJ Schanzlin, T Schneiderman, RN Weinreb. Tobramycin liposomes. Single subconjunctival therapy of pseudomonal keratitis. Invest Ophthalmol Vis Sci 32:3216-3220, 1991. REFERENCES
1206. E Meehan, Y Gross, D Davidson, M Martin, IA Tsals. Microinfusor device for the delivery of therapeutic levels of peptides and macromolecules. J Control Rel 46: 107-116, 1996.
1207. J Kelly. Delivery of macromolecules. Elan Rev 8-11, 1994.
1208. O Cabiri, M Sahar, D Katz, I Tsals. Delivery rate estimation through measurement MEDIPAD and Pump-In-A-Patch are trademarks of Elan plc. CADD-Micro is a trademark of SIMS Deltec, Inc. MSContin  is a trademark of The Purdue Pharma L.P. REFERENCES
1209. ND Fabricant. Nasal Medication. Baltimore, MD: Waverly Press, 1942, pp. 1-3.
1210. J Law. Not to be sniffed at. Scrip Magazine May: 35-38, 2000.
1211. JR Harkema. Comparative pathology of the nasal mucosa in laboratory animals exposed to inhaled irritants. Environ Health Perspect 85:231-238, 1990.
1212. N Mygind, A A ¨ngga ˚rd. Anatomy and physiology of the nose-pathophysiologic alterations in allergic rhinitis. Clin Rev Allergy 2:173-188, 1984.
1213. L Illum. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 11:1-18, 2000.
1214. S Mathison, R Nagilla, UB Kompella. Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target 5:415-441, 1998.
1215. NGM Schipper, JC Verhoef, FWHM Merkus. The nasal mucocilliary clearance: relevance to nasal drug delivery. Pharm Res 8:807-814, 1991.
1216. YW Chien, S Chang. Intranasal drug delivery for systemic medication. Crit Rev Ther Drug Carr Syst 4:67-194, 1987.
1217. YW Chien, KSE Su, S Chang. Nasal Systemic Drug Delivery. New York: Marcel Dekker, 1989, pp. 1-38.
1218. SS Hehar, JDT Mason, AB Stephen, N Washington, NS Jones, SJ Jackson, D Bush. Twenty-four hour ambulatory nasal pH monitoring. Clin Otolaryngol 24:24-25, 1999.
1219. GSMJE Duchateau, K Graamans, J Zuidema, FWHM Merkus. Correlation between nasal ciliary beat frequency and mucus transport rate in volunteers. Laryngoscope 95:854-859, 1985.
1220. NS Jones, S Quraishi, JDT Mason. The nasal delivery of systemic drugs. Int J Clin Pract 51:308-311, 1997.
1221. CJ Reed. Drug metabolism in the nasal cavity: relevance to toxicology. Drug Metab Rev 25:173-205, 1993.
1222. JR Thornton-Manning, AR Dahl. Metabolic capacity of nasal tissue interspecies comparisons of xenobiotic-metabolizing enzymes. Mutat Res 380:43-59, 1997.
1223. AR Dahl, JL Lewis. Respiratory tract uptake of inhalants and metabolism of xenobi- otics. Annu Rev Pharmacol Toxicol 32:383-407, 1993.
1224. J Jenner, GH Dodd. Xenobiotic metabolism in the nasal epithelia. Drug Metab Drug Interact 6:123-148, 1988.
1225. MA Sarkar. Drug metabolism in the nasal mucosa. Pharm Res 9:1-9, 1992.
1226. VH Lee. Enzymatic barriers to peptide and protein absorption. Crit Rev Ther Drug Carr Syst 5:69-97, 1988.
1227. PG Gervasi, V Longo, F Naldi, G Panattoni, F Ursino. Xenobiotic-metabolizing enzymes in the human respiratory nasal mucosa. Biochem Pharmacol 41:177-184, 1991.
1228. JL Lewis, KJ Nikula, R Novak, AE Dahl. Comparative localization of carboxyles- terase in F344 rat, beagle dog, and human nasal tissue. Anat Rec 239:55-64, 1994.
1229. A Aceto, CD Ilio, S Angelucci, V Longo, PG Gervasi, G Federici. Glutathione transferases in human nasal mucosa. Arch Toxicol 63:427-431, 1989.
1230. NSR Krishna, TV Getchell, YC Awasthi, N Dhooper, ML Getchell. Age-and gender-related trends in the expression of glutathione S-transferases in human nasal mucosa. Ann Otol Rhinol Laryngol 104:812-822, 1995.
1231. JL Lewis, CE Rhoades, PG Gervasi, WC Griffith, AR Dahl. The cyanide-metaboliz- ing enzyme rhodanese in human nasal respiratory mucosa. Toxicol Appl Pharmacol 108:114-120, 1991.
1232. B Winther. Effects on the nasal mucosa of upper respiratory viruses (common cold). Dan Med Bull 41:193-204, 1994.
1233. A Togias, RM Naclerio, D Proud, U Pipkorn, R Bascom, O Ilioupoulos, A Kagey- Sobotka, PS Norman, LM Lichtenstein. Studies on the allergic and nonallergic nasal inflammation. J Allergy Clin Immunol 81:782-790, 1988.
1234. RM Naclerio. Pathophysiology of perennial allergic rhinitis. Allergy 52(suppl 36): 7-13, 1997.
1235. AK Badhwar, HM Druce. Allergic rhinitis. Med Clin North Am 76:789-803, 1992.
1236. D Wang, P Clement. Pathogenic mechanisms underlying the clinical symptoms of allergic rhinitis. Am J Rhinol 14:325-333, 2000. Wermeling and Miller
1237. H Klementsson. Eosinophils and the pathophysiology of allergic rhinitis. Clin Exp Allergy 22:1058-1064, 1992.
1238. R Naclerio, W Solomon. Rhinitis and inhalant allergens. JAMA 278:1842-1848, 1997.
1239. G Philip, AG Togias. Nonallergic rhinitis. Eur Arch Otorhinolaryngol 252(suppl 1):S27-S32, 1995.
1240. A Sanico, A Togias. Noninfectious, nonallergic rhinitis (NINAR): considerations on possible mechanisms. Am J Rhinol 12:65-72, 1998.
1241. M Englender, D Chamovitz, M Harell. Nasal transit time in normal subjects and pathological conditions. Otolaryngol Head Neck Surg 103:909-912, 1990.
1242. EJ Kaminski, OE Fanher, CJ Calandra. In vivo studies of the ciliostatic effects of tobacco smoke. Arch Environ Health 16:188-193, 1968.
1243. DR Edelstein. Aging of the normal nose in adults. Laryngoscope 106(suppl 81): 1-25, 1996.
1244. A Molteni, RL Warpeha, L Brizio-Molteni, EM Fors. Estradiol receptor-binding protein in head and neck neoplastic and normal tissue. Arch Surg 116:207-210, 1981.
1245. N Hamano, N Terada, K Maesako, T Ikeda, S Fukuda, J Wakita, T Yamashita, A Konno. Expression of histamine receptors in nasal epithelial cells and endothelial cells-the effects of sex hormones. Int Arch Allergy Immunol 115:220-227, 1998.
1246. N Hamano, N Terada, K Maesako, T Numata, A Konno. Effect of sex hormones on eosinophilic inflammation in nasal mucosa. Allergy Asthma Proc 19:263-269, 1998.
1247. B Paulsson, T Gredmark, P Burian, M Bende. Nasal mucosal congestion during the menstrual cycle. J Laryngol Otol 111:337-339, 1997.
1248. H Toppozada. The human nasal mucosa in the menopause. J Laryngol Otol 102: 314-318, 1988.
1249. RL Mabry. Rhinitis of pregnancy. South Med J 79:965-971, 1986.
1250. M Bende, U Hallga ˚rde, C Sjo ¨gren, K Uvna ¨s-Moberg. Nasal congestion during preg- nancy. Clin Otolaryngol 14:385-387, 1989.
1251. UP Stu ¨bner, D Gruber, UE Berger, J Toth, B Marks, J Huber, F Horak. The influ- ence of female sex hormones on nasal reactivity in seasonal allergic rhinitis. Allergy 54:865-871, 1999.
1252. A Ginzel, P Illum. Nasal mucocilliary clearance in patients with septal deviation. Rhinology 18:177-181, 1980.
1253. CM Rossman, JB Forrest, RE Ruffin, MT Newhouse. Immotile cilia syndrome in persons with and without Kartagener's syndrome. Am Rev Respir Dis 121:1011- 1016, 1980.
1254. DF Proctor. Transnasal Systemic Medications. Amsterdam: Elsevier, 1985, pp. 101.
1255. K Khanvilkar, MD Donovan, DR Flanagan. Drug transfer through mucus. Adv Drug Del Rev 28:173-193, 2001.
1256. E Marttin, JC Verhoef, C Cullander, SG Romeijn, JF Nagelkerke, FWHM Merkus. Confocal laser scanning microscopic visualization of the transport of dextrans after nasal administration to rats: effects of absorption enhancers. Pharm Res 14:631- 637, 1997.
1257. C McMartin, LEF Hutchinson, R Hyde, GE Peters. Analysis of structural require- ments for the absorption of drugs and macromolecules from the nasal cavity. J Pharm Sci 76:535-540, 1987.
1258. V Agarwal, B Mishra. Recent trends in drug delivery systems: intranasal drug deliv- ery. Ind J Exp Biol 37:6-16, 1999.
1259. SP Newman, F More ´n, SW Clarke. Deposition pattern of nasal sprays in man. Rhinology 26:111-120, 1987.
1260. L Illum, SS Davis. Intranasal insulin. Clin Pharmacokinet 12:30-41, 1992.
1261. WAJJ Hermens, CWJ Belder, JMWM Merkus, PM Hooymans, J Verhoef, FWHM Merkus. Intranasal administration of estradiol in combination with progesterone to ovariectomized women: a pilot study. Eur J Obstet Gynecol Reprod Biol 43:65- 70, 1992.
1262. A Adjei, D Sundberg, J Miller, A Chun. Bioavailability of leuprolide acetate follow- ing nasal and inhalation delivery to rats and healthy humans. Pharm Res 9:244- 249, 1992.
1263. A Hoffman, E Ziv. Pharmacokinetic considerations of new insulin formulations and routes of administration. Clin Pharmacokinet 33:285-301, 1997.
1264. E Cincinelli, F Savino, I Cagnazzo, P Scorcia, P Galantino. Progesterone adminis- tration by nasal spray in menopausal women: comparison between two different spray formulations. Gynecol Endocrinol 6:247-251, 1992.
1265. N Eller, CJ Kollenz, G Hitzenberger. A comparative study of pharmacodynamics and bioavailability of 2 different desmopressin nasal sprays. Int J Clin Pharmacol Ther 36:139-145, 1998.
1266. A Hussain, T Foster, S Hirai, T Kashihara, R Batenhorst, M Jones. Nasal absorption of propanolol in humans. J Pharm Sci 69:1240, 1980.
1267. CJ Johnson, P Olsson, M Bende, T Carlsson, PO Gunnarsson. Absolute bioavail- ability of nicotine applied to different nasal regions. Eur J Clin Pharmacol 41:585- 588, 1991.
1268. T Sakane, M Akizuki, Y Taki, S Yamashita, H Sezaki, T Nadai. Direct drug trans- port from the rat nasal cavity to the cerebrospinal fluid: the relation to the molecular weight of drugs. J Pharm Pharmacol 47:379-384, 1995.
1269. Y Wang, R Aun, FLS Tse. Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. Biopharm Drug Dispos 19:571-575, 1998.
1270. T Sakane, S Yamashita, N Yata, H Sezaki. Transnasal delivery of 5-fluorouracil to the brain in the rat. J Drug Target 7:233-240, 1999.
1271. AN Fisher, K Brown, SS Davis, GD Parr, DA Smith. The effect of molecular size on the nasal absorption of water-soluble compounds in the albino rat. J Pharm Pharmacol 39:357-362, 1987.
1272. A De Ascentu ¨s, R Bettini, G Caponetti, PL Catellani, MT Peracchia, P Santi, P Colombo. Delivery of nasal powders of β-cyclodextrin by insufflation. Pharm Res 13:734-738, 1996.
1273. D Corbo, J Liu, YW Chien. Drug absorption through mucosal membranes: effect of mucosal route and penetrant hydrophilicity. Pharm Res 6:848-852, 1989.
1274. T Ohwaki, H Ando, S Watanabe, Y Miyake. Effects of dose, pH, and osmolarity on the nasal absorption of secretin in rats. J Pharm Sci 74:550-552, 1985.
1275. T Ohwaki, H Ando, F Kakimoto, K Uesugi, S Watanabe, Y Miyake, M Kayano. Wermeling and Miller Effects of dose, pH, and osmolarity on nasal absorption of secretin in rats. II. Histo- logical aspects of the nasal mucosa in relation to the absorption variation due to the effects of pH and osmolarity. J Pharm Sci 76:695-698, 1987.
1276. CR Behl, HK Pimplaskar, AP Sileno, J deMeireles, VD Romeo. Effects of physio- chemical properties and other factors on systemic nasal drug delivery. Adv Drug Del Rev 29:89-116, 1998.
1277. N Shimoda, Y Maitani, Y Machida, T Nagai. Effects of dose, pH and osmolarity on intranasal absorption of recombinant human erythropoietin in rats. Biol Pharm Bull 18:734-739, 1995.
1278. P Valensi, P Zirinis, P Nicolas, G Perret, D Sandre-Banon, JR Attali. Effect of insulin concentration on bioavailability during nasal spray administration. Path Biol 44:235-240, 1996.
1279. AA Hussain, R Bawarshi-Nassar, CH Huang. Physiochemical consideration in in- tranasal drug administrations. In: YW Chein, ed. Transnasal Systemic Medications. Amsterdam: Elsevier, 1985, pp. 121-137.
1280. AW Proetz. Applied Physiology of the Nose. St. Louis: Annals Publishing Com- pany, 1953.
1281. AS Harris, M Ohlin, S Lethagen, IM Nilsson. Effects of concentration and volume on nasal bioavailability and biological response to desmopressin. J Pharm Sci 77: 337-339, 1988.
1282. HJM van de Donk, FWHM Merkus. Decreases in ciliary beat frequency due to intranasal administration of propanolol. J Pharm Sci 71:595-596, 1982.
1283. IL Bernstein. Is the use of benzalkonium chloride as a preservative for nasal formu- lations a safety concern? A cautionary note based on compromised mucocilliary transport. J Allergy Clin Immunol 105:39-44, 2000.
1284. G Hillardal. Adverse reaction to locally applied preservatives in nose drops. ORL J Otorhinolaryngol Relat Spec 47:278-279, 1985.
1285. H Halle ´n, P Graf. Benzalkonium chloride in nasal decongestive sprays has a long- lasting adverse effect on the nasal mucosal of healthy volunteers. Clin Exp Allergy 25:401-405, 1995.
1286. P Graf, H Halle ´n. Effect on the nasal mucosa of long-term treatment with oxymeta- zoline, benzalkonium chloride, and placebo nasal sprays. Laryngoscope 106:605- 609, 1996.
1287. P Graf, H Halle ´n, J-E Juto. Benzalkonium chloride in a decongestant nasal spray aggravates rhinitis medicamentosa in healthy volunteers. Clin Exp Allergy 25:395- 400, 1995.
1288. M Quadir, H Zia, TE Needham. Development and evaluation of nasal formulations of ketorolac. Drug Deliv 7:223-229, 2000.
1289. N Griffith, S Howell, DG Mason. Intranasal midazolam for premedication of chil- dren undergoing day-case anaesthesia: comparison of two delivery systems with assessment of intra-observer variability. Br J Anaesth 81:865-869, 1998.
1290. SF Conley. Comparative trial of acceptability of beclomethasone dipropionate and a new formulation of flunisolide. Ann Allergy 72:829-832, 1994.
1291. EO Meltzer, HA Orgel, RK Bush, JR Haltom, J Metzger, BA Moss, DQ Mitchell, ZK Ballas, JM Seltzer, GG Shapiro, JH Van Bavel. Evaluation of symptom relief, nasal airflow, nasal cytology, and acceptability of two formulations of flunisolide nasal spray in patients with perennial allergic rhinitis. Ann Allergy 64:536-540, 1990.
1292. S Denyer. Pharmaceutical properties of fluticasone propionate nasal drops: a new formulation. Allergy 54:17-20, 1999.
1293. MI Ugwoke, N Verbeke, R Kinget. The biopharmaceutical aspects of nasal mu- coadhesive drug delivery. J Pharm Pharmacol 53:3-22, 2001.
1294. E Marttin, JC Verhoef, FWHM Merkus. Efficacy, safety and mechanism of cyclo- dextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J Drug Target 6:17-36, 1998.
1295. E Marttin, JC Verhoef, F Spies, J van der Meulen, JF Nagelkerke, HK Koerten, FWHM Merkus. The effect of methylated β-cyclodextrins on the tight junctions of the rat nasal respiratory epithelium: electron microscopic and confocal laser scanning microscopic visualization studies. J Control Rel 57:205-213, 1999.
1296. K Matsubara, K Abe, T Irie, K Uekema. Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, burserelin, by cyclodextrin deriva- tives in rats. J Pharm Sci 84:1295-1300, 1995.
1297. C Agerholm, L Bastholm, PB Johansen, MH Nielsen, F Elling. Epithelial trans- port and bioavailability of intranasally administered human growth hormone formu- lated with the absorption enhancers didecanoyl-l-α-phosphatidylcholine and α- cyclodextrin in rabbits. J Pharm Sci 83:1706-1711, 1994.
1298. FWHM Merkus, JC Verhoef, SG Romeijn, NGM Schipper. Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats. Pharm Res 8: 588-592, 1991.
1299. Y Watanabe, Y Matsumoto, K Kawamoto, S Yazawa, M Matsumoto. Enhancing effect of cyclodextrins on nasal absorption of insulin and its duration in rabbits. Chem Pharm Bull 40:3100-3104, 1992.
1300. Z Shao, R Krishnamoorthy, A Mitra. Cyclodextrins as nasal absorption promoters of insulin: mechanistic evaluations. Pharm Res 9:1157-1163, 1992.
1301. NGM Schipper, SG Romeijn, JC Verhoef, FWHM Merkus. Nasal insulin delivery with dimethyl-β-cyclodextrin as an absorption enhancer in rabbits: powder more effective than liquid formulations. Pharm Res 10:682-686, 1993.
1302. NGM Schipper, JC Verhoef, LM De Lannoy, SG Romeijn, JH Brakkee, VM Wie- gant, WH Gispen, FWHM Merkus. Nasal administration of an ACTH(4-9) peptide analogue with dimethyl-β-cyclodextrin as an absorption enhancer: pharmacokinet- ics and dynamics. Br J Pharmacol 110:1334-1340, 1993.
1303. NSM Schipper, JC Verhoef, SG Romeijn, FWHM Merkus. Methylated β-cyclodex- tins are able to improve the nasal absorption of salmon calcitonin. Calcif Tissue Int 56:280-282, 1995.
1304. M Machida, K Sano, M Arakawa, M Hayashi, S Awazu. Effects of surfactants and protease inhibitors on nasal absorption of recombinant human granulocyte colony- stimulating factor (rhG-CSF) in rats. Biol Pharm Bull 17:1375-1378, 1994.
1305. K Morimoto, H Yamaguchi, Y Iwakura, M Miyazaki, E Nakatani, T Iwamoto, Y Ohashi, Y Nakai. Effects of proteolytic enzyme inhibitors on the nasal absorption of vasopressin and an analogue. Pharm Res 8:1175-1179, 1991. Wermeling and Miller
1306. K Drejer, A Vaag, K Bech, P Hansen, AR Sørensen, N Mygind. Intranasal adminis- tration of insulin with phospholipid as absorption enhancer: pharmacokinetics in normal subjects. Diabet Med 9:335-340, 1992.
1307. BJ Aungst, NJ Rogers. Site dependence of absorption-promoting actions of laureth- 9, Na salicylate, Na 2 EDTA, and aprotinin on rectal, nasal, and buccal insulin deliv- ery. Pharm Res 5:305-308, 1988.
1308. S Kagatani, T Shinoda, M Fukui, T Ohmura, S Hasumi, T Sonobe. Enhancement of nasal salmon calcitonin absorption by lauroylcarnitine chloride in rats. Pharm Res 13:739-743, 1996.
1309. M Mishima, S Okada, Y Wakita, M Nakano. Promotion of nasal absorption of insulin by glycyrrhetinic acid derivatives. I. J Pharmacobio-Dyn 12:31-36, 1989.
1310. C Baglioni, RJ Phipps. Nasal absorption of interferon: enhancement by surfactant agents. J Interferon Res 10:497-504, 1990.
1311. MJM Duerloo, WAJJ Hermens, SG Romeyn, JC Verhoef, FWHM Merkus. Absorp- tion enhancement of intranasally administered insulin by sodium taurodihydrofusi- date (STDHF) in rabbits and rats. Pharm Res 6:853-856, 1989.
1312. K Hosoya, H Kubo, T Akutsu, H Natsume, K Sugibayashi, Y Morimoto. Effect of sodium taurodihydrofusidate on nasal drug delivery: differences in its concentra- tion and penetrant molecular weight. Arch Pharm Res 17:57-59, 1994.
1313. A Donnelly, IW Kellaway, G Taylor, M Gibson. Absorption enhancers as tools to determine the route of nasal absorption of peptides. J Drug Target 5:121-127, 1997.
1314. L Illum. Bioadhesive formulations for nasal peptide delivery. In: E Mathiowitz, DE Chickering III, C Lehr, eds. Bioadhesive Drug Delivery Systems. New York: Marcel Dekker, 1999, pp. 507-541.
1315. KA Janes, P Calvo, MJ Alonso. Polysaccharide colloidal particles as delivery sys- tems for macromolecules. Adv Drug Del Rev 47:83-97, 2001.
1316. P Tengamnuay, A Sahamethapat, A Sailasuta, AK Mitra. Chitosans as nasal absorp- tion enhancers of peptides: comparison between free amine chitosans and soluble salts. Int J Pharm 197:53-67, 2000.
1317. EA McNeela, D O'Connor, I Jabbal-Gill, L Illum, SS Davis, M Pizza, S Peppoloni, R Rappuoli, KHG Mills. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM 197 ) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 19:1188- 1198, 2001.
1318. C Sankar, M Rani, AK Srivastava, B Mishra. Chitosan based pentazocine micro- spheres for intranasal systemic delivery: development and biopharmaceutical evalu- ation. Pharmazie 56:223-226, 2001.
1319. L Illum, NF Farraj, SS Davis. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 11:1186-1189, 1994.
1320. J Woodley. Bioadhesion new possibilities for drug administration? Clin Pharma- cokinet 40:77-84, 2001.
1321. R Ferna ´ndez-Urrusono, P Calvo, C Remun ˜a ´n-Lo ´pez, JL Vila-Jato, MJ Alonso. En- hancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res 16:1576-1581, 1999.
1322. RJ Soane, M Frier, AC Perkins, NS Jones, SS Davis, L Illum. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 178:55- 65, 1999.
1323. H Critchley, SS Davis, NF Farraj, L Illum. Nasal absorption of desmopressin in rats and sheep. Effect of a bioadhesive microsphere delivery system. J Pharm Phar- macol 46:651-656, 1994.
1324. P Edman, E Bjork, L Ryden. Microspheres as a nasal delivery system for peptide drugs. J Control Rel 21:165-172, 1992.
1325. MI Ugwoke, E Sam, G Van Den Mooter, N Verbeke, R Kinget. Nasal mucoadhe- sive delivery systems of the anti-parkinsonian drug, apomorphine: influence of drug-loading on in vitro and in vivo release in rabbits. Int J Pharm 181:125-138, 1999.
1326. MI Ugwoke, RU Agu, M Jorissen, P Augustijns, R Sciot, N Verbeke, R Kinget. Nasal toxicological investigations of carbopol 971P formulation of apomorphine: effects on ciliary beat frequency of human nasal primary cell culture and in vivo on rabbit nasal mucosa. Eur J Pharm Sci 9:387-396, 2000.
1327. JS Chu, R Chandrasekharan, GL Amidon, ND Weiner, AH Goldberg. Viscometric study of polyacrylic acid systems as mucoadhesive sustained-release gels. Pharm Res 8:1408-1412, 1991.
1328. MI Ugwoke, RU Agu, M Jorissen, P Augustijns, R Sciot, N Verbeke, R Kinget. Toxicological investigations of the effects carboxymethylcellulose on ciliary beat frequency of human nasal epithelial cells in primary suspension culture and in vivo of rabbit nasal mucosa. Int J Pharm 205:43-51, 2000.
1329. MI Ugwoke, G Kaufmann, N Verbeke, R Kinget. Intranasal bioavailability of apo- morphine from carboxymethylcellulose-based drug delivery systems. Int J Pharm 202:125-131, 2000.
1330. K Nakamura, Y Maitani, AM Lowman, K Takayama, NA Peppas, T Nagai. Uptake and release of budesonide from mucoadhesive, pH-sensitive copolymers and their application to nasal delivery. J Control Rel 61:329-335, 1999.
1331. M Singh, M Briones, DT O'Hagan. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J Control Rel 70:267-276, 2001.
1332. LE Bromberg. Enhanced nasal retention of hydrophobically modified polyelectro- lytes. J Pharm Pharmacol 53:109-114, 2001.
1333. K Morimoto, H Katsumata, T Yabuta, K Iwanaga, M Kakemi, Y Tabata, Y Ikada. Evaluation of gelatin microspheres for nasal and intramuscular administrations of salmon calcitonin. Eur J Pharm Sci 13:179-185, 2001.
1334. B Brime, MP Ballesteros, P Frutos. Preparation and in vitro characterization of gelatin microspheres containing levodopa for nasal administration. J Microencapsul 17:777-784, 2000.
1335. K Aikawa, K Matsumoto, H Uda, S Tanaka, H Shimamura, Y Aramaki, S Tsuchiya. Prolonged release of drug from O/W emulsion and residence in rat nasal cavity. Pharm Dev Technol 3:461-469, 1998.
1336. TW Kim, H Chung, IC Kwon, HC Sung, SY Jeong. In vivo gene transfer to the mouse nasal cavity mucosa using a stable cationic lipid emulsion. Mol Cells 10: 142-147, 2000. Wermeling and Miller
1337. TT Kararli, TE Needham, G Schoenhard, DA Baron, RE Schmidt, B Katz, B Be- lonio. Enhancement of nasal delivery of a renin inhibitor in the rat using emulsion formulations. Pharm Res 9:1024-1028, 1992.
1338. SL Law, KJ Huang, HY Chou. Preparation of desmopressin-containing liposomes for intranasal delivery. J Control Rel 70:375-382, 2001.
1339. BH Jung, BC Chung, S Chung, M Lee, C Shim. Prolonged delivery of nicotine in rats via nasal administration of proliposomes. J Control Rel 66:73-79, 2000.
1340. D Betbeder, S Spe ´randio, J Latapie, J de Nadaı ´, A Etienne, J Zajac, B Frances. Biovector nanoparticles improve antinociceptive efficacy of nasal morphine. Pharm Res 17:743-748, 2000.
1341. M Tobı ´o, R Gref, A Sa ´nchez, R Langer, MJ Alonso. Stealth PLA-PEG nanopar- ticles as protein carriers for nasal administration. Pharm Res 15:270-275, 1998.
1342. JE Nally, S Artiushin, AS Sheoran, PJ Burns, B Simon, RM Gilley, J Gibson, S Sullivan, JF Timoney. Induction of mucosal and systemic antibody specific for SeMF3 of Streptococcus equi by intranasal vaccination using a sucrose acetate iso- butyrate based delivery system. Vaccine 19:492-497, 2001.
1343. Poly(ethylene oxide)-b- Poly(propylene oxide)-b- Poly(ethylene oxide)-g-Poly(acrylic acid) Copolymers as In Situ Gelling Vehicle for Nasal Delivery Lev Bromberg Massachusetts Institute of Technology, Cambridge, Massachusetts, U.S.A. REFERENCES
1344. L Bromberg, EC Lupton, ME Schiller, MJ Timm, G McKinney. Responsive polymer networks and methods of their use. US patent 5,939,485, 1999.
1345. AS Hoffman, G Chen. Block and graft copolymers and methods related thereto. Int patent appl WO 95/24430, 1995.
1346. ES Ron, L Bromberg, M Orkisz, M Kearney, S Luczak, MJ Timm, SJ Wrobel. Compositions for pharmaceutical applications. Int patent appl WO 98/06438, 1998.
1347. ES Ron, BJ Hand, L Bromberg, M Kearney, ME Schiller, PM Ahearn, S Luczak, THE Mendum. Compositions for cosmetic applications. Int patent appl WO 98/ 50005, 1998.
1348. ES Ron, LE Bromberg, M Temchenko. End modified thermal responsive hydrogels. UA patent 6,316,011, 2001.
1349. KJ Himmelstein, CL Baustian. Reversible gel-forming composition for sustained delivery of bio-affecting substances, and method of use. US patent 5,599,534, 1997.
1350. TX Viegas, LE Reeve, RS Levinson. Body cavity drug delivery with thermorevers- ible gels containing polyoxyalkylene copolymers. US patent 5,292,516, 1994.
1351. R Joshi, DH Robinson, KJ Himmelstein. In vitro properties of an in situ forming gel for the parenteral delivery of macromolecular drugs, Pharm Dev Technol 4:515- 522, 1999.
1352. L Bromberg. Hydrophobically modified polyelectrolytes and polyelectrolyte block- copolymers. In: HS Nalwa, ed. Handbook of Surfaces and Interfaces of Materials. Vol 4. New York: Academic Press, 2001, Chapter 7.
1353. L Bromberg. Biomedical applications of hydrophobically modified polyelectrolytes and polyelectrolyte block-copolymers. In: S Tripathy, J Kumar, HS Nalwa, eds. Handbook of Polyelectrolytes and Their Applications. American Scientific Publish- ers, Stevenson Ranch, CA, 2002, Vol. 1, Chaper 51.
1354. LE Bromberg, THE Mendum, M Orkisz, ES Ron, EC Lupton. Applications of poly(oxyethylene-b-oxypropylene-b-oxyethylene)-g-poly(acrylic acid) polymers (Smart Hydrogel) in drug delivery. Proc Polym Mater Sci Eng 76:273-275, 1997.
1355. MJ Orkisz, L Bromberg, R Pike, EC Lupton, ES Ron. Rheological properties of reverse thermogelling poly(acrylic acid)-g-poly(oxyethylene-b-oxypropylene-b- oxyethylene) polymers (Smart Hydrogel). Proc Polym Mater Sci Eng 76:276-277, 1997.
1356. L Bromberg, M Orkisz, E Roos, ES Ron, M Schiller. Interpenetrating networks of Poloxamer copolymers and poly(acrylic acid) as vehicles in controlled drug delivery. J Control Rel 48:305-308, 1997.
1357. LE Bromberg, THE Mendum, MJ Orkisz, EC Lupton, ES Ron. Polyoxyethylene- b-polyoxypropylene-b-polyoxyethylene-g-poly(acrylic acid) polymers (Smart Hy- drogel) as a carrier in controlled delivery of proteins and peptides. Polym Prep 38: 602-603, 1997.
1358. LE Bromberg, MJ Orkisz, ES Ron. Bioadhesive properties of polyoxyethylene-b- polyoxypropylene-b-polyoxyethylene-g-poly(acrylic acid) polymers (Smart Hy- drogel). Polym Prep 38:626-627, 1997.
1359. L Bromberg. A novel family of thermogelling materials via C-C bonding between poly(acrylic acid) and poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethyl- ene oxide). J Phys Chem B 102:1956-1963, 1998.
1360. LE Bromberg, ES Ron. Protein and peptide release from temperature-responsive gels and thermogelling polymer matrices. Adv Drug Del Rev 31:197-221, 1998.
1361. LE Bromberg, MG Goldfeld. Self-assembly in aqueous solutions of hydrophobically modified poly(acrylic acid). Polym Prep 39:681-682, 1998.
1362. L Bromberg. Scaling of rheological properties of hydrogels from associating poly- mers. Macromolecules 31:6148-6156, 1998.
1363. L Bromberg. Self-assembly in aqueous solutions of polyether-modified poly(acrylic acid). Langmuir 14:5806-5812, 1998.
1364. L Bromberg. Polyether-modified poly(acrylic acid): synthesis and properties. Ind Eng Chem Res 37:4267-4274, 1998.
1365. L Bromberg. Properties of aqueous solutions and gels of poly(ethylene oxide)-b- poly(propylene oxide)-b-poly(ethylene oxide)-g-poly(acrylic acid). J Phys Chem B 102:10736-10744, 1998.
1366. L Bromberg, L Salvati. Bioactive surfaces via immobilization of self-assembling polymers onto hydrophobic materials. Bioconjug Chem 10:678-686, 1999.
1367. LE Bromberg. Interactions between hydrophobically modified polyelectrolytes and mucin. Polym Prep 40:616-617, 1999.
1368. LE Bromberg, DP Barr. Aggregation phenomena in aqueous solutions of hydropho- bically modified polyelectrolytes: a probe solubilization study. Macromolecules 32: 3649-3657, 1999.
1369. PDT Huibers, LE Bromberg, BH Robinson, TA Hatton. Reversible gelation in semi- dilute aqueous solutions of associative polymers: a small-angle neutron scattering study. Macromolecules 32:4889-4894, 1999.
1370. L Bromberg, E Magner. Release of hydrophobic compounds from micellar solutions of hydrophobically modified polyelectrolytes. Langmuir 15:6792-6798, 1999.
1371. L Bromberg, M Temchenko. Loading of hydrophobic compounds into micellar solu- tions of hydrophobically modified polyelectrolytes. Langmuir 15:8627-8632, 1999.
1372. LE Bromberg, M Temchenko, RH Colby. Interactions among hydrophobically modified polyelectrolytes and surfactants of the same charge. Langmuir 16:2609-2614, 2000.
1373. N Plucktaveesak, LE Bromberg, RH Colby. Effect of surfactants on gelation threshold temperature in aqueous solutions of hydrophobically modified polyelectrolyte. Proc. XII- Ith International Congress on Rheology, Cambridge, UK. Vol. 3. 2000, pp. 307-309.
1374. L Bromberg. Enhanced nasal retention of hydrophobically modified polyelectrolytes. J Pharm Pharmacol 53:109-114, 2001.
1375. L Bromberg. Interactions among proteins and hydrophobically modified polyelectro- lytes. J Pharm Pharmacol 53:541-547, 2001.
1376. AK Ho, LE Bromberg, AJ O'Connor, JM Perera, GW Stevens, TA Hatton. Solute diffusion in solutions of associative polymers. Langmuir 17:3538-3544, 2001.
1377. RH Colby, N Plucktaveesak, L Bromberg. Critical incorporation concentration of surfactants added to micellar solutions of hydrophobically modified polyelectrolytes of the same charge. Langmuir 17:2937-2941, 2001.
1378. L Bromberg. Synthesis and self-assembly of poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide)-g-poly(acrylic acid) gels. Ind Eng Chem Res 40: 2437-2444, 2001.
1379. L Olivieri, M Seiller, L Bromberg, E Ron, P Couvreur, J-L Grossiord. Study of the breakup under shear of a new thermally reversible W/O/W multiple emulsion. Pharm Res 18:689-693, 2001.
1380. AK Ho, LE Bromberg, PDT Huibers, AJ O'Connor, JM Perera, GW Stevens, TA Hatton. Hydrophobic domains in thermogelling solutions of polyether-modified poly(acrylic acid). Langmuir, 18:3005-3013, 2002.
1381. AS Hoffman, GH Chen, SY Kaang, ZL Ding, K Randeri, B Kabra. Novel bioadhe- sive, pH-and temperature-sensitive graft copolymers for prolonged mucosal drug delivery. In: N Ogata, SW Kim, J Feijen, T Okano, eds. Advanced Biomaterials in Biomedical Engineering and Drug Delivery Systems. Tokyo: Springer, 1996, pp. 62-66.
1382. AS Hoffman, G Chen, X Wu, Z Ding, B Kabra, K Randeri, M Schiller, E Ron, NA Peppas, C Brazel. Graft copolymers of PEO-PPO-PEO triblock polyethers on bioadhe- sive polymer backbones: synthesis and properties. Polym Prep 38:524-525, 1997.
1383. G Chen, AS Hoffman, B Kabra, K Randeri. Temperature-induced gelation Pluronic- g-poly(acrylic acid) graft copolymers for prolonged drug delivery to the eye. In: M Harris, S Zalipsky, eds. Poly(ethylene glycol) Chemistry and Biological Applica- tions. ACS Symposium Series 680. Washington, DC: American Chemical Society. 1997, pp. 441-457. Chapter 27.
1384. AS Hoffman, G Chen, X Wu, Z Ding, JE Matsuura, WR Gombotz, Stimuli-respon- sive polymers grafted onto polyacrylic acid and chitosan backbones as bioadhesive carriers for mucosal drug delivery. In: RM Ottenbrite, ed. Frontiers in Biomedical Polymer Applications. Vol. 2. Lancaster, PA: Technomic Publishing Co., 1999, pp. 17-29.
1385. Carbopol. The Proven Polymers in Pharmaceuticals. Bulletin 14, Cleveland, OH: BF Goodrich Specialty Chemicals, 1994.
1386. JR Robinson, MA Longer, M Veillard. Bioadhesive polymers for controlled drug delivery. Ann NY Acad Sci 507:307-314, 1987.
1387. JW Lee, JH Park, JR Robinson. Bioadhesive-based dosage forms: the next genera- tion. J Pharm Sci 89:850-866, 2000.
1388. BASF Performance Chemicals. FDA and EPA status. North Mount Olive, NJ: BASF Corporation, 1993.
1389. L Illum. Bioadhesive formulations for nasal peptide delivery. In: E Mathiowitz, DE Chickering, CM Lehr, eds. Bioadhesive Drug Delivery Systems. New York: Marcel Dekker, 2000, pp. 507-562.
1390. M Hinchcliffe, L Illum. Intranasal insulin delivery and therapy. Adv Drug Del Rev 35:199-234, 1999.
1391. AM Potts, CG Wilson, HNE Stevens, DJ Dobrozsi, N Washington, M Frier, AC Perkins. Oesophageal bandaging: a new opportunity for thermosetting polymers. STP Pharma Sci 4:293-301, 2000.
1392. S Hirai, T Yashiki, T Matsuzawa, H Mima. Effect of surfactants on the nasal absorp- tion of insulin in rats. Int J Pharm 9:165-172, 1981.
1393. L Bromberg, M Temchenko, TA Hatton. Dually responsive microgels from poly- ether-modified poly(acrylic acid): swelling and drug loading. Langmuir, 18:4944- 4952, 2002.
1394. DA Edwards, KJ Gooch, I Zhang, GH McKinley, R Langer. The nucleation of recep- tor-mediated endocytosis. Proc Natl Acad Sci USA 93:1786-1791, 1996. REFERENCES
1395. DI Macht. The absorption of drugs and poisons through the vagina. J Pharmacol Pathol 10:509-522, 1918.
1396. RW Kistner. Physiology of the vagina. In: ESE Hafez, TN Evans, eds. Human Re- productive Medicine: The Human Vagina. Vol. 2. New York: North-Holland, 1978, pp. 109-120.
1397. J Paavonen. Physiology and ecology of the vagina. Scand J Infect Dis 40(suppl): 31-35, 1983.
1398. AA Deshpande, CT Rhodes, M Danish. Intravaginal drug delivery. Drug Dev Ind Pharm 18:1225-1279, 1992.
1399. VR Tindall. Jeffcoate's Principles of Gynaecology. London: Butterworth, 1987.
1400. LP Gartner, JL Hiatt. Color Atlas of Histology. Baltimore: Williams & Wilkins, 1994.
1401. MH Burgos, CE De Vargas-Linares. Ultrastructure of the vaginal mucosa. In: ESE Hafez, TN Evans, eds. Human Reproductive Medicine: The Human Vagina. Vol.
1402. K Yu, YW Chien. Vaginal delivery and absorption of drugs. In: J Swarbrick, JC Boylan, eds. Encyclopedia of Pharmaceutical Technology. New York: Marcel Dek- ker, 1995, pp. 153-185.
1403. TS Leeson, CR Leeson, AA Pap. Textbook of Histology. Philadelphia: Saunders, 1988.
1404. IR Telford. CF Bridgman. Introduction to Functional Histology. Grand Rapids, MI: Harper Collins, 1995.
1405. SI Fox. Human Physiology. 6th ed. Boston: McGraw-Hill, 1999.
1406. G Wagner, RJ Levin. Vaginal fluid. In: ESE Hafez, TN Evans, eds. Human Repro- ductive Medicine: The Human Vagina. Vol. 2. New York: North-Holland, 1978, pp. 121-137.
1407. N Washington, CG Wilson. Physiological factors affecting drug delivery and avail- ability. In: J Swarbrick, JC Boylan, eds. Encyclopedia of Pharmaceutical Technol- ogy. New York: Marcel Dekker, 1995, pp. 137-169.
1408. WH Masters, VE Johnson. Human Sexual Response. Boston: Little, Brown, 1966.
1409. JL Richardson, L Illum. Routes of delivery-case studies: the vaginal route of pep- tide and protein drug delivery. Adv Drug Del Rev 8:341-366, 1992.
1410. CP Wendell Smith, PM Wilson. The vulva, vagina and urethra and the musculature of the pelvic floor. In: E Philipp, M Setchell, J Ginsburg, eds. Scientific Foundations of Obstetrics and Gynaecology. London: Butterworth Heinemann, 1991, pp. 84-85.
1411. DL Draper, DV Landers, MA Krohn, SL Hillier, HC Wiesenfeld, RP Heine. Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections. Am J Obstet Gynecol 183:1243-1248, 2000.
1412. AM Weber, MD Walters, LR Schover, AV Mitchinson. Vaginal anatomy and sexual function. Obstet Gynecol 86:946-949, 1995.
1413. S Jaszczak, ESE Hafez. Human Reproduction, Conception and Contraception. 2nd ed. Philadelphia: Harper & Row, 1980.
1414. GGG Donders, E Bosmans, A Dekeersmaecker, A Vereecken, B Van Bulck, B Spitz. Pathogenesis of abnormal vaginal bacterial flora. Am J Obstet Gynecol 182:872- 878, 2000.
1415. EM Curtis, L Pine. Actinomyces in the vaginas of women with and without intra- uterine contraceptive devices. Am J Obstet Gynecol 140:880-884, 1981.
1416. JS Welch. Quantitative and qualitative effects of douche preparations on vaginal microflora. Obstet Gynecol 81:320-321, 1993.
1417. MJ Goldacre, B Watt, N Loudon, MP Vessey. Vaginal microbial flora in normal young women. Br Med J 1:1450-1459, 1979.
1418. S Roy, J Wilkins, DR Mishell. The effect of a contraceptive vaginal ring and oral contraceptives on the vaginal flora. Contraception 24:481-491, 1981.
1419. A Schwan, T Ahren, A Victor. Effects of contraceptive vaginal ring treatment on vaginal bacteriology and cytology. Contraception 28:341-347, 1983.
1420. S Roy, DR Mishell. Vaginal ring clinical studies: update. In: GI Zatuchni, A Gold- smith, JD Shelton, JJ Sciarra, eds. Long-Acting Contraceptive Delivery Systems. Philadelphia: Harper & Row, 1983, pp. 581-594.
1421. HA Nash, V Brache, F Alvarez-Sanchez, TM Jackanicz, TM Harmon. Estradiol delivery by vaginal rings: potential for hormone replacement therapy. Maturitas 26: 27-33, 1997.
1422. SJ Singer, GL Nicolson. The fluid mosaic model of the structure of cell membranes. Science 175:720-722, 1972.
1423. YW Chien. Novel Drug Delivery Systems. 2nd ed. New York: Marcel Dekker, 1992.
1424. GL Flynn, NFH Ho, S Hwang, E Owada, A Molokhia, CR Behl, WI Higuchi, T Yotsuyanagi, Y Shah, J Park. Controlled release polymeric formulations. In: DR Paul, FW Harris, eds. ACS Symposium Series 33. Washington, DC: American Chemical Society, 1976, pp. 87.
1425. AP Sayani, YW Chien. Systemic delivery of peptides and proteins across absorptive mucosae. Crit Rev Ther Drug Carr Syst 13:85-184, 1996.
1426. A Gursoy, A Bayhan. Testing of drug release from bioadhesive vaginal tablets. Drug Dev Ind Pharm 18:203-221, 1992.
1427. A Gursoy, I Sohtorik, N Uyanik, NA Peppas. Bioadhesive controlled release systems for vaginal delivery. STP Pharma Sci 5:886-892, 1989.
1428. TM Jackanicz. Vaginal ring steroid-releasing systems. In: GI Zatuchni, AJ Sobrero, JJ Speidel, J Sciarra, eds. Vaginal Contraception: New Developments. Philadelphia: Harper & Row, 1979, pp. 201-212.
1429. AD Woolfson, GRE Elliott, CA Gilligan, CM Passmore. Design of an intravaginal ring for the controlled delivery of 17beta-estradiol as its 3-acetate ester. J Control Rel 61:319-328, 1999.
1430. VHL Lee. Enzymatic barriers to peptide and protein absorption. Crit Rev Ther Drug Carr Syst 5:69-98, 1988.
1431. JL Richardson, NF Farraj, L Illum. Enhanced vaginal absorption of insulin in sheep using lysophosphatidylcholine and a bioadhesive microsphere system. Int J Pharm 88:319-325, 1992.
1432. D Duche ˆne, F Touchard, NA Peppas. Pharmaceutical and medical aspects of bio- adhesive systems for drug administration. Drug Dev Ind Pharm 14:283-318, 1988.
1433. L Brannon-Peppas. Novel vaginal drug-release applications. Adv Drug Del Rev 11: 169-177, 1993.
1434. CM Lehr, JA Bouwstra, HE Bodde ´, HE Junginger. A surface energy analysis of mucoadhesion: contact angle measurements on polycarbophil and pig intestinal mu- cosa in physiologically relevant fluids. Pharm Res 9:70-75, 1992.
1435. MA Longer, JR Robinson. Fundamental aspects of bioadhesion. Pharm Int 7:114- 117, 1986.
1436. M Zulfiqar, A Quddos, S Zulfiqar. Polyurethane networks based on poly(ethylene oxide). J Appl Polymer Sci 49:2055-2060, 1993.
1437. J Brown, G Hooper, CJ Kenyon, S Haines, J Burt, JM Humphries, SP. Newman, SS.
1438. Davis, RA Sparrow, IR. Wilding. Spreading and retention of vaginal formulations in post-menopausal women as assessed by gamma scintigraphy. Pharm Res 14:1073- 1078, 1997.
1439. J Rock, RH Barker, WB Bacon. Vaginal absorption of penicillin. Science 105:13- 15, 1947.
1440. DT O'Hagan, D Rafferty, S Wharton, L Illum. Intravaginal immunization in sheep using a bioadhesive microsphere antigen delivery system. Vaccine 11:660-664, 1993.
1441. JL Richardson, PA Ramires, MR Miglietta, M Rochira, L Bacelle, L Callegaro, L Benedetti. Novel vaginal delivery systems for calcitonin. 1. Evaluation of HYAFF calcitonin microspheres in rats. Int J Pharm 115:9-15, 1995.
1442. M Rochira, MR Miglietta, JL Richardson, L Ferrari, M Beccaro, ML Benedetti. Novel vaginal delivery systems for calcitonin. 2. Preparation and characterization of HYAFF(R) microspheres containing calcitonin. Int J Pharm 144:19-26, 1996.
1443. YD Sanzgiri, EM Topp, L Benedetti, L, VJ Stella. Evaluation of mucoadhesive prop- erties of hyluronic acid benzyl esters. Int J Pharm 107:91-97, 1994. REFERENCES
1444. PJ Dzuik, B Cook. Passage of steroids through silicone rubber. Endocrinology 87: 208-211, 1966.
1445. DI Macht. The absorption of drugs and poisons through the vagina. J Pharmacol Pathol 10:509-522, 1918.
1446. GW Duncan. US patent 3,545,439, 1970. Malcolm
1447. DR Mishell, M Talas, AF Parlow, DL Moyer. Contraception by means of a silastic vaginal ring impregnated with medroxyprogesterone acetate. Am J Obstet Gynecol 107:100-107, 1970.
1448. DR Mishell, ME Lumkin. Contraceptive effect of varying doses of progestogen in Silastic vaginal rings. Fertil Steril 21:99-103, 1970.
1449. J Vartiainen, T Wahlstrom, CG Nilsson. Effects and acceptability of a new 17β- estradiol-releasing vaginal ring in the treatment of postmenopausal complaints. Ma- turitas 117:129-137, 1993.
1450. F Roumen, T Dieben. Clinical acceptability of an ethylene-vinyl acetate nonmedi- cated vaginal ring. Contraception 59:59-62, 1999.
1451. G Lose, E. Englev. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. Br J Obstet Gynecol 107:1029-1034, 2000.
1452. BC Eriksen. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 180:1072-1079, 1999.
1453. R Barentsen, PHM vandeWeijer, JHN Schram. Continuous low dose estradiol re- leased from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol 71:73-80, 1997.
1454. D Botsis, D Kassanos, D Kalogirou, G Antoniou, P Karakitsos, PA Zourlas. A comparative study of an estradiol-releasing vaginal ring versus tibolone in post- menopausal women: a transvaginal color Doppler study. Maturitas 27:77-83, 1997.
1455. D Kalogirou, G Antoniou, P Karakitsos, O Kalogirou, D Antoniou, L Giannikos. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel- releasing IUD: Clinical findings and endometrial response. Int J Fertil 41:522-527, 1996.
1456. L Henriksson, M Stjernquist, L Boquist, I Cedergren, I Selinus. A one-year multicen- ter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 174:85-92, 1996.
1457. J Gabrielsson, I Wallenbeck, G Larsson, L Birgerson, G Heimer. New kinetic data on estradiol in light of the vaginal ring concept. Maturitas 22:S35-S39, 1995.
1458. G Schmidt, SB Andersson, O Nordle, CJ Johansson, PO Gunnarsson. Release of 17-beta-estradiol from a vaginal ring in postmenopausal women-pharmacokinetic evaluation. Gyneco Obste Invest 38:253-260, 1994.
1459. P Smith, G Heimer, M Lindskog, U Ulmsten. Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas 16:145-154, 1993.
1460. CJ Timmer, TMT Mulders. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 39:233- 242, 2000.
1461. FJME Roumen, ME Boon, D van Velzen, TOM Dieben, HJT Coelingh Bennink. The cervico-vaginal epithelium during 20 cycles' use of a combined contraceptive vaginal ring. Hum Reprod 11:2443-2448, 1996.
1462. GC Davies, TOM Dieben, LX Feng, JR Newton. Ovarian activity and bleeding pat- terns during extended continuous use of a combined contraceptive vaginal ring, Con- traception 46:269-278, 1992.
1463. GC Davies, TOM Dieben, LX Feng, JR Newton. The effects of a combined contra- ceptive vaginal ring releasing ethinyloestradiol and 3-ketodesogestrel on vaginal flora. Contraception 45:511-518, 1992.
1464. D Apter, B Cacciatore, UH Stenman. Clinical performance and endocrine profiles of contraceptive vaginal rings releasing 3-ketodesogestrel and ethinyloestradiol. Contraception 42:285-295, 1990.
1465. SE Olsson, V Odlind. Contraception with a vaginal ring releasing ethinyloestradiol and 3-ketodesogestrel. Contraception 42:563-572, 1990.
1466. F Roumen, T Dieben, R Assendorp, P Bouckaert. The clinical acceptability of a non-medicated vaginal ring. Contraception 42:201-207, 1990.
1467. CJ Timmer, D Apter, G Voortman. Pharmacokinetics of 3-ketodesogestrel and ethi- nyloestradiol released from different types of contraceptive vaginal rings. Contracep- tion 42:62, 1993.
1468. AD Woolfson, GRE Elliott, CA Gilligan, CM Passmore. Design of an intravaginal ring for the controlled delivery of 17β-estradiol as its 3-acetate ester. J Control Rel 61:319-328, 1999.
1469. JA Russell, RK Malcolm, K Campbell, AD Woolfson. High performance liquid chromatographic determination of 17β-estradiol and 17β-estradiol-3-acetate solubil- ities and diffusion coefficients in silicone elastomeric intravaginal rings. J Chrom Biom B 744:157-163, 2000.
1470. IS Fraser, E Weisberg, E Minehan, EDB Johansson. A detailed analysis of menstrual blood loss in women using Norplant and Nesterone progestogen-only contraceptive implants or vaginal rings. Contraception 61:241-251, 2000.
1471. IS Fraser, M Lacarra, DR Mishell. Vaginal epithelial surface appearances in women using vaginal rings for contraception. Contraception 61:131-138, 2000.
1472. Z Tuba, CW Bardin, A Dancsi. Synthesis and biological activity of a new progesto- gen, 14-methylene-17-alpha-hydroxy-18-methyl-19-norpregn-4-ene-3,20-dione ace- tate. Steroids 65:266-274, 2000.
1473. A Robbins, CW Bardin. Nestorone, progestin-the ideal progestin for use in con- trolled release delivery systems. Ann NY Acad Sci 828:38-46, 1997.
1474. F Li, N Kumar, YY Tsong. Synthesis and progestational activity of 16-methylene-17 alpha-hydroxy-19-norpregn-4-ene-3,20-dione and its derivatives. Steroids 62:403- 408, 1997.
1475. F Alvarez-Sanchez, V Brache, T Jackanicz, A Faundes. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles. Contraception 46:387-398, 1992.
1476. TM Jackanicz, F Alvarez-Sanchez, V Brache, K Elomaa, B Charbonnel, P Bouchard. Clinical studies of Nestorone progestin/ethynylestradiol contraceptive rings. Pro- ceedings of the 4th Congress of the European Society of Contraception. Eur J Cont Reprod Health Care 1:136, 1996.
1477. E Weisberg, IS Fraser, DR Mishell Jr., M Lacarra, P Darney, T Jackanicz. A compar- ative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol. Contraception 59:305-310, 1999.
1478. E Weisberg, IS Fraser, M Lacarra, DR Mishell Jr, F Alvarez, V Brache, HA Nash. Malcolm Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring. Contraception 59:311-318, 1999.
1479. E Weisberg, IS Fraser, M Lacarra, DR Mishell Jr, T Jackanicz. Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring. Contraception 56:233-239, 1997.
1480. E Weisberg, IS Fraser, DR Mishell Jr., M Lacarra, CW Bardin. The acceptability of a combined oestrogen/progestogen contraceptive vaginal ring. Contraception 51: 39-44, 1995.
1481. SA Ballagh, DR Mishell, Jr., M Lacarra, D Shoupe, T Jackanicz, P Eggena. A contra- ceptive vaginal ring releasing norethindrone acetate and ethinyl estradiol, Contracep- tion 50:517-533, 1994.
1482. R Massai, P Miranda, P Valdes, P Lavin, A Zepeda, ME Casado, MA Silva, G Fetis, C Bravo, O Chandia, O Peralta, HB Croxatto, S Diaz. Pre-registration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women. Contraception 60:9-14, 1999.
1483. JH Chen, SC Wu, WQ Shao, MH Zou, J Hu, L Cong, C Miao, C Wang, J Dong, J Gao, BL Xaio. The comparative trial of TCu 380A IUD and progesterone-releasing vaginal ring used by lactating women. Contraception 57:371-379, 1998.
1484. S Diaz, A Zepeda, X Maturana, MV Reyes, P Miranda, ME Casado, O Peralta, HB Croxatto. Fertility Regulation in Nursing Women. IX. Contraceptive performance, duration of lactation, infant growth, and bleeding patterns during use of progesterone vaginal rings, progestin-only pills, Norplant implants, and Copper T 380-A intrauter- ine devices. Contraception 56:223-232, 1997.
1485. I Sivin, S Diaz, HB Croxatto, P Miranda, M Shaaban, EH Sayed, B Xiao, S Wu, M Du, F Alvarez, V Brache, S Basnayake, T McCarthy, M Lacarra, DR Mishell Jr., S Koetsawang, J Stern, T Jackanicz. Contraceptives for lactating women: a com- parative trial of a progesterone-releasing vaginal ring and the Copper T 380A IUD. Contraception 55:225-232, 1997.
1486. BM Landgren, B Jonsson, SZ Cekan. The effect of small doses of progesterone released from two types of vaginal rings on ovarian activity and bleeding patterns during the first postpartum year. Contraception 51:255-260, 1995.
1487. BM Landgren, PE Hall, SZ Cekan. Progesterone-releasing vaginal rings for use in postpartum contraception. II. Pharmokinetic profiles in women. Contraception 45: 343-349, 1992.
1488. SA Matlin, A Belenguer, PE Hall. Progesterone-releasing vaginal rings for use in postpartum contraception. I. In vitro release rates of progesterone from core-loaded rings. Contraception 45:329-341, 1992.
1489. BM Landgren, AR Aedo, E Johannisson, SZ Cekan. Pharmacokinetic and pharmaco- dynamic effects of vaginal rings releasing levonorgestrel at a rate of 27 µg/24 hours: a pilot study. Contraception 49:139-150, 1994.
1490. BM Landgren, AR Aedo, E Johannisson, SZ Cekan. Studies on a vaginal ring releas- ing levonorgestrel at an initial rate of 27 µg/24h when used alone or in combination with transdermal systems releasing estradiol. Contraception 50:87-100, 1994.
1491. World Health Organisation task force on long-acting agents for fertility regulation. Special Programme of Research, Development and Research Training in Human Reproduction. Menstrual blood loss with use of a vaginal ring releasing 20 µg levo- norgestrel per day. Contraception 47:455-468, 1993.
1492. World Health Organisation task force on long-acting agents for fertility regulation. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. 1. Contraceptive efficacy and side effects. Contraception 41:105-124, 1990.
1493. T Higuchi. Mechanism of sustained-action medication: Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 52:1145, 1963.
1494. J Crank. The Mathematics of Diffusion. London: Oxford at the Clarendon Press, 1956.
1495. FG Burton. Fabrication and testing of vaginal contraceptive devices designed for release of prespecified dose levels of steroids. Contraception 17:221-230, 1978.
1496. TM Jackanicz. Levonorgestrel and estradiol release from an improved contraceptive vaginal ring. Contraception 24:323-339, 1981.
1497. DR Mishell Jr. Vaginal contraceptive rings. Ann Med 25:191-197, 1993.
1498. L Brannon-Peppas. Novel vaginal drug-release applications. Adv Drug Del Rev 11: 169-177, 1993.
1499. E Diczfalusy. New developments in oral, injectable and implantable contraceptives, vaginal rings and intrauterine devices-a review. Contraception 33:7-23, 1986.
1500. PJ Rowe. Steroid-releasing vaginal rings: a review. Fertility and Sterility: The Pro- ceedings of the 11th Congress on Fertility and Sterility (Dublin), Lancaster. 27:301- 309, 1983.
1501. AD Woolfson, RK Malcolm, R Gallagher. Drug delivery by the intravaginal route. Crit Rev Ther Drug Carr Syst 17:509-555, 2000.
1502. M Klitisch. Still waiting for the contraceptive revolution. Family Planning Perspect 27:6, 1995. (See also: http:/ /www.amaassn.org/special/contra/library/ readroom/other96/gutt.htm).
1503. Program for Appropriate Technology in Health. Enhancing the private sector's role in contraceptive research and development. In: PFA Van Look, G Perez-Palacios, eds. Contraceptive Research and Development, 1984-1994: The Road to Mexico City and Beyond. Oxford, UK: Oxford University Press, 1994.
1504. W Bounds, A Szarewski, D Lowe, J Guillebaud. Preliminary report of unexpected local reactions to a progestogen-releasing contraceptive vaginal ring. Eur J Obstet Gynecol Reprod Biol 48:123-125, 1993.
1505. IS Fraser, P Lahteenmaki, K Elomaa, M Lacarra, DR Mishell, F Alvarez, V Brache, E Weisberg, M Hickey, P Vallentine, HA Nash. Variations in vaginal epithelial surface appearance determined by colposcopic inspection in healthy, sexually active women. Hum Reprod 14:1974-1978, 1999.
1506. M Igarashi, M Iizuka, Y Ibuki. Novel vaginal danazol ring therapy for pelvic endo- metriosism in particular deeply infiltrating endometriosis. Hum Reprod 13:1952- 1956, 1998.
1507. TL Wyatt, KJ Waley, RA Cone, WM Saltzman. Antigen-releasing polymer rings and microspheres stimulate mucosal immunity in the vagina. J Control Rel 50:93- 102, 1998.
1508. WM Saltzman, LB Tena. Spermicide permeation through biocompatible polymers. Contraception 43:497-505, 1991. Malcolm
1509. R Tarantino, D Adair, S Bolton. In vitro and in vivo release of salicylic acid from povidone/polydimethylsiloxane matrices. Drug Dev Ind Pharm 16:1217-1231, 1990.
1510. V Carelli, G Di Colo, E Nannipieri, MF Serafini. Evaluation of a silicone based matrix containing crosslinked polyethylene glycol as a controlled drug delivery sys- tem for potential oral application. J Control Rel 33:153-162, 1995.
1511. G Di Colo, V Carelli, E Nannipieri, MF Serafini, D Vitale. Effect of water-soluble additives on drug release from silicone rubber matrices. II. Sustained release of pred- nisolone from non-swelling devices. Int J Pharm 30:1-7, 1986. REFERENCES
1512. GD Kobrinskii, VR Mel'nikov, VN Kulakov, ND L'vov, IM Bolotin, IF Barinskii. Treatment of experimental genital herpes with liposomal interferon, Biomed Sci 2: 29-32, 1991.
1513. SK Jain, R Singh, VV Jain. Mucoadhesive liposomes bearing metronidazole for con- trolled and localised vaginal delivery. Proc Int Symp Control Rel Mater 23:701-702, 1996.
1514. SK Jain, R Singh, B Sahu. Development of a liposome based contraceptive system for intravaginal administration of progesterone. Drug Dev Ind Pharm 23:827-830, 1997.
1515. M Foldvari, A Moreland. Clinical observations with topical liposome-encapsulated interferon alpha for the treatment of genital papilloma virus infections. J Liposome Res 7:115-126, 1997.
1516. Z Pavelic, N Skalko-Basnet, I Jalsenjak. Liposomes containing drugs for treatment of vaginal infections. Eur J Pharm Sci 8:345-351, 1999.
1517. P Williams. Liposomes and the pro-liposome method. Seifen, Oele, Fette, Wasche (SOEFW) J 6:377-378, 1992.
1518. S Perrett, M Golding, P Williams. A simple method for the preparation of liposomes for pharmaceutical applications: characterization of the liposomes. J Pharm Pharmacol 43:154-161, 1991.
1519. R Cuca. Stable high internal phase ratio topical emulsions. US patent 4,384,049, 1981. Levinson and Thompson
1520. T Riley, C Tharp, G Lapka. Vaginal delivery systems and their methods of preparation and use. US patent 4,551,148, 1988.
1521. T Riley. Solid controlled release bioadherent emulsions. US patent 5,055,303, 1991.
1522. T Riley. Vaginal delivery system. US patent 5,266,329, 1993.
1523. R Cuca, K Lienhop, T Riley, RS Levinson, M Kirschner. Improved bioadhesive deliv- ery system. US patent 5,554,380, 1996.
1524. L Weinstein, MR Henzel, IW Tsina. Vaginal retention of 2% butoconazole nitrate cream: comparison of a standard and a sustained release preparation. Clin Ther 16: 930-934, 1994.
1525. Data on file, KV Pharmaceutical Company, St. Louis, Missouri 63144.
1526. D Brown, MR Henzel, RH Kaufman, and the Gynazole-1 Study Group. Butoconazole nitrate 2% for vulvovaginal candidiasis: new single-dose vaginal cream formulation versus seven-day treatment with miconazole nitrate. J Reprod Med 44:933-938, 1999. REFERENCES
1527. I Gonda. Targeting by deposition. In: AJ Hickey, ed. Pharmaceutical Inhalation Aerosol Technology. New York: Marcel Dekker, 1992, pp. 61-82.
1528. I Gonda. Physico-chemical principles in aerosol delivery. In: DJA Crommelin, KK Middha, eds. Topics in Pharmaceutical Sciences 1991. Stuttgart: Medpharm Scien- tific Publishers, 1992, Chapter 7, pp. 95-115.
1529. I Gonda. Particle deposition in the human respiratory tract. In: RG Crystal, JB West, eds. The Lung: Scientific Foundations. 2nd ed. Philadelphia: Lippincott-Raven Pub- lishers, 1997, Chapter 176, pp. 2289-2294.
1530. PE Morrow, CP Yu. Models of aerosol behavior in airways. In: F Moren, MT New- house, MB Dolovich, eds. Aerosols in Medicine. Amsterdam: Elsevier, 1985, pp. 149-191.
1531. ED Palmes, B Altshuler, N Nelson. Deposition of aerosols in the human respiratory tract during breath holding. In: CN Davies, ed. Inhaled Particles and Vapours II. New York: Pergamon Press, 1967, pp. 339-349.
1532. WD Christensen, DL Swift. Aerosol deposition and flow limitation in a compliant tube. J Appl Physiol 60:630-637, 1986.
1533. I Gonda, JB Kayes, CV Groom, FJT Fildes. Characterisation of hygroscopic inhala- tion aerosols. In: N Stanley-Wood, T Allen, eds. Particle Size Analysis. London: Heyden, 1982, pp. 31-43.
1534. PR Phipps, I Gonda, SD Anderson, D Bailey, G Bautovich. Regional deposition of saline aerosols of different tonicities in normal and asthmatic subjects. Eur Respir J 7:1474-1482, 1994.
1535. I Gonda. The ascent of pulmonary drug delivery. J Pharm Sci 89:940-945, 2000.
1536. I Gonda. Deoxyribonuclease inhalation. In: AL Adjei, PR Gupta, eds. Inhalation Delivery of Therapeutic Peptides and Proteins. New York: Marcel Dekker, 1997, Chapter 12, pp. 355-365.
1537. RN Dalby, SL Tiano, AJ Hickey. Medical devices for the delivery of therapeutic aerosols to the lung. In: AJ Hickey, ed. Inhalation Aerosols: Physical and Biological Basis for Therapy. New York: Marcel Dekker, 1996, Chapter 14, pp. 441-473.
1538. SJ Farr, AM Rowe, R Rubsamen, G Taylor. Aerosol deposition in the human lung following administration from a microprocessor controlled pressurised metered dose inhaler. Thorax 50:639-644, 1995.
1539. R Rubsamen. Novel aerosol peptide drug delivery systems. In: AL Adjei, PK Gupta, eds. Inhalation Delivery of Therapeutic Peptides and Proteins. New York: Marcel Dekker, 1997, Chapter 24, pp. 703-731.
1540. L Borgstro ¨m, L Asking, O Beckman, E Bondesson, A Ka ¨lle ´n, B Olsson. Discrepancy between in vitro and in vivo dose variability for a pressurized metered dose inhaler and a dry powder inhaler. J Aerosol Med 11(suppl 1):S59-S64, 1998.
1541. M Berelowitz, G Becker. Inhaled insulin-clinical pharmacology and clinical study results. In: RN Dalby, PR Byron, SJ Farr, J Peart, eds. Respiratory Drug Delivery VII. Raleigh, NC: Serentec Press, 2000, pp. 151-154.
1542. PG Clauson, B Balent, GA Brunner, G Sendlhofer, JH Jendle, V Hatorp, UL Dahl, J Okikawa, TR Pieber. PK-PD of four different doses of pulmonary insulin delivered with the AERx diabetes management system. In: RN Dalby, PR Byron, SJ Farr, J Peart, eds. Respiratory Drug Delivery VII. Raleigh, NC: Serentec Press, 2000, pp. 155-161.
1543. EM Ward, A Woodhouse, LE Mather, SJ Farr, JK Okikawa, P Lloyd, JA Schuster, RM Rubsamen. Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. Clin Pharm Ther 62:596-609, 1997.
1544. LE Mather, A Woodhouse, ME Ward, SJ Farr, RA Rubsamen, LG Elterington. Pul- monary administration of aerosolized fentanyl: pharmacokinetic analysis of systemic delivery. Br J Clin Pharmacol 46:37-43, 1998.
1545. SJ Farr, A McElduff, LE Mather, J Okikawa, ME Ward, I Gonda, V Licko, RM Rubsamen. Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting vol- unteers. Diabetes Tech Ther 2:185-197, 2000.
1546. I Gonda. Drugs administered directly into the respiratory tract: modeling of the dura- tion of effective drug levels. J Pharm Sci 77:340-346, 1988. REFERENCES
1547. Inactive Ingredients Guide. Washington, DC: Division of Drug Information Re- sources, Food and Drug Administration, Center for Drug Evaluation and Research, January 1996, pp. 1-155.
1548. M Simon, V Gopalakrishnan. Aerodose inhaler-feasibility studies with the aerosol generator. In: RN Dalby, PR Byron, SJ Farr, J Peart, eds. Respiratory Drug Delivery VII. Raleigh, NC: Serentec Press, 2000, pp. 311-314.
1549. Y Ivri, CH Wu. Liquid dispensing apparatus and methods. US patent 5,758,637, 1998.
1550. Y Ivri, CH Wu. Liquid dispensing apparatus and methods. US patent 6,085,740, 2000.
1551. Y Ivri, CH Wu. Apparatus and methods for the delivery of therapeutic liquids to the respiratory system. US patent 5,586,550, 1996.
1552. Y Ivri. Methods and apparatus for dispensing liquids as an atomizer spray. US patent 5,938,117, 1999.
1553. Y Ivri. Methods and apparatus for storing chemical compounds in a portable inhaler. US patent 6,014,970, 2000.
1554. V Gopalakrishnan, CF Lange, WH Finlay. Aerodose inhaler: comparison of in vitro particle size data, computer modeled and scintigraphic lung deposition profiles. In: RN Dalby, PR Byron, SJ Farr, J Peart, eds. Respiratory Drug Delivery VII. Raleigh, NC: Serentec Press, 2000, pp. 303-306.
1555. V Gopalakrishnan, W Xia. Aerodose inhaler: effect of formulation physicochemical properties on aerosol properties. In: RN Dalby, PR Byron, SJ Farr, J Peart, eds. Respiratory Drug Delivery VII. Raleigh, NC: Serentec Press, 2000, pp. 299-301.
1556. M Simon, V Gopalakrishnan. Aerodose inhaler-aerosol characteristics of a systemic and a respiratory drug. In: RN Dalby, PR Byron, SJ Farr, J Peart, eds. Respiratory Drug Delivery VII. Raleigh, NC: Serentec Press, 2000, pp. 307-309.
1557. LR De Young, F Chambers, S Narayan, C Wu. Albuterol sulfate delivery from the aerodosea ¨liquid inhaler. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery VI. Hilton Head, SC: Serentec Press, 1998, pp. 315-316.
1558. RS Fishman, D Guinta, F Chambers, R Quintana, DA Shapiro. Insulin administration via the aerodose inhaler: comparison to subcutaneously injected insulin. American Diabetes Association 60th Scientific Sessions, San Antonio, TX, 2000, pp. 38-OR. REFERENCES
1559. G Taylor. The absorption and metabolism of xenobiotics in the lung. Adv Drug Deliv Rev 5:37-61, 1990.
1560. J Schuster, R Rubsamen, P Lloyd, J Lloyd. The AERX aerosol delivery system. Pharm Res 14:354-357, 1997.
1561. Task Group on Lung Dynamics. Deposition and retention models for internal dosim- etry of the human respiratory tract. Health Phys 12:173-207, 1966.
1562. PR Phipps, I Gonda, SD Anderson, D Bailey, G Bautovich. Regional deposition of saline aerosols of different tonicities in normal and asthmatic subjects. Eur Respir J 7:1474-1482, 1994.
1563. G Ferron, Kreyling, J Haider. Inhalation of salt aerosol particles. II. Growth and deposition in the human respiratory tract. J Aerosol Sci 19:611-631, 1987.
1564. NA Fuchs. Evaporation and Droplet Growth in Gaseous Media. Oxford: Pergamon Press, 1962, pp. 1-37.
1565. P Byron. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 75:433-438, 1986.
1566. Draft Guidance for Industry, Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products, Chemistry, Manufacturing and Controls Documentation. Washington, DC: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research 8, 1999.
1567. J Schuster, SJ Farr, D Cipolla, T Wilbanks, J Rosell, P Lloyd, I Gonda. Design and performance validation of a highly efficient and reproducible compact aerosol deliv- ery system: AERx. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery VI. Buffalo Grove, IL: Interpharm Press, 1998, pp. 83-90.
1568. SJ Farr, J Schuster, J Lloyd, P Lloyd, J Okikawa. R Rubsamen. AERx-develop- ment of a novel liquid aerosol delivery system: concept to clinic. In: I RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery V. Buffalo Grove, IL: Interpharm Press, 1996, pp. 175-185.
1569. SJ Farr, A Rowe, R Rubsamen, G Taylor. Aerosol deposition in the human lung following administration from a microprocessor-controlled pressurised metered- dose inhalaer. Thorax 50:639-644, 1995.
1570. J Schuster, G McKinley, P Lloyd, Igor Gonda. Developing systems for aerosol drug delivery that are independent of ambient conditions. Abstracts of the Aerosol Societ- ies Drug Delivery to the Lungs X, London, 1999, pp. 147-150.
1571. I Gonda, J Schuster, R Rubsamen, P Lloyd, D Cipolla, SJ Farr. Inhalation delivery systems with compliance and disease management capabilities. J Control Rel 53: 269-274, 1998.
1572. J Schuster, D. Hasegawa. Dose titration with the AERx system. Abstracts of the Aerosol Societies Drug Delivery to the Lungs XI, London, 2000, pp. 68-71.
1573. RD Lasker. The diabetes control and complications trial, implications for policy and practice. N Engl J Med 329:1035-1036, 1993.
1574. LE Mather, A Woodhouse, M Elizabeth Ward, SJ Farr, R Rubsamen, L Eltherington. Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of sys- temic delivery. Br J Clin Pharmacol 46:37-43, 1998.
1575. S Mudumba, M Khossravi, D Yim, T Rossi, D Pearce, M Hughes, D Cipolla, T. Sweeney. Delivery of rhDNase by the AERx pulmonary delivery system, In: RN Dalby, PR Byron, SJ Farr J Peart, eds. Respiratory Drug Delivery VII. Buffalo Grove, IL: Interpharm Press, 2000, pp. 329-331.
1576. D Cipolla, B Boyd, R Evans, S Warren, G Taylor, SJ Farr. Bolus administration of INS365: studying the feasibility of delivering high dose drugs using the AERx pulmonary delivery system. In: RN Dalby, PR Byron, SJ Farr J Peart, eds. Respira- tory Drug Delivery VII. Buffalo Grove, IL: Interpharm Press, 2000, pp. 231- 239.
1577. D Cipolla, SJ Farr, I Gonda, R Moutvic, M Placke, T Pollock, J Schuster. Pulmonary delivery and systemic absorption of a therapeutic protein using the AERx system. J Aerosol Med 10:254, 1997.
1578. F Sorgi, L Gagne, S Sharif, D Cipolla, S Farr, I Gonda, H Schrier. Aerosol Gene Delivery using the AERx delivery system. Proc Int Symp Control Rel Bioact Mater 25:184-185, 1998.
1579. H Chan, E Daviskas, S Eberl, M Robinson, G Bautovich, I Young. Deposition of aqueous aerosol of technetium-99m diethylene triamine penta-acetic acid generated and delivered by a novel system, AERx, in healthy subjects. Eur J Nucl Med 26: 320-324, 1999.
1580. M Robinson, D Glass, D Bailey, P Ind, A Peters. Evaluation of a new aerosol deliv- ery device, AERx for ventilation scans in patients with chronic obstructive airways disease, COAD. Respir Crit Care Med 155:A596, 1997.
1581. ME Ward, A Woodhouse, LE Mather, SJ Farr, J Okikawa, P Lloyd, J Schuster, R. Rubsamen. Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. Clin Pharmacol Ther 62:596-609, 1997.
1582. M Dershwitz, J Walsh, R Morishige, P Connors, R Rubsamen, S Shafer, C Rosow. Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. Anesthesiology 93:619-628, 2000.
1583. S Farr, A McElduff, L Mather, J Okikawa, ME Ward, I Gonda, V Licko, R Rubsa- men. Pulmonary insulin administration using the AERx system: physiological and Schuster and Farr physicochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Tech Ther 2:185-197, 2000.
1584. P Clauson, B Balent, G Briunner, G Sendlhofer, J Jendle, V Hatorp, U Dahl, J Oki- kawa, T Pieber. PK-PD of four different doses of pulmonary insulin delivered with the AERx diabetes management system. In: RN Dalby, PR Byron, SJ Farr J Peart, eds. Respiratory Drug Delivery VII. Buffalo Grove, IL: Interpharm Press, 2000, pp. 155-161.
1585. SJ Farr, I Gonda, V Licko. Physicochemical and physiological factors influencing the effectiveness of inhaled insulin. In: RN Dalby, PR Byron, SJ Farr, eds. Respira- tory Drug Delivery VI. Buffalo Grove, IL: Interpharm Press, 1998, pp. 25-33.
1586. AJ Hickey, I Gonda, W Irwin, F Fildes. Effect of hydrophobic coating on the behav- ior of a hygroscopic aerosol powder in an environment of controlled temperature and relative humidity. J Pharm Sci 79:1009-1014, 1990. Formulation Challenges of Powders for the Delivery of Small- Molecular-Weight Molecules as Aerosols Anthony J. Hickey University of North Carolina, Chapel Hill, North Carolina, U.S.A. REFERENCES
1587. MA Kaliner, PJ Barnes, CGA Persson. Asthma: Its Pathology and Treatment. New York: Marcel Dekker, 1991.
1588. A Gringauz. Introduction to Medicinal Chemistry. New York: Wiley-VCH, 1997.
1589. PR Byron, JS Patton. Drug delivery via the respiratory tract. J Aerosol Med 7:49- 75, 1994.
1590. DA Edwards, G Caponetti, JS Hrkach, N Lotan, J Hanes, AA Ben-Jebria, RS Langer. Aerodynamically light particles for pulmonary drug delivery. US patent 5,874,064, 1999.
1591. D Ganderton, NM Kassem. Aerosol carriers. US patent 5,254,330, 1991.
1592. AR Baichwal, JN Staniforth. Controlled release insufflation carrier for medicaments. US patent 5,738,865, 1996.
1593. AR Clark, CC Hsu, AJ Walsh. Preparation of sodium chloride aerosol formulations. US patent 5,747,002, 1998.
1594. J Hanes, DA Edwards, C Evora, R Langer. Particles incorporating surfactants for pulmonary drug delivery. US patent 5,855,913, 1999.
1595. DA Edwards, RS Langer, R Vanbever, J Mintzes, J Wang, D Chen. Preparation of particles for inhalation. US patent 5,985,309, 1999.
1596. RN Boyes, TR Tice, RM Gilley, KL Pledger. Pharmaceutical formulations compris- ing microcapsules. US patent 5,384,133, 1995.
1597. D Ganderton, NM Kassem. Dry powder inhalers. In: D Ganderton, T Jones, eds. Advances in Pharmaceutical Sciences. London: Academic Press, 1992, pp. 165- 191.
1598. KH Leong. Theoretical principles and devices used to generate aerosols for research. In: AJ Hickey, ed. Pharmaceutical Inhalation Aerosol Technology. New York: Marcel Dekker, 1992, pp. 129-154.
1599. RN Dalby, SL Tiano, AJ Hickey. Medical devices for the delivery of therapeutic aerosols to the lungs. In: AJ Hickey, ed. Inhalation Aerosols: Physical and Biological Basis for Therapy. New York: Marcel Dekker, 1996, pp. 441-473.
1600. JN Israelachvili. Intermolecular and Surface Forces. London: Academic Press, 1992. Hickey
1601. W Pietsch. Size Enlargement by Agglomeration. New York: Wiley, 1991.
1602. J Van Cleef. Powder technology: the powders that lend flavor, beauty and strength to many products are created by fearsome machines that force coherent materials to fail. Am Sci 79:304-315, 1991.
1603. NM Concessio, MM Van Oort, M Knowles, AJ Hickey. Pharmaceutical dry powder aerosols: correlation of powder properties with dose delivery and implications for pharmacodynamic effect. Pharm Res 16:833-839, 1999.
1604. JN Staniforth. The importance of electrostatic measurements in aerosol formulation and preformulation. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Deliv- ery IV. Buffalo Grove, IL: Interpharm Press. 1994, pp. 303-311.
1605. PR Byron, J Peart, JN Staniforth. Aerosol electrostatics. I. Properties of fine powders before and after aerosolization by dry powder inhalers. Pharm Res 14:698-705, 1997.
1606. JT Carstensen. Pharmaceutics of Solids and Solid Dosage Forms. New York: Wiley, 1989.
1607. JT Carstensen. Pharmaceutical Principles of Solid Dosage Forms. Lancaster, PA: Technomic, 1993.
1608. JW Mullin. Crystallization. 3rd ed. Oxford, UK: Butterworth-Heinemann, 1993.
1609. CA Dunbar, AJ Hickey, P Holzner. Dispersion and characterization of pharmaceuti- cal dry powder aerosols. KONA 167:44, 1998.
1610. AJ Hickey, CA Dunbar. A new millenium for inhaler technology. Pharm Tech 21: 116-125, 1997.
1611. AJ Hickey. Targeting of pharmaceutical aerosols to the lung: what can be learned from inhalation toxicology and industrial hygiene. Aerosol Sci Tech 18:290-304, 1993.
1612. M Sacchetti, MM Van Oort. Spray-drying and supercritical fluid particle generation techniques. In: AJ Hickey, ed. Inhalation Aerosols: Physical and Biological Basis for Therapy. New York: Marcel Dekker, 1996, pp. 337-384.
1613. JW Tom, PG Debendetti. Particle formation with supercritical fluids-a review. J Aerosol Sci 22:555-584, 1991.
1614. A Kordikowski, P York, D Latham. Resolution of ephedrine in supercritical CO 2 : a novel technique for the separation of chiral drugs. J Pharm Sci 88:786-791, 1999.
1615. S Palakodaty, P York. Phase behavioral effects on particle formation processes using supercritical fluids. Pharm Res 16:976-985, 1999.
1616. P York, M Hanna, BY Shekunov, GO Humphreys. Microfine particle formation by SEDS (solution enhanced dispersion by supercritical fluids): scale up by design. In RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery VI. Hilton Head, SC. Interpharm Press, Buffalo Grove, IL: 1998, pp. 169-175.
1617. JC Feeley, DJ Gilbert, P Srinivas, SE Walker, P York. Engineering of particle size distributions for respiratory drug delivery by supercritical fluid processing. In: RN Dalby, PR Byron, SJ Farr, J Peart, eds. Respiratory Drug Delivery VII. Tarpon Springs, FL. Serentec, Raleigh, NC: 2000, pp. 357-360.
1618. DB Yeates, GJ Besseris, LB Wong. Physicochemical properties of mucus and its propulsion. In: RG Crystal, JB West, eds. The Lung: Scientific Foundation. Philadel- phia: Lippincott-Raven, 1997, pp. 487-503.
1619. M Bhat, AJ Hickey. Effect of chloroquine on phagolysosomal fusion in cultured guinea pig alveolar macrophages: implications in drug delivery. AAPS PharmSci 2000. 2(4) article 34.
1620. PR Byron. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 75:433-438, 1986.
1621. I Gonda. Drugs administered directly into the respiratory tract: modeling of the dura- tion of effective drug levels. J Pharm Sci 77:340-346, 1988.
1622. M Van Oort. In vitro testing of dry powder inhalers. Aerosol Sci Tech 22:364-373, 1995.
1623. M Hindle, PR Byron, NC Miller. Cascade impaction methods for dry powder inhal- ers using the high flowrate Marple-Miller impactor. Int J Pharm 134:137-146, 1996.
1624. PKP Burnell, AC Grant, PA Haywood, D Prime, BS Sumby. Powder inhalers- exploring the limits of performance. In: RN Dalby, PR Byron, SJ Farr, eds. Respira- tory Drug Delivery VI. Hilton Head, SC. Interpharm Press, Buffalo Grove, IL: 1998, pp. 259-275.
1625. CA Dunbar, B Morgan, M Van Oort, AJ Hickey. A comparison of dry powder in- haler dose delivery characteristics using power performance criterion. PDA. J Pharm Sci Tech 54:478-484, 2000.
1626. NC Miller. A cascade impactor for aerodynamic size measurement for MDI's and powder inhalers. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery IV. Richmond, VA. Interpharm Press, Buffalo Grove, IL: 1994, pp. 342-343.
1627. PR Byron. Compendial specifications for inhaled drugs. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery VI. Hilton Head, SC. Interpharm Press, Buffalo Grove, IL: 1998, pp. 139-144.
1628. RS Pillai, DB Yeates, M Eljamal, IF Miller, AJ Hickey. Generation of concentrated aerosols for inhalation studies. J Aerosol Sci 25:187-197, 1994.
1629. J Talton, J Fitz-Gerald, R Singh, G Hochhaus. Nano-thin coatings for improved lung targeting of glucocorticoid dry powders: in-vitro and in-vivo characteristics. In: RN Dalby, PR Byron, SJ Farr, J Peart, eds. Respiratory Drug Delivery. VII. Tarpon Springs, FL. Serentec, Raleigh, NC: 2000, pp. 67-74.
1630. J Wang, A Ben-Jebria, DA Edwards. Inhalation of estradiol for sustained systemic delivery. J Aerosol Med 12:27-36, 1999.
1631. MT Vidgren, A Karkkainen, TP Paronen, P Karjalainen. Respiratory tract deposition of 99mTc-labelled drug particles administered via a dry powder inhaler. Int J Pharm 39:101-105, 1987.
1632. M Vidgren, A Ka ¨rkka ¨inen, P Karjalainen, P Paronen, J Nuutinen. Effect of powder inhaler design on drug deposition in the respiratory tract. Int J Pharm 42:211-216, 1988.
1633. RS Pillai, DB Yeates, IF Miller, AJ Hickey. Controlled dissolution from wax-coated aerosol particles in canine lungs. J Appl Physiol 84:717-725, 1998.
1634. G Hochhaus, S Suarez, RJ Gonzalez-Rothi, H Schreier. Pulmonary targeting of in- haled glucocorticoids: how is it influenced by formulation. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery V. Hilton Head, SC. Interpharm Press, Buf- falo Grove, IL: 1998, pp. 45-52.
1635. AJ Hickey, NM Concessio, MM Van Oort, RM Platz. Factors influencing the disper- sion of dry powders as aerosols. Pharm Tech 18:58-64, 82, 1994.
1636. D Ganderton, AJ Hickey. Unit processes in pharmacy: the operations. In: J Swar- Hickey brick, JC Boylan, eds. Encyclopedia of Pharmaceutical Technology. New York: Marcel Dekker, 1997, pp. 1-113.
1637. AJ Hickey, LD Jones. Particle-size analysis of pharmaceutical aerosol. Pharm Tech 24:48-58, 2000.
1638. G Buckton. Conversions between different amorphous states and crystal polymorphs of significance for inhalation systems. In: RN Dalby, PR Byron, SJ Farr, eds. Respi- ratory Drug Delivery VI. Hilton Head, SC. Interpharm Press, Buffalo Grove, IL: 1998, pp. 145-151.
1639. MT Carvajal, JN Staniforth. Polymorphism and dispersibility of dry powders. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery VI. Hilton Head, SC. Interpharm Press, Buffalo Grove, IL: 1998, pp. 283-289.
1640. MJ Kontny, JJ Conners, ET Graham. Moisture distribution and packaging of dry powder systems. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery IV. Richmond, VA. Interpharm Press, Buffalo Grove, IL: 1994, pp. 125-136.
1641. RS Pillai, DB Yeates, IF Miller, AJ Hickey. Controlled release from condensation coated respirable aerosol particles. J Aerosol Sci 25:461-477, 1994.
1642. AR Clark, AM Hollingworth. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro test- ing. J Aerosol Med 6:99-110, 1993.
1643. H Schreier, WC Mobley, N Concessio, AJ Hickey, RW Niven. Formulation and in- vitro performance of liposome powder aerosols. STP Pharma 4:8-44, 1994.
1644. WC Mobley. The effect of jet-milling on lyophilized liposomes. Pharm Res 15:149- 152, 1998.
1645. P Goldbach, H Brochart, A Stamm. Spray-drying of liposomes for a pulmonary administration. I. Chemical stability of phospholipids. Drug Dev Ind Pharm 19: 2611-2622, 1993.
1646. P Goldbach, H Brochart, A Stamm. Spray-drying of liposomes for a pulmonary administration. II. Retention of encapsulated materials. Drug Dev Ind Pharm 19: 2623-2636, 1993.
1647. P Giffard. Improvement in vaporizers. US patent 211,234, 1878.
1648. AJ Palmer, GH Palmer. Kaiserliches patentamt. Zerstaeuber patent 47181, 1888.
1649. WH Finlay. An Introduction to the Mechanics of Inhaled Pharmaceutical Aerosols. London: Academic Press, 2001.
1650. JH Dennis, SC Stenton, JR Beach, AJ Avery, EH Walters, DJ Hendrick. Jet and ultrasonic nebuliser output: use of a new method for direct measurement of aerosol output. Thorax 45:728-732, 1990.
1651. WH Finlay, KW Stapleton, P Zuberbuhler. Predicting lung dosages of a nebulized suspension: Pulmicort (Budesonide). Particulate Sci Tech 15:243-251, 1997.
1652. KMG Taylor, SJ Farr. Preparation of liposomes for pulmonary drug delivery. In: G Gregoriadis, ed. Liposome Preparations and Related Techniques. 2nd ed. Vol. 1. Boca Raton, FL: CRC Press, 1993, pp. 177-195.
1653. WH Finlay, JP Wong. Regional lung deposition of nebulized liposome-encapsulated ciprofloxacin. Int J Pharm 167:121-127, 1998. Knoch and Finlay
1654. RW Niven, M Speer, H Schreier. Nebulization of liposomes II. The effects of size and modelling of solute release profiles. Pharm Res 8:217-221, 1991.
1655. M Knoch, E Sommer. Jet nebulizer design and function. Eur Respir Rev 10:183- 186, 2000.
1656. WH Finlay. Estimating the type of hygroscopic behaviour exhibited by aqueous droplets. J Aerosol Med 11:221-229, 1998.
1657. WH Finlay, KW Stapleton. Undersizing of droplets from a vented nebulizer caused by aerosol heating during transit through an Anderson impactor. J Aerosol Sci 30: 105-109, 1999.
1658. RMG Boucher, J Kreuter. The fundamentals of the ultrasonic atomization of medi- cated solutions. Ann Allergy 26:591-600, 1968.
1659. K Nikander, M Turpeinen, P Wollmer. The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J Aerosol Med 12:47-53, 1999.
1660. WH Finlay, CF Lange, M King, D Speert. Lung delivery of aerosolized dextran. Am J Respir Crit Care Med 161:91-97, 2000.
1661. DC Cipolla, AR Clark, H-K Chan, I Gonda, SJ Shire. Assessment of aerosol delivery systems for recombinant human deoxyribonuclease. STP Pharma Sci 4:50-62, 1994.
1662. N Maehara, S Uhea, E Mori. Influence of the vibrating system of a multipinhole- plate ultrasonic nebulizer on its performance. Rev Sci Instrum 57:2870-2876, 1986.
1663. BJ Greenspan. Ultrasonic and electrohydrodynamic methods for aerosol generation. In: AJ Hickey, ed. Inhalation Aerosols. New York: Marcel Dekker, 1996, pp. 313- 335.
1664. GMH Meesters, PHW Vercoulen, JCM Marijnissen, B Scarlett. Generation of micron-sized droplets from the Taylor cone. J Aerosol Sci 23:37-49, 1992.
1665. A Jaworek, A Krupa. Generation and characteristics of the precession mode of EHD spraying. J Aerosol Sci 27:75-82, 1996.
1666. WC Zimlich, JY Ding, DR Busick, RR Moutvic, ME Placke, PH Hirst, GR Pitcairn, S Malik, SP Newman, F Macintyre, PR Miller, MT Shepherd, TM Lukas. The devel- opment of a novel electrohydrodynamic pulmonary drug delivery device. In: RN Dalby, PR Byron, SJ Farr, J Peart, eds. Respiratory Drug Delivery VII. Raleigh, NC: Serentec Press, 2000, pp. 241-246.
1667. D Sinclair. Handbook on Aerosols. Washington, DC: 1950, pp. 64.
1668. CSMA. Aerosol Guide. 1957, pp. 27.
1669. H Helbing, G Pertsch. Collodium mixture. US patent 628,463, 1889.
1670. RW Moore. Perfumery atomizer. US patent 746,866, 1903.
1671. LK Mobley. Method of applying liquid antiseptics. US patent 1,378,481, 1921.
1672. E Rotheim. Method and apparatus for atomizing materials. US patent 1,892,750, 1931.
1673. E Rotheim. Method and apparatus for atomizing or distribution of liquid or semisolid materials. US patent 1,800,156, 1931.
1674. TM Midgley, Jr. AL Henne, RR McNary. Process of preventing fire by nontoxic substances. US patent 1,926,396, 1933.
1675. LD Goodhue. Insecticidal aerosol production: spray solutions and liquified gases. Ind Eng Chem News 34:1436, 1942.
1676. LD Goodhue, WN Sullivan. Method of applying parasiticides. US patent 2,321,023, 1943.
1677. WN Sullivan, LD Goodhue, JH Fales. Toxicity to adult mosquitoes of aerosols pro- duced by spraying solutions of insecticides in liquefied gas. J Econ Ent 35:48, 1942.
1678. JW Soffer. Beaded-stem dispensing valve for gas-pressure containers. US patent 2,788,924, 1953.
1679. CG Thiel. Self-propelling powder dispensing compositions. US patent 3,014,844, 1961.
1680. A Adjei, J Garren. Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers. Pharm Res 7:565- 569, 1990.
1681. ER Weibel. Morphometry of the Human Lung. Berlin: Springer-Verlag, 1963, pp. 1- 151.
1682. KH Kilburn. Functional morphology of the distal lung. Int Rev Cytol 37:153-270, 1974.
1683. JB Forrest. Lower airway: structure and function. In: MF Newhouse, MB Dolovich, eds. Aerosols in Medicine, Principles, Diagnostics and Therapy. New York: Elsevier, 1985, Chapter 2.
1684. S Newman, PH Hirst, GR Pitcarin, AR Clark. Understanding regional lung deposi- tion data in gamma scintigraphy. respiratory drug delivery. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery VI. Buffalo Grove, IL: Interpharm Press, 1998.
1685. P Colthorpe, S Farr, G Taylor, I Smith, ID Wyatt. The pharmacokinetics of pulmo- nary-delivered insulin: a comparison of intratracheal and aerosol administration to the rabbit. Pharm Res 9:764-768, 1992. Adjei
1686. M Takada, T Yuzuriha, K Katayama, K Iwamoto, J Sunamoto. Increased lung uptake of liposomes coated with polysaccharides. Biochim Biophys Acta 802:237-244, 1984.
1687. T Sato, K Sakai, K Akiyoshi, J Sunamoto. Cell recognition of liposome as coated with cell specific polysaccharides. Proc Int Symp Control Rel Bioact Mater 15:231- 232, 1988.
1688. P Gupta, A Adjei. Pulmonary Delivery of Therapeutic Peptides and Proteins. New York: Marcel Dekker, 1997, Chapter 26, Table 4, pp. 798-801.
1689. A Pettanazzo, A Jobe, M Ikegami, R Abra, P Mihalko. Clearance of phosphatidyl- choline and cholesterol from liposomes, liposomes loaded with metaproterenol, and rabbit surfactant from adult rabbit lung. Am Rev Respir Dis 139:752-758, 1989.
1690. TR Tice, DR Cowsar. Biodegradable controlled-release parenteral systems. Pharm Technol 8:26-35, 1984.
1691. Y Ogawa, M Yamamoto, H Okada, T Yashiki, T Shimamoto. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly lactic/glycolic acid. Chem Pharm Bull 36:1095-1103, 1988.
1692. FG Hutchinson, BJA Furr. Biodegradable polymers for controlled release of peptides and proteins. In: FHD Roerdink, AM Kroon, eds. Drug Carrier Systems. New York: John Wiley & Sons, 1989, pp. 111-153
1693. PK Gupta. Drug targeting in cancer chemotherapy: a clinical perspective. J Pharm Sci 79:949-962, 1990.
1694. T Kissel, Z Brich, S Bantle, I Lancranjan, N Nimmerfall, P Vit. Parenteral depot- systems on the basis of biodegradable polyesters. J Control Rel 16:27-42, 1991.
1695. ZT Chowhan, AA Amaro. Pulmonary absorption studies utilising in situ rat lung model: designing dosage regimen for bronchial delivery of new drug entities. J Pharm Sci 65:1669-1672, 1976.
1696. R Niven, P Byron. Solute absorption from the airways of the isolated rat lung. I. The use of absorption data to quantify drug dissolution or release in the respiratory tract. Pharm Res 5:574-579, 1988.
1697. R Niven, Feasibility studies with recombinant human granulocyte colony stimulating factor. In: A Adjei, P Gupta, eds. Inhalation Delivery of Therapeutic Peptides and Proteins. Lung Physiology Series. New York: Marcel Dekker, 1997, Chapter 15, pp. 419.
1698. KMG Taylor, G Taylor, IW Kellaway, J Stevens. The influence of liposomal encap- sulation on sodium cromoglycate pharmacokinetics in man. Pharm Res 6:633-636, 1989.
1699. IW Kellaway, KMG Taylor, G Taylor, J Stevens. The pharmacokinetics of liposomal sodium cromoglycate nebulised to volunteers. Proc Int Symp Control Rel Bioact Mater 15:197-198, 1988.
1700. JH Bell, PS Hartley, JSG Cox. Dry powder aerosols. I. A new powder inhalation device. J Pharm Sci 60:1559-1564, 1971.
1701. GW Hallworth. An improved design of powder inhaler. Br J Clin Pharmacol 4:689- 690, 1977.
1702. BS Sumby, KM Churcher, IJ Smith, AC Grant, KG Truman, RJ Marriott, SJ Booth. Dose reliability of the Serevent Diskhaler system. Pharm Tech Int 20-27, June 1993.
1703. K Wetterlin. Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm Res 5:506-508, 1988.
1704. A Brindley, BS Sumby, IJ Smith, D Prime, PA Haywood, AC Grant. Design, manu- facture and dose consistency of the Serevent Diskus inhaler. Pharm Tech Eur 7:14- 22, 1995.
1705. A Malton, BS Sumby, IJ Smith. A comparison of in-vitro drug delivery from two multi-dose powder inhalation devices. Eur J Clin Res 7:177-193, 1995.
1706. MT Newhouse, RG Campbell. Evaluation of inter lot variability of the Turbuhaler. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery V. Buffalo Grove, IL: Interpharm Press, 1996, pp. 390-391.
1707. D Prime, AL Slater, PA Haywood, IJ Smith. Assessing dose delivery from the Flixo- tide Diskus inhaler-a multi-dose powder inhaler. Pharm Tech Eur 8:23-36, 1996.
1708. A Malton, BS Sumby, Y Dandiker. A comparison of in-vitro drug delivery from salbutamol Diskus and terbutaline Turbuhaler inhalers. J Pharm Med 6:35-48, 1996.
1709. H Bisgaard, B Klug, BS Sumby, PKP Burnell. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J 11:1111-1115, 1998.
1710. AH de Boer, HMI Winter, CF Lerk. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. P 1. Inhalation characteristics, work of breathing and volunteers preference in dependence of the inhaler resistance. Int J Pharm 130:231-244, 1996.
1711. JJ Sciarra. Pharmaceutical and medicinal aerosols. In: A Herzka, ed. International Encyclopaedia of Pressurized Packaging (Aerosols). London: Pergamon Press, 1966, pp. 571-619.
1712. AR Clark, AM Hollingworth. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers. J Aerosol Med 6:99-110, 1993.
1713. AH de Boer, D Gjaltema, P Hagedoorn. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. P 2. Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. Int J Pharm 138:45-56, 1996.
1714. K Chippendale. Ultrahaler-design and function. Proceedings: Recent Advances in Dry Powder Inhalers. Management Forum Ltd., London, 1997.
1715. M Parry-Billings, RN Boyes, LM Clisby, P Braithwaite, S Williams, AE Harper. Design, development and performance of a multidose dry powder inhaler. Pharm Tech Eur 2:38-46, 2000.
1716. PKP Burnell, A Malton, K Reavill, MHE Ball. Design, validation and initial testing of the electronic lung. J Aerosol Sci 29:1011-1025, 1998.
1717. PKP Burnell, L Petchey, D Prime, BS Sumby. Patient inhalation profiles and dose emission characteristics from dry powder inhalers. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery V. Buffalo Grove, IL: Interpharm Press, 1996, pp. 314-316.
1718. T Small, S Doig, GJ Gibson, B Johal, PKP Burnell, R Jenkins. Use of inhalation profiles from patients with severe obstructive lung disease using the Diskus inhaler and the Turbuhaler inhaler to evaluate device performance exvivo. Eur Respir J 10: 258S, 1997.
1719. L Borgstrom, L Asking, O Beckman, E Bondesson, A Kallen, B Olsson. Dose varia- tion within and between individuals with different inhalation systems. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery V. Buffalo Grove, IL: Interpharm Press, 1996, pp. 19-24.
1720. SP Newman, F Moren, E Trofast, N Talaee, SW Clarke. Terbutaline sulphate Turbu- haler inhaler: effect of inhaled flow rate on drug deposition and efficacy. Int J Pharm 74:209-213, 1991.
1721. PJ Barnes. Beta-adrenergic receptors and their regulators. Am J Respir Crit Care Med 152:838-860, 1995.
1722. JI Cater, M Vare, WS Peters. Comparison of the efficacy of fluticasone propionate given twice daily via the Diskus/Accuhaler inhaler and the Diskhaler in patients with asthma. Eur Respir J 8:427S, 1995.
1723. KG Nielsen, IL Auk, K Bojsen, M Ifversen, B Klug, H Bisgaard. Clinical effect of Diskus dry powder inhaler at low and high inspiratory flow rates in asthmatic chil- dren. Eur Respir J 11:350-354, 1998.
1724. IC Ashurst, A Malton, D Prime, B Sumby. Latest advances in the development of dry powder inhalers. Pharm Sci Tech Today 3:246-256, 2000.
1725. H-K Chan, Gonda I. Solid state characterization of spray-dried powders of recombi- nant human deoxyribonuclease (rhDNase). J Pharm Sci 87:647-654, 1998.
1726. AR Clark, N Dasovich, I Gonda, H-K Chan. The balance between biochemical and physical stability for inhalation protein powders: rhDNase as an example. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery V. Buffalo Grove, IL: Interpharm Press, 1996, pp. 167-174.
1727. JD Andya, Y-F Maa, HR Costantino, P-A Nguyen, N Dasovich, T Sweeney, CC Hsu, SJ Shire. The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE mono- clonal antibody. Pharm Res 16:350-358, 1999.
1728. JS Patton, L Foster, RM Platz. Methods and compositions for pulmonary delivery of insulin. US patent 5,997,848, 1999.
1729. CP Quan, N Dasovich, C Hsu, T Patapoff, E Canova-Davis. Susceptibility of rhDNase I to glycation in the dry-powder state. Anal Chem 71:4445-4454, 1999.
1730. F Frank. Long-term stabilization of biologicals. Biotechnology 12:253-256, 1994.
1731. K Izutsu, S Yoshioka, T Terao. Decreased protein-stabilizing effects of cryoprotec- tants due to crystallization. Pharm Res 10:1232-1237, 1993.
1732. MJ Pikal, KM Dellerman, ML Roy, RM Riggin. The effects of formulation variables on the stability of freeze-dried human growth hormone. Pharm Res 8:427-436, 1991.
1733. JF Carpenter, SJ Prestrelski, A Dong. Application of infrared spectroscopy to devel- opment of stable lyophilized protein formulations. Eur J Pharm Biopharm 45:231- 238, 1998.
1734. MJ Hageman. Water sorption and solid-state stability of proteins. In: TJ Ahern, MC Manning, eds. Stability of Protein Pharmaceuticals. Part A. New York: Plenum Press, 1992, pp. 273-309.
1735. F Separovic, YH Lam, X Ke, H-K Chan. A solid-state NMR study of protein hydra- tion and stability. Pharm Res 15:1816-1821, 1998.
1736. H-K Chan JK-L Au-Yeung, I Gonda. Development of a mathematical model for the water distribution in freeze-dried solids. Pharm Res 16:660-665, 1999.
1737. B Hancock, S Shamblin, G Zografi. Molecular mobility of amorphous pharmaceuti- cal solids below their glass transition temperatures. Pharm Res 12:799-806, 1995.
1738. Y Roos, M Karel. Plasticizing effect of water on thermal behavior and crystallization of amorphous food models. J Food Sci 56:38-43, 1991.
1739. JS Patton. Deep-lung delivery of therapeutic proteins. Chem Tech December:34- 38, 1997.
1740. NYK Chew, H-K Chan. Effect of humidity on the dispersion of dry powders. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery VII. Raleigh, NC: Serentec Press, 2000, pp. 615-617.
1741. C Yamashita, T Nishibayashi, S Akashi, H Toguchi, M Odomi. A novel formulation of dry powder for inhalation of peptides and proteins. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery V. Buffaloa Grove, IL: Interpharm Press, 1996, pp. 483-485.
1742. H-K Chan, A Clark, I Gonda, M Mumenthaler, C Hsu. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol de- livery. Pharm Res 14:431-437, 1997.
1743. NYK Chew, H-K Chan. Dispersion of mannitol powders as aerosols: influence of particle size, air flow and inhaler device. Pharm Res 16:1098-1103, 1999.
1744. DL French, DA Edwards, RW Niven. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J Aerosol Sci 27:769- 783, 1996.
1745. P Lucas, K Anderson, JN Staniforth. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers. Pharm Res 15:562-569, 1998.
1746. DA Edwards, J Hanes, G Caponetti, J Hrkach, A Ben-Jebria, ML Eskew, J Mintzes, D Deaver, N Lothan, R Langer. Large porous particles for pulmonary drug delivery. Science 276:1868-1871, 1997.
1747. Y-F Maa, P-A Nguyen, T Sweeney, SJ Shire, CC Hsu. Protein inhalation powders: spray drying vs spray freeze drying. Pharm Res 16:249-254, 1999.
1748. AI Bot, TE Tarara, DJ Smith, SR Bot, CM Woods, JG Weers. Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respi- ratory tract. Pharm Res 17:275-283, 2000.
1749. NYK Chew, H-K Chan. Effect of particle size and surface morphology on the disper- sion of albumin powders. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery VII. Raleigh, NC: Serentec Press, 2000, pp. 619-622.
1750. M Mumenthaler, CC Hsu, R Pearlman. Feasibility study on spray-drying protein pharmaceuticals: recombinant human growth hormone and tissue-plasminogen acti- vator. Pharm Res 11:12-20, 1994.
1751. Y-F Maa, P-A Nguyen, SW Hsu. Spray-drying of air-liquid interface sensitive re- combinant human growth hormone. J Pharm Sci 87:152-159, 1998.
1752. HR Costantino, JD Andya, P-A Nguyen, N Dasovich, T Sweeney, SJ Shire, CC Chan Hsu, Y-F Maa. Effect of mannitol crystallization on the stability and aerosol perfor- mance of a spray-dried pharmaceutical protein, recombinant humanized anti-IgE monoclonal antibody. J Pharm Sci 87:1406-1411, 1998.
1753. RM Platz, JS Patton, L Foster, M Eljamal. Dispersible antibody compositions and methods for their preparation and use. US patent 6,019,968, 2000.
1754. M Eljamal, JS Patton. Methods and apparatus for pulmonary administration of dry powder α1-antitrypsin. US patent 5,993,783, 1999.
1755. R Vanbever, JD Mintzes, J Wang, J Nice, D Chen, R Batychy, R Langer, DA Ed- wards. Formulation and physical characterization of large porous particles for inhala- tion. Pharm Res 16:1735-1741, 1999.
1756. RM Platz, A Ip, CL Whitham. Process for preparing micronized polypeptide drugs. US patent 5,354,562, 1994.
1757. MA Winters, PG Debenedetti, J Carey, HG Sparks, SU Sane, TM Przybycien. Long- term and high-temperature storage of supercritically-processed microparticulate pro- tein powders. Pharm Res 14:1370-1378, 1997.
1758. R Sloan, HE Hollowood, GO Hupreys, W Ashraf, P York. Supercritical fluid pro- cessing: preparation of stable protein particles. Proceedings of the 5th Meeting of Supercritical Fluids, Nice, France, 1998.
1759. RE Sievers, SP Sellers, KD Kusek, GS Clark, BJ Korte. Fine-particle formation using supercritical carbon dioxide-assisted aerosolization and bubble drying. Pro- ceedings of 218th ACS National Meeting, New Orleans, 1999.
1760. R Bustami, H-K Chan, NR Foster. Aerosol delivery of protein powders processed by supercritical fluid technology. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery VII. Raleigh, NC: Serentec Press, 2000, pp. 611-613.
1761. R Bustami, H-K Chan, F Dehaghani, NR Foster. Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide. Pharm Res 17:1360-1366, 2000.
1762. D Edwards, J Hanes, G Caponetti, JS Hrkach, A Ben-Jebria, ML Eskew, J Mintzes, D Deaver, N Lotan, R Langer. Large porous aerosols for pulmonary drug delivery. Science 276:1868-1871, 1997.
1763. L Adjei, J Garren. Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers. Pharm Res 7:565- 569, 1990.
1764. AR Clark, M Egan. Modelling the deposition of inhaled powder drug aerosols. J Aerosol Sci 25:175-186, 1994.
1765. CN Davies, J Heyder, MC Subba Rumma. Breathing of half-micron aerosols. I. Experimental. J Appl Physiol 32:591-600, 1972.
1766. I Gonda. Physicochemical principles in aerosol delivery. In: DJA Crommelin, KK Midha, eds. Topics in Pharmaceutical Sciences 1991. Stuttgart: Medpharm Scien- tific, 1992, pp. 95-115.
1767. DA Edwards, A Ben-Jebria, R Langer. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 85:379-385, 1998.
1768. R Vanbever, JD Mintzes, J Wang, J Nice, D Chen, R Batycky, R Langer, DA Ed- wards. Formulation and physical characterization of large porous particles for inhala- tion. Pharm Res 16:1735-1742, 1999.
1769. J Wang, A Ben-Jebria, DA Edwards. Inhalation of estradiol for sustained systemic delivery. J Aerosol Med 12:27-36, 1999.
1770. A Ben-Jebria, D Chen, ML Eskew, R Vanbever, R Langer, DA Edwards. Large porous particles for sustained protection from carbachol-induced bronchoconstric- tion in guinea pigs. Pharm Res 16:555-561, 1999.
1771. R Vanbever, A Ben-Jebria, JD Mintzes, R Langer, DA Edwards. Sustained release of insulin from insoluble inhaled particles. Drug Dev Res 48:178-185, 1999.
1772. J Israelachvilli. Intermolecular and Surface Forces. 2nd ed. London: Academic Press, 1992.
1773. Bot AI, Tarara TE, DJ Smith, SR Bot, CM Woods, JG Weers. Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respi- ratory tract. Pharm Res 17:275-283, 2000.
1774. RH Perry, DW Green. Perry's Chemical Engineers' Handbook. 6th ed. Section 20. New York: McGraw-Hill, 1984.
1775. L Svarovsky. Solid-gas separation. In: JC Williams, T Allen, eds. Handbook of Pow- der Technology. New York: Elsevier, 1981, pp. 33-52.
1776. WM Thurlock. The internal surface area of nonemphysematous lungs. Am Rev Re- spir Dis 95:765-770, 1967.
1777. W Stahlhofen, J Gebhart, J Heyder. Experimental determination of the regional de- position of aerosol particles in the respiratory tract. Am Ind Hyg Assoc J 41:385- 398, 1980.
1778. RK Wolff, RW Niven. Generation of aerosol drugs. J Aerosol Med 7:89-106, 1994.
1779. Kassem, NM. Generation of deeply inspirable clouds from dry powder mixtures. PhD thesis, King's College, University of London, London, 1990.
1780. MJ Rocchio, DE Wightmam, K Naydo, DJ Parks, AE Smith. Powder filling systems, apparatus and methods. US patent 5,826,633, 1998.
1781. JD Burr, JM Anthony, GS Axford, JW Etter, AE Smith. Apparatus and methods for dispensing dry powder medicaments. US patent 6,089,228, 2000.
1782. M Gansslen. Uber inhalation von insulin. Wien Klin Wochenschr 4:71-81, 1925.
1783. JS Patton. Deep-lung delivery of therapeutic proteins. Chemtechnology 27:34-38, 1997.
1784. PR Byron, JS Patton. Drug delivery via the respiratory tract. J Aerosol Med 7:49- 75, 1994.
1785. A Adjei, J Garren. Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers. Pharmacol Res 7: 565-569, 1990.
1786. RB Elliott, BW Edgar, CC Pilcher, C Quested, J McMaster. Parenteral absorption of insulin from the lung in diabetic children. Aust Paediatr J 23:293-297, 1987.
1787. LJ Deftos, BL Seely, PC Clopton. Intrapulmonary delivery of bone-active peptides: bioactivity of inhaled salmon calcitonin approximates that of injected calcitonin. Proc Am Soc Bone Min Res Annual Meeting, Seattle, 1996.
1788. RS Pillari, BL Hughes, RK Wolff, JA Heisserman. The effect of pulmonary deliv- ered insulin on blood glucose levels using two nebulizer systems. J Aerosol Med 9:227-239, 1996.
1789. P Colthorpe, SJ Farri, IJ Smith, D Wyatt, G Taylor. The influence of regional deposi- tion on the pharmacokinetics of pulmonary delivered growth hormone in rabbits. Pharm Res 12:356-359, 1995.
1790. RH Hastings, M Grady, T Sakuma, MA Matthay. Clearance of different sized pro- teins from the alveolar space in humans and rabbits. J Appl Physiol 73:1310-1316, 1992.
1791. RK Wolff. Safety of inhaled proteins for therapeutic use. J Aerosol Med 11:197- 219, 1998.
1792. BL Laube, A Georgopoulos, GKI Adams. Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. JAMA 269:2106-2109.
1793. JS Patton, RM Platz. Pulmonary delivery of peptides and proteins for systemic ac- tion. Adv Drug Del Rev 8:179-196, 1992.
1794. American Conference of Governmental Industrial Hygienists. Threshold limit values for chemical substances and physical agents and biological exposure indices. ACGIH, Cincinnati, 2:33, 1995. Clark
1795. WT Cefalu, RA Gelfand, I Kourides, for the Inhaled Insulin Phase II Study Group. Treatment of type 2 diabetes mellitus with inhaled human insulin: a 3-month, multicenter trial. Diabetes 47(suppl 1):A61, 1998 (abstract 237).
1796. WT Cefalu, CC Balagtas, WH Landschulz, RA Gelfand. Sustained efficacy and pul- monary safety of inhaled insulin during 2-years of outpatient therapy. Diabetes 49(suppl 1):A101, 2000 (abstract 406-P).
1797. JS Skyler, RA Gelfand, IA Kourides, for the Inhaled Insulin Phase II Study Group. Treatment of type 1 diabetes mellitus with inhaled human insulin: a 3-month, multicenter trial. Diabetes 47(suppl 1):A61, 1998 (abstract 236). REFERENCES
1798. DR Williams, MB Mecikalski, DO Thueson. Apparatus for aerosolizing powdered medicine and process and using. US patent 5,327,883, 1994.
1799. PR Byron. The prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 75:433-438, 1986.
1800. L Adjei, J Garren. Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers. Pharm Res 7:565- 569, 1990.
1801. RM Platz, A Ip, CL Witham. Process for preparing micronized polypeptide drugs. US patent 5,354,562, 1994.
1802. E Phillips, E Allsopp, T Christensen, M Fitzgerald, L Zhao. Size reduction of peptides and proteins by jet-milling. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery VI. Buffalo Grove, IL: Interpharm Press, 1998, pp. 161-168.
1803. M Hill, L Vaughan, M Dolovich. Dose targeting for dry powder inhalers. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery V. Buffalo Grove, IL: Interpharm Press, 1996, pp. 197-208.
1804. D Ganderton. Targeted delivery of inhaled drugs: current challenges and future goals. J Aerosol Med 12:3-8, 1999.
1805. LR De Young, I Chambers, S Narayan, C Wa. The Aerodose Multidose Inhaler device design and delivery characteristics. In: RN Dalby, PR Byron, SJ Farr, eds. Respiratory Drug Delivery VI. Buffalo Grove, IL: Interpharm Press, 1998, pp. 91-95.
1806. J Schuster, R Rubsmen, P Lloyd, J Loyd. The AERx aerosol delivery system. Pharm Res 14:354-357, 1997.
1807. WC Zimlich, JY Ding, DR Busick, RR Montvic, ME Placke, PH Hirst, GR Pitcarn, S Malik, SP Newman, F Macintyre, PR Miller, MT Shepherd, TM Lukas. The devel- opment of a novel electrohydrodynamic pulmonary drug delivery device. In: RN Dalby, PR Byron, SJ Farr, J Peart, eds. Respiratory Drug Delivery VII. Raleigh, NC: Seratec Press, 2000, pp. 241-246.
1808. B Zierenberg. Optimizing the in vitro performance of Respimat. J Aerosol Med 12: 19-24, 1999.
1809. SP Newman. Use of gamma scintigraphy to evaluate the performance of new inhalers. J Aerosol Med 12:25-31, 1999.
1810. FV Measen, JA van Noord, JJ Smeets, APM Greefhorst. Dose range finding study comparing a new soft mist inhaler with a conventional metered dose inhaler (MDI) to deliver fenoterol in patients with asthma. Eur Respir J 10:1281, 1997.
1811. J Goldberg, E Freund, B Jahnel, R Hinzmann. Combination fenoterol/ipratropium bromide delivered via a new soft mist inhaler: dose range finding study in patients with asthma in comparison with a conventional metered dose inhaler (MDI). Am J Respir Crit Care Med 157:801, 1998. REFERENCES
1812. Intercenter Agreement Between the Center for Drug Evaluation and Research and the Center for Devices and Radiological Health, October 1991.
1813. Guidance for Industry. Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products. Chemistry, Manufacturing, and Controls Documentation, October 1998.
1814. Guidance for Industry. Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products Chemistry, Manufacturing, and Controls Documentation, May 1999.
1815. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on Dry Powder Inhalers, December 1998.
1816. Sterility Requirement for Aqueous-Based Drug Products for Oral Inhalation. Final Rule. Federal Register, Volume 65, Number 103, May 26, 2000.
1817. JJ DeGeorge. Considerations for toxicology studies of respiratory drug products. Regul Toxicol Pharmacol 25:189-193, 1997.
1818. RK Wolff, MA Dorato. Toxicologic testing of inhaled pharmaceutical aerosols. Crit Rev Toxicol 23:343-369, 1993.
1819. RF Phalen. Methods in Inhalation Toxicology New York: CRC Press, 1997.
1820. Interim Guidance for Documentation of In Vivo Bioequivalence of Albuterol Inhala- tion Aerosols (Metered Dose Inhalers), January 1994.
1821. Points to Consider. Clinical Development Programs for MDI and DPI Products, September 1994.
1822. JA Schuster. The AERx aerosol delivery system. Pharm Res 14:354-357, 1997. Regulatory Issues Relating to Modified-Release Drug Formulations Patrick J. Marroum Food and Drug Administration, Rockville, Maryland, U.S.A. REFERENCES
1823. PJ Marroum. Bioavailability/Bioequivalence for Oral Controlled Release Products, Controlled Release Drug Delivery Systems: Scientific and Regulatory Issues, Fifth International Symposium on Drug Development, East Brunswick, NJ, May 15-17, 1997.
1824. Guidance on BA and BE studies for orally administered drug products-general considerations. Center for Drug Evaluation and Research, Food and Drug Adminis- tration, August 2000.
1825. Code of Federal Regulations 21 314.54.
1826. Code of Federal Regulations 21 320.25.
1827. JP Skelly. Division guidelines for the evaluation of controlled release drug products. Center for Drug Evaluation and Research, Food and Drug Administration, April 1984.
1828. C Duarte. Cardizem CD, medical review. Division of Cardio-Renal Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, February 1991.
1829. PJ Marroum. Clinical pharmacology and biopharmaceutics review. Center for Drug Evaluation and Research, Food and Drug Administration, June 1991.
1830. Guidance for providing clinical evidence of effectiveness for human drug and bio- logical products. Center for Drug Evaluation and Research, Food and Drug Adminis- tration, May 1998.
1831. Approved Drug Products with Therapeutic Equivalence Evaluations. Center for Drug Evaluation and Research, Food and Drug Administration, 20th ed. 2000, pp. vii-xxi.
1832. Draft guidance on the food-effect bioavailability and bioequivalence studies. Center for Drug Evaluation and Research, Food and Drug Administration, October 1997.
1833. A El-Tahtawy, A Jackson, T Ludden. Pharm Res 11:1330-1336, 1994
1834. Guidance bioavailability and bioequivalence studies for orally administered drug products-general considerations. Center for Drug Evaluation and Research, Food and Drug Administration, October 2000.
1835. Guidance for oral extended (controlled) release dosage forms: in vivo bioequivalence and in vitro dissolution testing. Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, 1993.
1836. H Malinowski, PJ Marroum, R Uppoor, et al. FDA guidance for industry, extended release solid oral dosage forms: development, evaluation and application of in vivo/ in vitro correlations. Diss Tech 4:23-32, 1997.
1837. Guidance for modified release solid oral dosage forms, scale up and post approval changes: chemistry and controls: in vitro dissolution testing and in vivo bioequiva- lence documentation. Center for Drug Evaluation and Research, Food and Drug Ad- ministration, July 1997.
1838. US Pharmacopeia 23. General Information/In vitro and In vivo Evaluation of Dosage Forms, 〈1088〉 1995, pp. 1924-1929.
1839. H Malinowski. ER guidance. In: G Amidon, JR Robinson, RL Williams, eds. Scien- tific Foundations for Regulating Drug Product Quality. Alexandria, VA: AAPS Press, 1997, pp. 259-273.
1840. M Siewert. Perspectives of in vitro dissolution tests in establishing in vivo in vitro correlations. Eur J Drug Metab Pharmacokin 18:7-18, 1993.
1841. JP Skelly, GF Shiu. In vitro/in vivo correlations in biopharmaceutics: scientific and regulatory implications. Eur J Drug Metab Pharmacokin 18:121-129, 1993.
1842. HH Blume, I McGilvery, KK Midha. Eur J Pharm Sci 3:113-124, 1995.
1843. J Wagner. Absorption analysis and bioavailability. In: J Wagner, ed. Pharmacokinet- ics for the Pharmaceutical Scientist. Lancaster, PA: Technomic Publishing Com- pany, 1993, pp. 159-205.
1844. PJ Marroum. Development of in vivo in vitro correlations, SUPAC-MR/IVIVC guidance FDA training program manual. Center for Drug Evaluation and Research, Food and Drug Administration, July 1997, pp. 62-76.
1845. D. Brockmeier, D. Voegele, HM Hattingberg. In vitro-in vivo correlations, a time scaling problem? Drug Res 33:598-601, 1983.
1846. R Uppoor. Evaluation of predictability of in vitro in vivo correlations, SUPAC-MR/ IVIVC guidance FDA training program manual. Center for Drug Evaluation and Research, Food and Drug Administration, July 1997, pp. 97-110.
1847. PJ Marroum. Regulatory examples: dissolution specifications and bioequivalence product standards. In: G Amidon, JR Robinson, RL Williams, eds. Scientific Foun- dations for Regulating Drug Product Quality. Alexandria VA: AAPS Press, 1997, pp. 305-319.
1848. PJ Marroum. Role of in vivo-in vitro correlations in setting dissolutions specifica- tions. Am Pharm Rev 2:39-42, 1999.